Fused ring derivative, preparation method therefor and use thereof in medicine
Patent Information
- Application Number
- MYPI2026002780
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-11-01
- Filing Date
- 2024-11-08
- Publication Date
- 2025-05-10
AI Technical Summary
The prior art is difficult to effectively control refractory hypertension, especially after using a variety of antihypertensive drugs, blood pressure cannot be effectively controlled, and long-term use of drugs such as spironolactone has side effects and risk of hyperkalemia.
A novel fused ring derivative is developed as a selective inhibitor of CYP11B2 to treat and prevent aldosterone-mediated diseases by reducing aldosterone production.
This compound can effectively reduce aldosterone levels, reduce sodium and water retention and potassium excretion effects, thereby controlling blood pressure, reducing the risk of cardiac metabolic diseases, and avoiding the side effects of spironolactone.
Smart Images

Figure PI2026002780_DRAWING_001 
Figure PI2026002780_DRAWING_002
Abstract
Description
Condensed ring derivative, preparation method thereof and application thereof in medicine
[0001] This disclosure requires the following Chinese patent applications filed with the China Patent Office on November 10, 2023, with application number CN202311501230.1 and the invention title “Fused ring derivatives, preparation methods thereof and their applications in medicine”, the following Chinese patent applications filed with the China Patent Office on December 19, 2023, with application number CN202311755774.0 and the invention title “Fused ring derivatives, preparation methods thereof and their applications in medicine”, the following Chinese patent applications filed with the China Patent Office on March 19, 2024, with application number CN202410316983.3 and the invention title “Fused ring derivatives, preparation methods thereof and their applications in medicine”, the following Chinese patent applications filed with the China Patent Office on April 24, 2024, with application number CN202410502260.2 and the invention title The present invention claims priority from the Chinese patent application for “Fused ring derivatives, preparation methods thereof and applications in medicine”, the Chinese patent application with application number CN202410510376.0 filed with the Patent Office of China on April 25, 2024, and the invention title “Fused ring derivatives, preparation methods thereof and applications in medicine”, the Chinese patent application with application number CN202410970662.5 filed with the Patent Office of China on July 18, 2024, and the invention title “Fused ring derivatives, preparation methods thereof and applications in medicine”, and the Chinese patent application with application number CN202411558530.8 filed with the Patent Office of China on November 1, 2024, and the invention title “Fused ring derivatives, preparation methods thereof and applications in medicine”, all of which are incorporated by reference into this disclosure. Technical Field
[0002] The present disclosure relates to the field of medicine and relates to a fused ring derivative, a method for preparing the same, and its use in medicine. Specifically, the present disclosure relates to a fused ring derivative represented by general formula (IA), a method for preparing the same, a pharmaceutical composition containing the same, and its use as a therapeutic agent, particularly as a CYP11B2 inhibitor and in the preparation of a medicament for treating and / or preventing CYP11B2-mediated diseases. Background Art
[0003] Hypertension is a major risk factor for cardiovascular disease worldwide, affecting approximately 30% of the world's population. A comprehensive analysis of global hypertension trends published in The Lancet in 2021 stated that there are approximately 1.3 billion hypertensive patients worldwide (DOI: 10.1016 / S0140-6736(21)01330-1). Long-term poor blood pressure control can lead to damage to blood vessels and organs, inducing heart disease, kidney damage, and retinopathy. Hypertension is closely related to diseases such as diabetes, chronic kidney disease, and obesity.
[0004] For the vast majority of hypertensive patients, blood pressure can be controlled to normal levels (below 140 / 90 mmHg) after taking three different types of full-dose antihypertensive drugs. Despite the availability of a wide range of antihypertensive drugs, approximately 10% of patients with refractory hypertension still cannot effectively control their blood pressure despite concurrent use of at least three different types of full-dose antihypertensive drugs (the combination must include a diuretic), such as angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACE-I), diuretics, calcium channel blockers (CCBs), and alpha / beta blockers. Refractory hypertension is often caused by excessive sodium retention. In a British Heart Foundation-funded clinical trial initiated by Cambridge University in May 2009 (PATHWAY-2, ClinicalTrials.gov number NCT02369081), it was confirmed that, compared with ACE inhibitors, ARBs or renin inhibitors, CCBs or diuretics, the addition of the mineralocorticoid antagonist spironolactone achieved effective blood pressure control (systolic blood pressure <135 mm Hg) in 60% of patients with refractory hypertension within 3 months of treatment. Due to the off-target blockade of multiple steroid hormone receptors by spironolactone, long-term use of refractory hypertension patients may lead to side effects such as breast development in male patients and menstrual irregularities and postmenopausal bleeding in female patients. In addition, spironolactone also has the risk of inducing hyperkalemia, which greatly limits its application in the treatment of refractory hypertension (DOI:10.1016 / S0140-6736(15)00257-3).
[0005] Aldosterone is synthesized by aldosterone synthase (AS, encoded by the CYP11B2 gene) and regulates salt balance. Aldosterone promotes sodium and water retention by binding to and activating the mineralocorticoid receptor (MR) in the epithelial cells of the distal tubules and collecting ducts of the kidneys, while inducing the excretion of potassium and hydrogen ions. Excessive aldosterone can overactivate the mineralocorticoid receptor, causing significant sodium and water retention and potassium excretion, leading to symptoms such as hypokalemia, tissue edema, and hypertension. In addition, excessive aldosterone levels can also lead to inflammation and myocardial and vascular interstitial fibrosis related to cardiometabolic diseases, ventricular and vascular remodeling, induce leukocyte infiltration, cause coronary artery and myocardial damage, arrhythmias, etc.
[0006] Aldosterone synthase (AS) is expressed in cells of the zona glomerulosa (ZG) of the adrenal gland. There are two isoenzymes of aldosterone synthase: cortisol synthase (CYP11B1) and aldosterone synthase (CY11B2), which share 93% homology. CYP11B1 converts 11-deoxycortisol to cortisol. Both CYP11B2 and CYP11B1 11-beta-hydroxylate 11-deoxycorticosterone (11-DOC) to corticosterone. CYP11B2 then hydroxylates corticosterone to 18-hydroxycorticosterone. Finally, CYP11B2 oxidizes 18-hydroxycorticosterone to aldosterone.
[0007] LCI699, developed by Novartis, was one of the first aldosterone synthase inhibitors (ASI) to enter clinical development. Preclinical data showed that it is a dual inhibitor of CYP11B2 and CYP11B1, effectively lowering aldosterone while also strongly inhibiting CYP11B1, thereby reducing blood cortisol. Phase I clinical data showed that this compound reduced plasma aldosterone levels in healthy subjects and patients with primary aldosteronism, and could be used to treat patients with primary aldosteronism, essential hypertension, and refractory hypertension. However, at clinically effective therapeutic doses, LCI699 lacked sufficient selectivity for CYP11B2 (in vitro selectivity factor of 3-15), resulting in inhibition of cortisol synthesis. Ultimately, Novartis terminated its development program for hypertension, but its use of plasma aldosterone reduction as a human hypertension treatment strategy has provided new insights for subsequent drug development.
[0008] Cortisol synthesis is catalyzed by another enzyme with 93% sequence similarity to aldosterone synthase and has important physiological effects. It is necessary to selectively inhibit aldosterone synthase (AS) to avoid inhibition of cortisol synthesis. Following the discovery of FAD286 and LCI669, new next-generation aldosterone synthase inhibitors (ASIs) have been developed one after another, with significantly improved efficacy and selectivity. Aldosterone synthase inhibitors (ASIs) directly attenuate the production of aldosterone and have been proposed as an upgraded alternative to mineralocorticoid receptor antagonists for the treatment of diseases caused by excessive aldosterone. At present, the number of drugs for this target entering the clinical drug development stage is relatively small, so the development of highly specific CYP11B2 selective drugs will hopefully address the urgent needs of domestic patients with refractory hypertension.
[0009] Summary of the Invention
[0010] The object of the present disclosure is to provide a compound represented by general formula (IA), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts thereof;
[0011] in:
[0012] Ring A is selected from 5- to 6-membered heteroaryl groups;
[0013] Ring B is selected from a 3- to 8-membered heterocyclyl, a 3- to 8-membered monocyclic cycloalkyl, a 3- to 8-membered monocyclic cycloalkenyl, a 5- to 10-membered fused cyclic group, a 5- to 10-membered spirocyclic group, and a 5- to 10-membered bridged cyclic group;
[0014] Ring C is selected from phenyl, 5- to 6-membered heteroaryl, 7- to 14-membered fused aryl, 6- to 14-membered fused heterocyclyl, 6- to 14-membered fused heteroaryl, and 6- to 14-membered fused cyclyl;
[0015] L is selected from -NR n1 -、-(CR d R e ) r -、-(CR d =CR e ) r -、-O-(CR d R e ) r -、-(CR d R e ) r -O-, -NR n1 -(CR d R e ) r -、-(CR d R e ) r -NR n1 -、-(CR d R e ) r -C(O)-、-C(O)-(CR d R e ) r -, -OC(O)-, -C(O)-O-, -OC(O)-NR n1 -、-NR n1 -C(O)-O-、-NR n1 -C(O)-NR n1 -、-(CR d R e ) r -NR n1 -C(O)-, -C(O)-NR n1 -(CR d R e ) r -、-NR n1 -C(O)-(CR d R e ) r -、-NR n1-S(O)2- and -S(O)2-NR n1 -;
[0016] R is selected from hydrogen atom, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, cyano, -OR o 、-NR n2 R n3 , 3 to 8 membered heterocyclic group, 3 to 8 membered cycloalkyl group, 3 to 8 membered cycloalkenyl group, 6 to 10 membered aryl group and 5 to 10 membered heteroaryl group, wherein the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from deuterium atoms, halogen, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o , hydroxyl, hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0017] or R n1 and R and the atoms to which it is connected together form a 3- to 8-membered heterocyclic group or a 5- to 10-membered heteroaryl group; wherein the 3- to 8-membered heterocyclic group or the 5- to 10-membered heteroaryl group are each independently selected from deuterium atoms, halogens, oxo groups, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , hydroxy C1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0018] Each R a 、R b and R c are the same or different and are each independently selected from hydrogen atoms, deuterium atoms, C 1-6 Alkyl, -OR o 、-NR n2 R n3 , halogen, cyano, oxo, -C(O)NR n2 R n3 、-C(O)R o 、-C(O)OR o 、-C(O)NR n1 OR o , 3 to 8 membered heterocyclic group, 3 to 8 membered cycloalkyl group, 3 to 8 membered cycloalkenyl group, 6 to 10 membered aryl group and 5 to 10 membered heteroaryl group, wherein the C 1-6 Alkyl, 3 to 8 membered heterocyclic group, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from deuterium atoms, halogen, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o , hydroxyl, hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0019] Or two of the R b Together with the atoms to which it is attached, it forms a 3- to 8-membered heterocyclic group or a 3- to 8-membered cycloalkyl group, wherein the 3- to 8-membered heterocyclic group and the 3- to 8-membered cycloalkyl group are each independently selected from deuterium atoms, halogens, oxo groups, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 Rn5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0020] Or two of the R c Together with the atoms to which it is attached, it forms a 3- to 8-membered heterocyclic group or a 3- to 8-membered cycloalkyl group, wherein the 3- to 8-membered heterocyclic group and the 3- to 8-membered cycloalkyl group are each independently selected from deuterium atoms, halogens, oxo groups, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0021] or R b and R and the atoms to which it is connected together form a 3- to 8-membered heterocyclic group, a 3- to 8-membered cycloalkyl group, a 3- to 8-membered cycloalkenyl group, a 6- to 10-membered aryl group and a 5- to 10-membered heteroaryl group; wherein the 3- to 8-membered heterocyclic group, the 3- to 8-membered cycloalkyl group, the 3- to 8-membered cycloalkenyl group, the 6- to 10-membered aryl group and the 5- to 10-membered heteroaryl group are each independently optionally selected from a deuterium atom, a halogen, an oxo group, a C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NRn4 OR o 、-OR o , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0022] R d and R e are the same or different at each occurrence and are independently selected from hydrogen atoms, deuterium atoms, C 1-6 Alkyl, halogen, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxy C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, -OR o and halogenated C 1-6 alkoxy;
[0023] R o are the same or different at each occurrence and are independently selected from hydrogen atoms, C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxy C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from deuterium atoms, halogen, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , hydroxy C 1-6substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0024] R n1 、R n2 、R n3 、R n4 and R n5 are the same or different at each occurrence and are independently selected from hydrogen atoms, C 1-6 Alkyl, hydroxy C 1-6 alkyl, 3 to 8 membered heterocyclic group, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein, the C 1-6 Alkyl, 3 to 8 membered heterocyclic group, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from deuterium atoms, halogen, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0025] or R n2 and R n3 、R n4 and R n5 Together with the nitrogen atoms to which they are attached, they form a 3- to 8-membered heterocyclic group; wherein the 3- to 8-membered heterocyclic group is optionally selected from deuterium atoms, halogens, oxo groups, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NRn4 OR o 、-OR o , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0026] n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
[0027] m is 0, 1, 2, 3, 4, 5 or 6;
[0028] p is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; and
[0029] r is 0, 1, 2, 3 or 4.
[0030] The object of the present disclosure is to provide a compound represented by general formula (IA), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts thereof;
[0031] in:
[0032] Ring A is selected from 5- to 6-membered heteroaryl groups;
[0033] Ring B is selected from a 3- to 8-membered heterocyclyl, a 3- to 8-membered monocyclic cycloalkyl, a 3- to 8-membered monocyclic cycloalkenyl, a 5- to 10-membered fused cyclic group, a 5- to 10-membered spirocyclic group, and a 5- to 10-membered bridged cyclic group;
[0034] Ring C is selected from phenyl, 5- to 6-membered heteroaryl, 7- to 14-membered fused aryl, 6- to 14-membered fused heterocyclyl, 6- to 14-membered fused heteroaryl, and 6- to 14-membered fused cyclyl;
[0035] L is selected from -NR n1 -、-(CR d R e ) r -、-(CR d =CR e ) r -、-O-(CR d R e ) r -、-(CR d R e ) r -O-, -NR n1 -(CR d R e ) r -、-(CR d R e ) r -NRn1 -、-(CR d R e ) r -C(O)-, -C(O)-(CR d R e ) r -, -OC(O)-, -C(O)-O-, -OC(O)-NR n1 -、-NR n1 -C(O)-O-, -NR n1 -C(O)-NR n1 -、-(CR d R e ) r -NR n1 -C(O)-, -C(O)-NR n1 -(CR d R e ) r -、-NR n1 -C(O)-(CR d R e ) r -、-NR n1 -S(O)2- and -S(O)2-NR n1 -;
[0036] R is selected from hydrogen atom, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, cyano, -OR o 、-NR n2 R n3 , 3 to 8 membered heterocyclic group, 3 to 8 membered cycloalkyl group, 3 to 8 membered cycloalkenyl group, 6 to 10 membered aryl group and 5 to 10 membered heteroaryl group, wherein the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from deuterium atoms, halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o , hydroxyl, hydroxy C1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0037] or R n1 and R and the atoms to which it is connected together form a 3- to 8-membered heterocyclic group or a 5- to 10-membered heteroaryl group; wherein the 3- to 8-membered heterocyclic group or the 5- to 10-membered heteroaryl group are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0038] Each R a 、R b and R c are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl, -OR o 、-NR n2 R n3 , halogen, cyano, oxo, -C(O)NR n2 R n3 、-C(O)R o 、-C(O)OR o 、-C(O)NR n1 OR o , 3 to 8 membered heterocyclic group, 3 to 8 membered cycloalkyl group, 3 to 8 membered cycloalkenyl group, 6 to 10 membered aryl group and 5 to 10 membered heteroaryl group, wherein the C 1-6 Alkyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 Rn5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o , hydroxyl, hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0039] Or two of the R b Together with the atoms to which it is attached, it forms a 3- to 8-membered heterocyclic group or a 3- to 8-membered cycloalkyl group, wherein the 3- to 8-membered heterocyclic group and the 3- to 8-membered cycloalkyl group are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0040] Or two of the R c Together with the atoms to which it is attached, it forms a 3- to 8-membered heterocyclic group or a 3- to 8-membered cycloalkyl group, wherein the 3- to 8-membered heterocyclic group and the 3- to 8-membered cycloalkyl group are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0041] or Rb and R and the atoms to which it is connected together form a 3- to 8-membered heterocyclic group, a 3- to 8-membered cycloalkyl group, a 3- to 8-membered cycloalkenyl group, a 6- to 10-membered aryl group and a 5- to 10-membered heteroaryl group; wherein the 3- to 8-membered heterocyclic group, the 3- to 8-membered cycloalkyl group, the 3- to 8-membered cycloalkenyl group, the 6- to 10-membered aryl group and the 5- to 10-membered heteroaryl group are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0042] R d and R e are the same or different at each occurrence and are independently selected from hydrogen atoms, C 1-6 Alkyl, halogen, halogenated C 1-6 Alkyl, hydroxy C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, -OR o and halogenated C 1-6 alkoxy;
[0043] R o are the same or different at each occurrence and are independently selected from hydrogen atoms, C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxy C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0044] R n1 、R n2 、R n3 、R n4 and R n5 are the same or different at each occurrence and are independently selected from hydrogen atoms, C 1-6 Alkyl, hydroxy C 1-6 alkyl, 3 to 8 membered heterocyclic group, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein, the C 1-6 Alkyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0045] or R n2 and R n3 、R n4 and R n5 Together with the nitrogen atoms to which they are attached, they form a 3- to 8-membered heterocyclic group; wherein the 3- to 8-membered heterocyclic group is optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0046] n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
[0047] m is 0, 1, 2, 3, 4, 5 or 6;
[0048] p is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; and
[0049] r is 0, 1, 2, 3 or 4.
[0050] The object of the present disclosure is to provide a compound represented by general formula (IA), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts thereof;
[0051] in:
[0052] Ring A is selected from 5- to 6-membered heteroaryl groups;
[0053] Ring B is selected from a 3- to 8-membered heterocyclyl, a 3- to 8-membered monocyclic cycloalkyl, a 3- to 8-membered monocyclic cycloalkenyl, a 5- to 10-membered fused cyclic group, a 5- to 10-membered spirocyclic group, and a 5- to 10-membered bridged cyclic group;
[0054] Ring C is selected from phenyl, 5- to 6-membered heteroaryl, 7- to 14-membered fused aryl, 6- to 14-membered fused heterocyclic group, 6- to 14-membered fused heteroaryl, and 6- to 14-membered fused cyclic group;
[0055] L is selected from -NR n1 -、-(CR d R e ) r -、-(CR d =CR e ) r -、-O-(CR d R e )r -、-(CR d R e ) rr -O-, -NR n1 -(CR d R e ) r -、-(CR d R e ) r -NR n1 -、-(CR d R e ) r -C(O)-、-C(O)-(CR d R e ) r -, -OC(O)-, -C(O)-O-, -OC(O)-NR n1 -、-NR n1 -C(O)-O-、-NR n1 -C(O)-NR n1 -、-(CR d R e ) r -NR n1 -C(O)-, -C(O)-NR n1 -(CR d R e ) r -、-NR n1 -C(O)-(CR d R e ) r -、-NR n1 -S(O)2- and -S(O)2-NR n1 -;
[0056] R is selected from hydrogen atom, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, cyano, -OR o 、-NR n2 R n3 , 3 to 8 membered heterocyclic group, 3 to 8 membered cycloalkyl group, 3 to 8 membered cycloalkenyl group, 6 to 10 membered aryl group and 5 to 10 membered heteroaryl group, wherein the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o , hydroxyl, hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0057] or R n1 and R and the atoms to which it is connected together form a 3- to 8-membered heterocyclic group; wherein the 3- to 8-membered heterocyclic group is optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0058] Each R a 、R b and R c are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl, -OR o 、-NR n2 R n3 , halogen, cyano, oxo, -C(O)NR n2 R n3 、-C(O)R o 、-C(O)OR o 、-C(O)NR n1 OR o , 3 to 8 membered heterocyclic group, 3 to 8 membered cycloalkyl group, 3 to 8 membered cycloalkenyl group, 6 to 10 membered aryl group and 5 to 10 membered heteroaryl group, wherein the C 1-6Alkyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o , hydroxyl, hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0059] or R b and R and the atoms to which it is connected together form a 3- to 8-membered heterocyclic group, a 3- to 8-membered cycloalkyl group, a 3- to 8-membered cycloalkenyl group, a 6- to 10-membered aryl group and a 5- to 10-membered heteroaryl group; wherein the 3- to 8-membered heterocyclic group, the 3- to 8-membered cycloalkyl group, the 3- to 8-membered cycloalkenyl group, the 6- to 10-membered aryl group and the 5- to 10-membered heteroaryl group are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0060] R d and R e are the same or different at each occurrence and are independently selected from hydrogen atoms, C 1-6 Alkyl, halogen, halogenated C 1-6 Alkyl, hydroxy C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C2-6 Alkynyl, -OR o and halogenated C 1-6 alkoxy;
[0061] R o are the same or different at each occurrence and are independently selected from hydrogen atoms, C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxy C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0062] R n1 、R n2 、R n3 、R n4 and R n5 are the same or different at each occurrence and are independently selected from hydrogen atoms, C 1-6 Alkyl, hydroxy C 1-6 alkyl, 3 to 8 membered heterocyclic group, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein, the C 1-6 Alkyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NRn4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0063] or R n2 and R n3 、R n4 and R n5 Together with the nitrogen atoms to which they are attached, they form a 3- to 8-membered heterocyclic group; wherein the 3- to 8-membered heterocyclic group is optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0064] n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
[0065] m is 0, 1, 2, 3, 4, 5 or 6;
[0066] p is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; and
[0067] r is 0, 1, 2, 3 or 4.
[0068] In some embodiments of the present disclosure, the compound represented by general formula (IA), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts, wherein ring A is selected from a 5- to 6-membered heteroaryl group containing 1 to 3 nitrogen atoms; preferably, ring A is selected from a pyridyl group, a pyrimidinyl group, a pyridazinyl group and a 5-membered heteroaryl group containing 1 to 3 nitrogen atoms.
[0069] In some embodiments of the present disclosure, the compound represented by the general formula (IA), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts thereof, is a compound represented by the general formula (I), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts thereof;
[0070] in:
[0071] R a1 、R a2 The same or different, and each independently as R in the general formula (IA) a defined;
[0072] Ring B is selected from a 3- to 8-membered heterocyclyl, a 5- to 6-membered cycloalkenyl, a 7- to 8-membered monocyclic cycloalkyl, a 5- to 10-membered fused cyclic group, a 5- to 10-membered spirocyclic group, and a 5- to 10-membered bridged cyclic group;
[0073] Ring C is selected from phenyl, 5- to 6-membered heteroaryl, 7- to 14-membered fused aryl, 6- to 14-membered fused heterocyclyl, 6- to 14-membered fused heteroaryl, and 6- to 14-membered fused cyclyl;
[0074] L is selected from -NR n1 -、-NR n1 C(O)-、-NR n1 -C(O)-NR n1 -and-CR d =CR e -; or R n1 and R and the atoms to which it is connected together form a 3- to 8-membered heterocyclic group or a 5- to 10-membered heteroaryl group; wherein the 3- to 8-membered heterocyclic group or the 5- to 10-membered heteroaryl group are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-ORo , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0075] or R b and R and the atoms to which it is connected together form a 3- to 8-membered heterocyclic group, a 3- to 8-membered cycloalkyl group, a 3- to 8-membered cycloalkenyl group, a 6- to 10-membered aryl group and a 5- to 10-membered heteroaryl group; wherein the 3- to 8-membered heterocyclic group, the 3- to 8-membered cycloalkyl group, the 3- to 8-membered cycloalkenyl group, the 6- to 10-membered aryl group and the 5- to 10-membered heteroaryl group are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0076] The condition is that the compound represented by the general formula (I) is not a compound whose cas is 1428652-88-3;
[0077] R, R a 、R b 、R c 、R n1 、R n4 、R n5 、R o 、R d 、R e , n and p are as defined in the general formula (IA).
[0078] The structural formula of the compound cas 1428652-88-3 described in this application is:
[0079] In some embodiments of the present disclosure, the compound represented by the general formula (I), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or its pharmaceutically acceptable salts, wherein the structural unit wherein ring B is selected from a 5- to 6-membered heterocyclic group, a 5- to 6-membered cycloalkenyl group, a 6- to 10-membered fused ring group, and a 6- to 10-membered bridged ring group, and R a1 、R a2 The same or different, and each independently as R in the general formula (IA) a As defined, n and R b As defined in general formula (IA); preferably, the structural unit wherein ring B is selected from a 5- to 6-membered heterocyclic group, a 5- to 6-membered cycloalkenyl group, a 6- to 10-membered fused ring group, and a 6- to 10-membered bridged ring group, and each R b The same or different, and each independently selected from halogen, hydroxyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 Alkoxy, n is 0, 1, 2, 3 or 4, R a1 、R a2 The same or different, and each independently selected from hydrogen atom, halogen, hydroxyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 Alkoxy; more preferably, Selected from Each R b The same or different, and each independently selected from halogen, hydroxyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 Alkoxy, n is 0, 1, 2, 3 or 4, R a1 、R a2 The same or different, and each independently selected from hydrogen atom, halogen, hydroxyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 Alkoxy; further preferably, Selected from Each R b The same or different, and each independently selected from halogen, hydroxyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 Alkoxy, n is 0, 1, 2, 3 or 4; more preferably, Selected from
[0080] In some embodiments of the present disclosure, the compound represented by general formula (I), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts thereof, wherein ring B is selected from a 5- to 6-membered heterocyclic group, a 5- to 6-membered cycloalkenyl group, a 6- to 10-membered fused ring group and a 6- to 10-membered bridged ring group; preferably, ring B is selected from a 6-membered heterocyclic group, a cyclohexenyl group, a 7-membered fused ring group and a 7-membered bridged ring group; more preferably, ring B is selected from More preferably, ring B is selected from in Connected to L.
[0081] In some embodiments of the present disclosure, the compound represented by the general formula (I), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or its pharmaceutically acceptable salts, wherein ring B is in Connected to L.
[0082] In some embodiments of the present disclosure, the compound represented by the general formula (IA) or the general formula (I), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts thereof, is a compound represented by the general formula (I-1) or the general formula (I-2), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts thereof;
[0083] in:
[0084] Ring C, R, R n1 、R b 、R c , n and p are as defined in formula (IA) or formula (I).
[0085] In some embodiments of the present disclosure, the compound represented by general formula (IA), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts thereof, is a compound represented by general formula (II), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts thereof;
[0086] in:
[0087] x 1 Select N or CR a1 ;
[0088] x 2 Select N or CR a2 ;
[0089] x 3 Select N or CR a3 ; R a1 、R a2 、R a3 The same or different, and each independently as R in the general formula (IA) a defined;
[0090] x 1 、x 2 、x 3 At least one of them is N, and when x 1 Selected from CR a1 ;x 2 Selected from CR a2 When x 3 Not selected from N;
[0091] Ring B is selected from a 3- to 8-membered heterocyclyl, a 3- to 8-membered monocyclic cycloalkyl, a 3- to 8-membered monocyclic cycloalkenyl, a 5- to 10-membered fused cyclic group, a 5- to 10-membered spirocyclic group, and a 5- to 10-membered bridged cyclic group;
[0092] Ring C is selected from phenyl, 5- to 6-membered heteroaryl, 7- to 14-membered fused aryl, 6- to 14-membered fused heterocyclyl, 6- to 14-membered fused heteroaryl, and 6- to 14-membered fused cyclyl;
[0093] L is selected from -NR n1 -、-NR n1 C(O)-、-NR n1 -C(O)-NR n1 -and-CR d =CR e -; or Rn1 and R and the atoms to which it is connected together form a 3- to 8-membered heterocyclic group or a 5- to 10-membered heteroaryl group; wherein the 3- to 8-membered heterocyclic group or the 5- to 10-membered heteroaryl group are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0094] or R b and R and the atoms to which it is connected together form a 3- to 8-membered heterocyclic group, a 3- to 8-membered cycloalkyl group, a 3- to 8-membered cycloalkenyl group, a 6- to 10-membered aryl group and a 5- to 10-membered heteroaryl group; wherein the 3- to 8-membered heterocyclic group, the 3- to 8-membered cycloalkyl group, the 3- to 8-membered cycloalkenyl group, the 6- to 10-membered aryl group and the 5- to 10-membered heteroaryl group are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0095] R, R a 、R b 、R c 、R n1 、R n4 、R n5 、R d 、R e , n and p are as defined in the general formula (IA).
[0096] In some embodiments of the present disclosure, the compound represented by the general formula (II), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or its pharmaceutically acceptable salts, wherein the structural unit Selected from wherein Ring B is selected from a 5- to 6-membered heterocyclic group, a 5- to 6-membered cycloalkyl group, a 5- to 6-membered cycloalkenyl group, a 6- to 10-membered fused ring group, and a 6- to 10-membered bridged ring group, and R a1 、R a2 The same or different, and each independently as R in the general formula (IA) a As defined, n and R b As defined in general formula (IA); preferably, Selected from wherein Ring B is selected from a 5- to 6-membered heterocyclic group or a 5- to 6-membered cycloalkyl group, each R b The same or different, and each independently selected from halogen, hydroxyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 Alkoxy, n is 0, 1, 2, 3 or 4, R a1 、R a2 The same or different, and each independently selected from hydrogen atom, halogen, hydroxyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 Alkoxy; more preferably, Selected from Each R b The same or different, and each independently selected from halogen, hydroxyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 Alkoxy, n is 0, 1, 2, 3 or 4, R a1 、R a2The same or different, and each independently selected from hydrogen atom, halogen, hydroxyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 Alkoxy; further preferably, Selected from Each R b The same or different, and each independently selected from halogen, hydroxyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 Alkoxy, n is 0, 1, 2, 3 or 4; more preferably, Selected from
[0097] In some embodiments of the present disclosure, the compound represented by general formula (II), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts thereof, wherein ring B is selected from a 5- to 6-membered heterocyclic group, a 5- to 6-membered cycloalkyl group, a 5- to 6-membered cycloalkenyl group, a 6- to 10-membered fused ring group and a 6- to 10-membered bridged ring group; preferably, ring B is selected from a 5- to 6-membered heterocyclic group or a 5- to 6-membered cycloalkyl group; more preferably, ring B is selected from a 5- to 6-membered cycloalkyl group; further preferably, ring B is selected from in Connected to L.
[0098] In some embodiments of the present disclosure, the compound represented by the general formula (IA), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts thereof, is a compound represented by the general formula (III), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts thereof;
[0099] in:
[0100] x 4 Selected from N, NR a4 , O, S, S(O), S(O)2 and CR a4 ;
[0101] x 5 Selected from N, NR a5 , O, S, S(O), S(O)2 and CR a5 ;
[0102] x 6 Selected from N or C;
[0103] x 7 Selected from N or C;
[0104] x 8 Selected from N or C; R a4 、R a5 For example, R a defined;
[0105] Ring B is selected from a 3- to 8-membered heterocyclyl, a 3- to 8-membered monocyclic cycloalkyl, a 3- to 8-membered monocyclic cycloalkenyl, a 5- to 10-membered fused cyclic group, a 5- to 10-membered spirocyclic group, and a 5- to 10-membered bridged cyclic group;
[0106] Ring C is selected from phenyl, 5- to 6-membered heteroaryl, 7- to 14-membered fused aryl, 6- to 14-membered fused heterocyclyl, 6- to 14-membered fused heteroaryl, and 6- to 14-membered fused cyclyl;
[0107] L is selected from -NR n1 -、-NR n1 C(O)-、-NR n1 -C(O)-NR n1 -and-CR d =CR e -; or R n1 and R and the atoms to which it is connected together form a 3- to 8-membered heterocyclic group or a 5- to 10-membered heteroaryl group; wherein the 3- to 8-membered heterocyclic group or the 5- to 10-membered heteroaryl group are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0108] or R band R and the atoms to which it is connected together form a 3- to 8-membered heterocyclic group, a 3- to 8-membered cycloalkyl group, a 3- to 8-membered cycloalkenyl group, a 6- to 10-membered aryl group and a 5- to 10-membered heteroaryl group; wherein the 3- to 8-membered heterocyclic group, the 3- to 8-membered cycloalkyl group, the 3- to 8-membered cycloalkenyl group, the 6- to 10-membered aryl group and the 5- to 10-membered heteroaryl group are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0109] R, R a 、R b 、R c 、R n1 、R n4 、R n5 、R o 、R d 、R e , n and p are as defined in the general formula (IA).
[0110] In some embodiments of the present disclosure, the compound represented by the general formula (III), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or its pharmaceutically acceptable salts, wherein the structural unit Selected from wherein Ring B is selected from a 5- to 6-membered heterocyclic group, a 5- to 6-membered cycloalkyl group, a 5- to 6-membered cycloalkenyl group, a 6- to 10-membered fused ring group, and a 6- to 10-membered bridged ring group, and R a4 、R a5 The same or different, and each independently as R in the general formula (IA) a As defined, n and R b As defined in general formula (IA); preferably, Selected from wherein Ring B is selected from a 5- to 6-membered heterocyclic group or a 5- to 6-membered cycloalkyl group, each R b The same or different, and each independently selected from halogen, hydroxyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 Alkoxy, n is 0, 1, 2, 3 or 4, R a4 、R a5 are the same or different and are each independently selected from hydrogen atom, halogen, hydroxyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 Alkoxy; more preferably, Selected from Each R b The same or different, and each independently selected from halogen, hydroxyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 Alkoxy, n is 0, 1, 2, 3 or 4, R a4 、R a5 The same or different, and each independently selected from hydrogen atom, halogen, hydroxyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 Alkoxy; further preferably, Selected from Each R b The same or different, and each independently selected from halogen, hydroxyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6Alkoxy, n is 0, 1, 2, 3 or 4; more preferably, Selected from
[0111] In some embodiments of the present disclosure, the compound represented by the general formula (III), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts thereof, wherein ring B is selected from a 5- to 6-membered heterocyclic group, a 5- to 6-membered cycloalkyl group, a 5- to 6-membered cycloalkenyl group, a 6- to 10-membered fused ring group and a 6- to 10-membered bridged ring group; preferably, ring B is selected from a 5- to 6-membered heterocyclic group or a 5- to 6-membered cycloalkyl group; more preferably, ring B is selected from in Connected to L.
[0112] In some embodiments of the present disclosure, the compound represented by the general formula (IA), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts thereof, is a compound represented by the general formula (IV), the general formula (IV-1), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts thereof;
[0113] in:
[0114] R a1 、R a2 For example, R a defined;
[0115] s is 0, 1, 2, 3, or 4;
[0116] Ring C is selected from phenyl, 5- to 6-membered heteroaryl, 7- to 14-membered fused aryl, 6- to 14-membered fused heterocyclyl, 6- to 14-membered fused heteroaryl, and 6- to 14-membered fused cyclyl; and Not for
[0117] L is selected from -NR n1 -、-NR n1 C(O)-、-NR n1 -C(O)-NR n1 -and-CR d =CR e -; or R n1 and R and the atoms to which it is connected together form a 3- to 8-membered heterocyclic group or a 5- to 10-membered heteroaryl group; wherein the 3- to 8-membered heterocyclic group or the 5- to 10-membered heteroaryl group are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0118] or R b and R and the atoms to which it is connected together form a 3- to 8-membered heterocyclic group, a 3- to 8-membered cycloalkyl group, a 3- to 8-membered cycloalkenyl group, a 6- to 10-membered aryl group and a 5- to 10-membered heteroaryl group; wherein the 3- to 8-membered heterocyclic group, the 3- to 8-membered cycloalkyl group, the 3- to 8-membered cycloalkenyl group, the 6- to 10-membered aryl group and the 5- to 10-membered heteroaryl group are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0119] R, R a 、R b 、R c 、R n1 、R n4 、R n5 、R o 、R d 、R e , n and p are as defined in the general formula (IA).
[0120] In some embodiments of the present disclosure, the compound represented by the general formula (IA), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts thereof, is a compound represented by the general formula (V), the general formula (V-1), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts thereof;
[0121] in:
[0122] R a1 、R a2 For example, in the general formula (IA), R a defined;
[0123] s is 0, 1, 2, 3, or 4;
[0124] Ring C is selected from phenyl, 5- to 6-membered heteroaryl, 7- to 14-membered fused aryl, 6- to 14-membered fused heterocyclyl, 6- to 14-membered fused heteroaryl, and 6- to 14-membered fused cyclyl;
[0125] L is selected from -NR n1 -、-NR n1 C(O)-、-NR n1 -C(O)-NR n1 -and-CR d =CR e -; or R n1 and R and the atoms to which it is connected together form a 3- to 8-membered heterocyclic group or a 5- to 10-membered heteroaryl group; wherein the 3- to 8-membered heterocyclic group or the 5- to 10-membered heteroaryl group are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0126] or R band R and the atoms to which it is connected together form a 3- to 8-membered heterocyclic group, a 3- to 8-membered cycloalkyl group, a 3- to 8-membered cycloalkenyl group, a 6- to 10-membered aryl group and a 5- to 10-membered heteroaryl group; wherein the 3- to 8-membered heterocyclic group, the 3- to 8-membered cycloalkyl group, the 3- to 8-membered cycloalkenyl group, the 6- to 10-membered aryl group and the 5- to 10-membered heteroaryl group are each independently optionally selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;
[0127] When L is selected from -NHC(O)-, R is not methyl, ethyl, cyclopropyl, CH3CH(OH)- and
[0128] R, R a 、R b 、R c 、R n1 、R n4 、R n5 、R o 、R d 、R e , n and p are as defined in the general formula (IA).
[0129] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates or their pharmaceutically acceptable salts, wherein the structural unit wherein ring C is selected from phenyl, 5- to 6-membered heteroaryl, 7- to 14-membered fused aryl, 6- to 14-membered fused heterocyclic group and 6- to 14-membered fused heteroaryl, and each R c The same or different, and each independently selected from halogen, hydroxy, oxo, hydroxy 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl, C 1-6 Alkoxy, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 3 to 8 membered heterocyclyl, 5 to 6 membered heteroaryl, wherein the 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 3 to 8 membered heterocyclyl, 5 to 6 membered heteroaryl are optionally selected from halogen, hydroxy, oxo, hydroxy, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl, C 1-6 The alkoxy group is substituted by one or more substituents, and p is 0, 1, 2, 3 or 4; preferably, the structural unit wherein ring C is selected from phenyl, 5- to 6-membered heteroaryl, 5- to 8-membered monocyclic heterocyclylphenyl, 7- to 10-membered fused heterocyclylphenyl, 5- to 8-membered monocyclic heterocyclyl and 5- to 6-membered heteroaryl, 7- to 10-membered fused heterocyclyl and 5- to 6-membered heteroaryl, 5- to 6-membered heteroarylphenyl, and each R c The same or different, and each independently selected from halogen, hydroxy, oxo, hydroxy 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl, C 1-6 Alkoxy, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 3 to 8 membered heterocyclyl, 5 to 6 membered heteroaryl, wherein the 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 3 to 8 membered heterocyclyl, 5 to 6 membered heteroaryl are optionally selected from halogen, hydroxy, oxo, hydroxy, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl, C 1-6 is substituted by one or more substituents in the alkoxy group, p is 0, 1, 2, 3 or 4; more preferably, the structural unit Selected from Each R cThe same or different, and each independently selected from hydrogen atom, halogen, hydroxyl, oxo, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl, C 1-6 Alkoxy and 5 to 6 membered heteroaryl, wherein the 5 to 6 membered heteroaryl is optionally selected from halogen, hydroxy, oxo, hydroxy 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl, C 1-6 The alkoxy group is substituted by one or more substituents, and p is 0, 1, 2, 3 or 4; more preferably, the structural unit Selected from
[0130] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates or their pharmaceutically acceptable salts, wherein the structural unit wherein ring C is selected from 7 to 10-membered spiroheterocyclylphenyl groups, each R c The same or different, and each independently selected from halogen, hydroxy, oxo, hydroxy 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl, C 1-6 Alkoxy, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 3 to 8 membered heterocyclyl, 5 to 6 membered heteroaryl, wherein the 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 3 to 8 membered heterocyclyl, 5 to 6 membered heteroaryl are optionally selected from halogen, hydroxy, oxo, hydroxy, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 The alkoxy group is substituted by one or more substituents, and p is 0, 1, 2, 3 or 4.
[0131] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates or their pharmaceutically acceptable salts, wherein the structural unit Selected from Each R c The same or different, and each independently selected from hydrogen atom, halogen, hydroxyl, oxo, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl, C 1-6 Alkoxy, 3 to 6 membered cycloalkyl and 5 to 6 membered heteroaryl, wherein the 3 to 6 membered cycloalkyl and 5 to 6 membered heteroaryl are optionally selected from halogen, hydroxy, oxo, hydroxy 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 The alkoxy group is substituted by one or more substituents, and p is 0, 1, 2, 3 or 4.
[0132] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates or their pharmaceutically acceptable salts, wherein the structural unit Selected from Each R c The same or different, and each independently selected from hydrogen atom, halogen, hydroxyl, oxo, hydroxyl C 1-6 Alkyl, halogenated C1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl, C 1-6 Alkoxy, 3 to 6 membered cycloalkyl and 5 to 6 membered heteroaryl, wherein the 3 to 6 membered cycloalkyl and 5 to 6 membered heteroaryl are optionally selected from halogen, hydroxy, oxo, hydroxy 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 The alkoxy group is substituted by one or more substituents, and p is 0, 1, 2, 3 or 4.
[0133] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates or their pharmaceutically acceptable salts, wherein the structural unit wherein ring C is selected from phenyl, 5- to 6-membered heteroaryl, 7- to 14-membered fused aryl, 6- to 14-membered fused heterocyclic group and 6- to 14-membered fused heteroaryl, and each R c The same or different, and each independently selected from halogen, hydroxy, oxo, hydroxy 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 3 to 8 membered heterocyclyl and 5 to 6 membered heteroaryl, wherein the 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 3 to 8 membered heterocyclyl and 5 to 6 membered heteroaryl are optionally selected from halogen, hydroxy, oxo, hydroxy, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C1-6 The alkoxy group is substituted by one or more substituents, and p is 0, 1, 2, 3 or 4;
[0134] Preferably, the structural unit wherein ring C is selected from phenyl, 5- to 6-membered heteroaryl, 5- to 8-membered monocyclic heterocyclylphenyl, 7- to 10-membered fused heterocyclylphenyl, 7- to 10-membered spiroheterocyclylphenyl, 5- to 8-membered monocyclic heterocyclyl and 5- to 6-membered heteroaryl, 7- to 10-membered fused heterocyclyl and 5- to 6-membered heteroaryl, 5- to 6-membered heteroarylphenyl, and each R c The same or different, and each independently selected from halogen, hydroxy, oxo, hydroxy 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 3 to 8 membered heterocyclyl, 5 to 6 membered heteroaryl, wherein the 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 3 to 8 membered heterocyclyl, 5 to 6 membered heteroaryl are optionally selected from halogen, hydroxy, oxo, hydroxy, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 The alkoxy group is substituted by one or more substituents, and p is 0, 1, 2, 3 or 4;
[0135] More preferably, the structural unit Selected from Each R c The same or different, and each independently selected from hydrogen atom, halogen, hydroxyl, oxo, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6Alkoxy, 3 to 6 membered cycloalkyl and 5 to 6 membered heteroaryl, wherein the 3 to 6 membered cycloalkyl and 5 to 6 membered heteroaryl are optionally selected from halogen, hydroxy, oxo, hydroxy 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 The alkoxy group is substituted by one or more substituents, and p is 0, 1, 2, 3 or 4.
[0136] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates or their pharmaceutically acceptable salts, wherein the structural unit Selected from
[0137] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates or their pharmaceutically acceptable salts, wherein the structural unit Selected from
[0138] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates or their pharmaceutically acceptable salts, wherein the structural unit Selected from
[0139] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates or their pharmaceutically acceptable salts, wherein the structural unit Selected from
[0140] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates or their pharmaceutically acceptable salts, wherein the structural unit Selected from
[0141] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates or their pharmaceutically acceptable salts, wherein the structural unit Selected from
[0142] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates or their pharmaceutically acceptable salts, wherein the structural unit Selected from
[0143] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), stereoisomers thereof, isotopic derivatives thereof, prodrugs thereof, nitrogen oxides thereof, solvates thereof, or pharmaceutically acceptable salts thereof, wherein ring C is selected from phenyl, 5- to 6-membered heteroaryl, 7- to 14-membered fused aryl, 6- to 14-membered fused heterocyclic group, 6- to 14-membered fused heteroaryl; preferably, ring C is selected from phenyl, 5- to 6-membered heteroaryl, 5- to 8-membered monocyclic heterocyclic group and phenyl, 7- to 10-membered fused heterocyclic group and phenyl, 5- to 8-membered monocyclic heterocyclic group and 5- to 6-membered heteroaryl, 7- to 10-membered fused heterocyclic group and 5- to 6-membered heteroaryl, 5- to 6-membered heteroaryl and phenyl; more preferably, ring C is selected from
[0144] In some embodiments of the present disclosure, the compounds represented by general formula (IA), general formula (I), general formula (I-1), general formula (I-2), general formula (II), general formula (III), general formula (IV), general formula (IV-1), general formula (V), general formula (V-1), their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates or their pharmaceutically acceptable salts, wherein ring C is selected from 5- to 6-membered heteroaryl and 5- to 6-membered heteroaryl.
[0145] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), stereoisomers, isotopic derivatives, prodrugs, nitrogen oxides, solvates, or pharmaceutically acceptable salts thereof, wherein ring C is selected from
[0146] In some embodiments of the present disclosure, the compounds represented by general formula (IA), general formula (I), general formula (I-1), general formula (I-2), general formula (II), general formula (III), general formula (IV), general formula (IV-1), general formula (V), general formula (V-1), their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates or their pharmaceutically acceptable salts, wherein ring C is selected from 7 to 10-membered spiroheterocyclic and phenyl groups.
[0147] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), stereoisomers, isotopic derivatives, prodrugs, nitrogen oxides, solvates, or pharmaceutically acceptable salts thereof, wherein ring C is selected from
[0148] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates or their pharmaceutically acceptable salts, wherein ring C is selected from a 5- to 6-membered heterocyclic group and a phenyl group or a 5- to 6-membered heterocyclic group and a 6-membered heteroaryl group.
[0149] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), stereoisomers, isotopic derivatives, prodrugs, nitrogen oxides, solvates, or pharmaceutically acceptable salts thereof, wherein ring C is selected from
[0150] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), stereoisomers thereof, isotopic derivatives thereof, prodrugs thereof, nitrogen oxides thereof, solvates thereof, or pharmaceutically acceptable salts thereof, wherein each R c are the same or different and are independently selected from hydrogen, halogen, oxo, halogenated C 1-6 Alkyl, cyano, -CONH2, amino, C 1-6 alkyl, 3 to 8 membered cycloalkyl optionally substituted with -CONH2 and optionally substituted with C 1-6 Alkyl-substituted 5- to 6-membered heteroaryl; or two R attached to the same carbon atom or to adjacent carbon atoms c Together with the carbon atom to which it is attached, it forms a 3- to 6-membered cycloalkyl group.
[0151] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), stereoisomers thereof, isotopic derivatives thereof, prodrugs thereof, nitrogen oxides thereof, solvates thereof, or pharmaceutically acceptable salts thereof, wherein each R c are the same or different and are independently selected from hydrogen, halogen, oxo, halogenated C 1-4 Alkyl, cyano, -CONH2, amino, C 1-4 alkyl, 3 to 6 membered cycloalkyl optionally substituted with -CONH2 and optionally substituted with C 1-4 Alkyl-substituted 5- to 6-membered heteroaryl; or two R attached to the same carbon atom or to adjacent carbon atoms c Together with the carbon atom to which it is attached, it forms a 3- to 6-membered cycloalkyl group.
[0152] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), stereoisomers thereof, isotopic derivatives thereof, prodrugs thereof, nitrogen oxides thereof, solvates thereof, or pharmaceutically acceptable salts thereof, wherein each R c The same or different, and each independently selected from hydrogen atom, halogen, hydroxyl, oxo, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONR n2 R n3 、-NR n2 R n3 、C 1-6 Alkyl, C 1-6 Alkoxy, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 3 to 8 membered heterocyclyl and 5 to 6 membered heteroaryl, wherein the 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 3 to 8 membered heterocyclyl and 5 to 6 membered heteroaryl are optionally selected from halogen, hydroxy, hydroxy 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -C(O)NR n4 R n5 、-NR n4 R n5 、C 1-6 Alkyl and C 1-6 The alkoxy group is substituted by one or more substituents, R n2 、R n3 、Rn4 and R n5 As defined in formula (IA); preferably, each R c are the same or different and are each independently selected from hydrogen atom, halogen, C 1-6 Alkyl, oxo, amino, NH(C 1-6 alkyl), N(C 1-6 alkyl) 2, -CONH 2, 3 to 8-membered cycloalkyl, 3 to 8-membered cycloalkenyl, 3 to 8-membered heterocyclyl and 5 to 6-membered heteroaryl, wherein the 3 to 8-membered cycloalkyl, 3 to 8-membered cycloalkenyl, 3 to 8-membered heterocyclyl and 5 to 6-membered heteroaryl are optionally selected from halogen, amino, NH (C 1-6 alkyl), N(C 1-6 alkyl)2, -CONH2 and C 1-6 More preferably, each R c are the same or different and are each independently selected from hydrogen atom, halogen, C 1-6 Alkyl, oxo, amino, NH(C 1-6 alkyl), N(C 1-6 alkyl) 2, -CONH 2, 3 to 8-membered cycloalkyl, 3 to 8-membered cycloalkenyl and 5 to 6-membered heteroaryl, wherein the 3 to 8-membered cycloalkyl, 3 to 8-membered cycloalkenyl and 5 to 6-membered heteroaryl are optionally selected from halogen, amino, NH (C 1-6 alkyl), N(C 1-6 alkyl)2, -CONH2 and C 1-6 The alkyl group is substituted by one or more substituents.
[0153] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), stereoisomers thereof, isotopic derivatives thereof, prodrugs thereof, nitrogen oxides thereof, solvates thereof, or pharmaceutically acceptable salts thereof, wherein each R c The same or different, and each independently selected from hydrogen atom, halogen, hydroxyl, oxo, hydroxyl C 1-4 Alkyl, halogenated C 1-4 Alkyl, halogenated C 1-4 Alkoxy, cyano, amino, -CONR n2 R n3 、-NR n2 R n3 、C 1-4 Alkyl, deuterated C 1-4 Alkyl, C 1-4Alkoxy, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 3 to 8 membered heterocyclyl and 5 to 6 membered heteroaryl, wherein the 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 3 to 8 membered heterocyclyl and 5 to 6 membered heteroaryl are optionally selected from halogen, hydroxy, hydroxy 1-4 Alkyl, halogenated C 1-4 Alkyl, halogenated C 1-4 Alkoxy, cyano, amino, -C(O)NR n4 R n5 、-NR n4 R n5 、C 1-4 Alkyl and C 1-4 The alkoxy group is substituted by one or more substituents, R n2 、R n3 、R n4 and R n5 As defined in general formula (IA).
[0154] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), stereoisomers thereof, isotopic derivatives thereof, prodrugs thereof, nitrogen oxides thereof, solvates thereof, or pharmaceutically acceptable salts thereof, wherein each R c are the same or different and are each independently selected from hydrogen atom, halogen, C 1-4 Alkyl, deuterated C 1-4 Alkyl, oxo, amino, NH(C 1-4 alkyl), N(C 1-4 alkyl) 2, -CONH 2, 3 to 8-membered cycloalkyl, 3 to 8-membered cycloalkenyl, 3 to 8-membered heterocyclyl and 5 to 6-membered heteroaryl, wherein the 3 to 8-membered cycloalkyl, 3 to 8-membered cycloalkenyl, 3 to 8-membered heterocyclyl and 5 to 6-membered heteroaryl are optionally selected from halogen, amino, NH (C 1-4 alkyl), N(C 1-4 alkyl)2, -CONH2 and C 1-4 The alkyl group is substituted by one or more substituents.
[0155] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), stereoisomers thereof, isotopic derivatives thereof, prodrugs thereof, nitrogen oxides thereof, solvates thereof, or pharmaceutically acceptable salts thereof, wherein each R c are the same or different and are each independently selected from hydrogen atom, halogen, C 1-4Alkyl, deuterated C 1-4 Alkyl, oxo, amino, NH(C 1-4 alkyl), N(C 1-4 alkyl) 2, -CONH 2, 3 to 6-membered cycloalkyl, 3 to 6-membered cycloalkenyl and 5 to 6-membered heteroaryl, wherein the 3 to 6-membered cycloalkyl, 3 to 6-membered cycloalkenyl and 5 to 6-membered heteroaryl are optionally selected from halogen, amino, NH (C 1-4 alkyl), N(C 1-4 alkyl)2, -CONH2 and C 1-4 The alkyl group is substituted by one or more substituents.
[0156] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates or their pharmaceutically acceptable salts, wherein the two R c Together with the atoms to which it is attached, it forms a 3- to 6-membered heterocyclic group or a 3- to 6-membered cycloalkyl group.
[0157] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), stereoisomers, isotopic derivatives, prodrugs, nitrogen oxides, solvates, or pharmaceutically acceptable salts thereof, wherein two R c Together with the carbon atom to which it is attached, it forms a 3- to 6-membered cycloalkyl group.
[0158] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates or their pharmaceutically acceptable salts, wherein the two R c Together with the carbon atom to which it is attached, it forms a cyclopropyl group.
[0159] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), stereoisomers thereof, isotopic derivatives thereof, prodrugs thereof, nitrogen oxides thereof, solvates thereof, or pharmaceutically acceptable salts thereof, wherein each R c are the same or different and are each independently selected from hydrogen atom, F, methyl, amino, -CONH2,
[0160] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), stereoisomers thereof, prodrugs thereof, nitrogen oxides thereof, solvates thereof, or pharmaceutically acceptable salts thereof, wherein each R c are the same or different and are each independently selected from cyano, -CHF2, cyclopropyl and Cl.
[0161] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), stereoisomers thereof, prodrugs thereof, nitrogen oxides thereof, solvates thereof, or pharmaceutically acceptable salts thereof, wherein each R c The same or different, and each independently selected from deuterated C 1-4 The alkyl group is preferably a deuterated methyl group, and more preferably -CD3.
[0162] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), stereoisomers thereof, isotopic derivatives thereof, prodrugs thereof, nitrogen oxides thereof, solvates thereof, or pharmaceutically acceptable salts thereof, wherein each R c are the same or different and are each independently selected from hydrogen atom, halogen, C 1-6 The alkyl group is preferably a hydrogen atom, F, or a methyl group.
[0163] In some embodiments of the present disclosure, the compounds represented by general formula (IA), general formula (I), general formula (I-1), general formula (I-2), general formula (II), general formula (III), general formula (IV), general formula (IV-1), general formula (V), general formula (V-1), their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates or their pharmaceutically acceptable salts, wherein p is 0, 1, 2, 3 or 4; preferably, p is 0, 1, 2 or 3; more preferably, p is 0, 1 or 2.
[0164] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), stereoisomers thereof, isotopic derivatives thereof, prodrugs thereof, nitrogen oxides thereof, solvates thereof, or pharmaceutically acceptable salts thereof, wherein each R b The same or different, and each independently selected from hydrogen atom, halogen, hydroxyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -CONR n2 R n3 、-NR n2 R n3 、C 1-6 Alkyl and C 1-6 Alkoxy, R n2 and R n3 As defined in formula (IA); preferably, each R b are the same or different and are each independently selected from hydrogen, halogen and C 1-6 alkyl; more preferably, each R b All are hydrogen atoms.
[0165] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), stereoisomers thereof, isotopic derivatives thereof, prodrugs thereof, nitrogen oxides thereof, solvates thereof, or pharmaceutically acceptable salts thereof, wherein each R b The same or different, and each independently selected from hydrogen atom, halogen, hydroxyl, hydroxyl C 1-4 Alkyl, halogenated C 1-4 Alkyl, halogenated C 1-4 Alkoxy, cyano, -CONR n2 R n3 、-NR n2 R n3 、C 1-4Alkyl and C 1-4 Alkoxy, R n2 and R n3 As defined in formula (IA); preferably, each R b are the same or different and are each independently selected from hydrogen, halogen and C 1-4 alkyl.
[0166] In some embodiments of the present disclosure, the compound represented by general formula (IA), general formula (I), general formula (I-1), general formula (I-2), general formula (II), general formula (III), general formula (IV), general formula (IV-1), general formula (V), general formula (V-1), stereoisomers, isotopic derivatives, prodrugs, nitrogen oxides, solvates or pharmaceutically acceptable salts thereof, wherein n is 0, 1, 2, 3 or 4; preferably, n is 0 or 1. In some embodiments of the present disclosure, the compound represented by general formula (IA), stereoisomers, isotopic derivatives, prodrugs, nitrogen oxides, solvates or pharmaceutically acceptable salts thereof, is a compound represented by general formula (Ia), stereoisomers, isotopic derivatives, prodrugs, nitrogen oxides, solvates or pharmaceutically acceptable salts thereof;
[0167] in:
[0168] X is selected from -CH2-, -O-, -NH-, -S-;
[0169] L is selected from -NR n1 C(O)-、-NR n1 -C(O)-NR n1 -;
[0170] Bond a is a single bond or a double bond;
[0171] When bond a is a single bond, Y and Z are the same or different and are each independently selected from -O-, -NH- and -CR c5 R c6 -;
[0172] When bond a is a double bond, Y and Z are the same and are both selected from CH;
[0173] R c1 Selected from hydrogen atoms, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, 3- to 6-membered heterocyclyl, and 3- to 6-membered cycloalkyl;
[0174] R c2 、R c3 、R c4 、R c5 、R c6are the same or different and are each independently selected from hydrogen atom, halogen, C 1-6 Alkyl and halogenated C 1-6 alkyl;
[0175] R n1 and R is as defined in formula (IA);
[0176] The condition is: when X is -CH2-, It is not -CH2-CH2- at the same time, and -LR is not -NHC(O)-CH2CH3 at the same time.
[0177] In some embodiments of the present disclosure, the compound represented by general formula (Ia), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts, wherein X is selected from -CH2-, -O-.
[0178] In some embodiments of the present disclosure, the compound represented by the general formula (Ia), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts, wherein when bond a is a single bond, one of Y and Z is selected from -O-, and the other is selected from -CR c5 R c6 -;R c5 and R c6 As defined in general formula (Ia).
[0179] In some embodiments of the present disclosure, the compound represented by the general formula (Ia), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts, wherein R c2 、R c3 、R c4 、R c5 、R c6 are the same or different and are each independently selected from hydrogen atom, halogen, C 1-4 Alkyl and halogenated C 1-4 Alkyl; preferably, R c2 、R c3 、R c4 、R c5 、R c6 are the same or different and are each independently selected from a hydrogen atom, F, Cl, -CHF2 and a methyl group.
[0180] In some embodiments of the present disclosure, the compound represented by the general formula (Ia), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or its pharmaceutically acceptable salts, wherein R c1 Selected from hydrogen atoms, C 1-4 Alkyl, deuterated C 1-4 Alkyl, halogenated C1-4 alkyl, 3 to 6 membered heterocyclic group and 3 to 6 membered cycloalkyl; preferably, R c1 is selected from hydrogen, cyclopropyl, methyl and deuterated methyl; more preferably, R c1 is selected from methyl and deuterated methyl; further preferably, R c1 is selected from methyl and -CD3; further preferably, R c1 Selected from methyl.
[0181] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), stereoisomers, isotopic derivatives, prodrugs, nitrogen oxides, solvates, or pharmaceutically acceptable salts thereof, wherein L is selected from -NR n1 -、-NR n1 C(O)-、-NR n1 -C(O)-NR n1 -and-CR d =CR e -;R n1 、R d 、R e As defined in formula (IA); R is selected from C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, cyclopropyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, deuterated C 1-6 Alkoxy and C 1-6 Alkoxy C 1-6 Alkyl; or R n1 and the atoms to which R is attached together form a 3- to 8-membered heterocyclic group or a 5- to 10-membered heteroaryl group; or R b and R and the atoms to which it is attached together form a 3- to 6-membered heterocyclic group;
[0182] wherein the 3 to 8-membered heterocyclic group, the 3 to 6-membered heterocyclic group and the 5 to 10-membered heteroaryl are each independently selected from halogen, hydroxyl, hydroxyl, 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 substituted by one or more substituents in the alkoxy group;
[0183] Preferably, L is selected from -NR n1C(O)-、-NR n1 -C(O)-NR n1 -and-CR d =CR e -;R n1 Selected from hydrogen atoms, C 1-6 Alkyl and deuterated C 1-6 Alkyl, R d 、R e are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl and halogen, R is selected from C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, cyclopropyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, deuterated C 1-6 Alkoxy and C 1-6 Alkoxy C 1-6 Alkyl; or R n1 and the atoms to which R is attached together form a 5- to 8-membered heterocyclic group; or R b and R and the atoms connected thereto together form a 5- to 6-membered heterocyclic group; wherein the 5- to 8-membered heterocyclic group and the 5- to 6-membered heterocyclic group are each independently optionally selected from halogen, hydroxyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 substituted by one or more substituents in the alkoxy group;
[0184] More preferably, L is selected from -NR n1 C(O)-、-NR n1 -C(O)-NR n1 -and-CR d =CR e -;R n1 Selected from hydrogen atoms, C 1-6 Alkyl and deuterated C 1-6 Alkyl, R d 、R e are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl and halogen, R is selected from C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, cyclopropyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, deuterated C 1-6 Alkoxy and C1-6 Alkoxy C 1-6 Alkyl; or R n1 Together with R and the atoms it is connected to, or R b Together with R and the atoms it is connected to, Each R f and R g The same or different, and each independently selected from hydrogen atom, halogen, hydroxyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl, C 1-6 Alkoxy, t is 0, 1, 2, 3 or 4, and u is 0, 1, 2, 3, 4 or 5;
[0185] More preferably, L is selected from -NHC(O)-, -NH-C(O)-NH-, -NH-C(O)-N(CH3)-, -NH-C(O)-N(CD3)- and -CH=CF-; R is selected from C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, deuterated C 1-6 Alkoxy and C 1-6 Alkoxy C 1-6 Alkyl; or R n1 Together with R and the atoms it is connected to, or R b Together with R and the atoms it is connected to,
[0186] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), stereoisomers, isotopic derivatives, prodrugs, nitrogen oxides, solvates, or pharmaceutically acceptable salts thereof, wherein L is selected from -NR n1 -、-NR n1 C(O)-、-NR n1 -C(O)-NR n1 -and-CR d =CR e -;R n1 、R d 、R e As defined in formula (IA); R is selected from C 1-6Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl and cyclopropyl; or R n1 and the atoms to which R is attached together form a 3- to 6-membered heterocyclic group or a 5- to 10-membered heteroaryl group; or R b and R and the atoms to which it is attached together form a 3- to 6-membered heterocyclic group;
[0187] wherein the 3 to 6 membered heterocyclic group or the 5 to 10 membered heteroaryl group are each independently selected from halogen, hydroxyl, hydroxyl, 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 substituted by one or more substituents in the alkoxy group;
[0188] Preferably, L is selected from -NR n1 C(O)-、-NR n1 -C(O)-NR n1 -and-CR d =CR e -;R n1 Selected from hydrogen atoms and C 1-6 Alkyl, R d 、R e are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl and halogen, R is selected from C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl and cyclopropyl; or R n1 and the atoms to which R is attached together form a 5- to 6-membered heterocyclic group; or R b and R and the atoms to which it is connected together form a 5- to 6-membered heterocyclic group; wherein the 5- to 6-membered heterocyclic group is independently optionally selected from halogen, hydroxyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 substituted by one or more substituents in the alkoxy group;
[0189] More preferably, L is selected from -NR n1 C(O)-、-NR n1 -C(O)-NR n1-and-CR d =CR e -;R n1 Selected from hydrogen atoms and C 1-6 Alkyl, R d 、R e are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl and halogen, R is selected from C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl and cyclopropyl; or R n1 Together with R and the atoms it is connected to, or R b Together with R and the atoms it is connected to, Each R f and R g The same or different, and each independently selected from hydrogen atom, halogen, hydroxyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 Alkoxy, t is 0, 1, 2, 3 or 4, u is 0, 1, 2, 3, 4 or 5; more preferably, L is selected from -NHC(O)-, -NH-C(O)-NH- and -CH=CF-; R is selected from C 1-6 Alkyl or C 1-6 Alkoxy; or R n1 Together with R and the atoms it is connected to, or R b Together with R and the atoms it is connected to,
[0190] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), stereoisomers, isotopic derivatives, prodrugs, nitrogen oxides, solvates, or pharmaceutically acceptable salts thereof, wherein L is selected from -NR n1 -、-NR n1 C(O)-、-NR n1 -C(O)-NR n1 -and-CR d =CR e -;R n1 、R d 、R eAs defined in the general formula (IA); R is selected from the group consisting of halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl and C 1-6 Alkoxy C 1-6 Alkyl; preferably, L is selected from -NR n1 C(O)-、-NR n1 -C(O)-NR n1 -and-CR d =CR e -;R n1 Selected from hydrogen atoms and C 1-6 Alkyl, R d 、R e are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl and halogen, R is selected from haloC 1-6 Alkyl, deuterated C 1-6 Alkyl and C 1-6 Alkoxy C 1-6 Alkyl; More preferably, L is selected from -NHC(O)-, -NH-C(O)-NH- and -CH=CF-; R is selected from halo-C 1-6 Alkyl, deuterated C 1-6 Alkyl and C 1-6 Alkoxy C 1-6 alkyl.
[0191] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), stereoisomers, isotopic derivatives, prodrugs, nitrogen oxides, solvates, or pharmaceutically acceptable salts thereof, wherein L is selected from -NR n1 -、-NR n1 C(O)-、-NR n1 -C(O)-NR n1 -、-CR d =CR e -;R n1 、R d 、R e As defined in formula (IA); preferably, L is selected from -NR n1 C(O)-、-NR n1 -C(O)-NR n1 -、-CR d =CR e -;R n1 Selected from hydrogen atoms and C 1-6 Alkyl, R d and R e are the same or different and are each independently selected from hydrogen, halogen and C1-6 Alkyl; more preferably, L is selected from -NHC(O)-, -NH-C(O)-NH-, -CH=CF-.
[0192] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), stereoisomers, isotopic derivatives, prodrugs, nitrogen oxides, solvates, or pharmaceutically acceptable salts thereof, wherein L is selected from -NR n1 C(O)-、-NR n1 -C(O)-NR n1 -and-CR d =CR e -;R n1 Selected from hydrogen atoms, C 1-6 Alkyl and deuterated C 1-6 Alkyl, R d 、R e are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl and halogen.
[0193] In some embodiments of the present disclosure, the compounds represented by general formula (IA), general formula (I), general formula (II), general formula (III), general formula (IV), general formula (IV-1), general formula (V), general formula (V-1), general formula (Ia), their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates or their pharmaceutically acceptable salts, wherein L is -NH-C(O)-N(CH3)- or -NH-C(O)-N(CD3)-.
[0194] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), stereoisomers, isotopic derivatives, prodrugs, nitrogen oxides, solvates, or pharmaceutically acceptable salts thereof, wherein L is selected from -NR n1 C(O)-、-NR n1 -C(O)-NR n1 -;R n1 Selected from hydrogen atoms, C 1-6 Alkyl and deuterated C 1-6 alkyl.
[0195] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), stereoisomers, isotopic derivatives, prodrugs, nitrogen oxides, solvates, or pharmaceutically acceptable salts thereof, wherein L is selected from -NR n1 C(O)-、-NR n1 -C(O)-NR n1 -;R n1 Selected from hydrogen atoms, C 1-4 Alkyl and deuterated C 1-4 alkyl.
[0196] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), stereoisomers thereof, isotopic derivatives thereof, prodrugs thereof, nitrogen oxides thereof, solvates thereof, or pharmaceutically acceptable salts thereof, wherein L is selected from -NHC(O)-, -NH-C(O)-NH-, -NH-C(O)-N(CH3)-, and -NH-C(O)-N(CD3)-.
[0197] In some embodiments of the present disclosure, the compounds represented by general formula (IA), general formula (I), general formula (II), general formula (III), general formula (IV), general formula (IV-1), general formula (V), general formula (V-1), general formula (Ia), stereoisomers thereof, isotopic derivatives thereof, prodrugs thereof, nitrogen oxides thereof, solvates thereof, or pharmaceutically acceptable salts thereof, wherein L is selected from -NHC(O)-.
[0198] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), stereoisomers thereof, isotopic derivatives thereof, prodrugs thereof, nitrogen oxides thereof, solvates thereof, or pharmaceutically acceptable salts thereof, wherein R is selected from C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, cyclopropyl; preferably, R is selected from C 1-6 Alkyl or C 1-6 Alkoxy; more preferably, R is selected from methyl, ethyl and methoxy.
[0199] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), stereoisomers thereof, isotopic derivatives thereof, prodrugs thereof, nitrogen oxides thereof, solvates thereof, or pharmaceutically acceptable salts thereof, wherein R is selected from halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 1-6 Alkyl, C 1-6 Alkoxy and deuterated C 1-6 Alkoxy.
[0200] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), stereoisomers thereof, isotopic derivatives thereof, prodrugs thereof, nitrogen oxides thereof, solvates thereof, or pharmaceutically acceptable salts thereof, wherein R is selected from halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl; preferably, R is selected from
[0201] In some embodiments of the present disclosure, the compounds represented by general formula (IA), general formula (I), general formula (I-1), general formula (I-2), general formula (II), general formula (III), general formula (IV), general formula (IV-1), general formula (V), general formula (V-1), general formula (Ia), their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates or their pharmaceutically acceptable salts, wherein R is selected from ethyl, methyl and methoxy.
[0202] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), stereoisomers, isotopic derivatives, prodrugs, nitrogen oxides, solvates, or pharmaceutically acceptable salts thereof, wherein R is selected from halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 1-6 Alkyl, C 1-6Alkoxy and deuterated C 1-6 Alkoxy.
[0203] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), stereoisomers, isotopic derivatives, prodrugs, nitrogen oxides, solvates, or pharmaceutically acceptable salts thereof, wherein R n1 Selected from hydrogen atoms, C 1-6 Alkyl and deuterated C 1-6 alkyl.
[0204] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), stereoisomers, isotopic derivatives, prodrugs, nitrogen oxides, solvates, or pharmaceutically acceptable salts thereof, wherein R is selected from C 1-4 Alkyl, C 1-4 Alkoxy, hydroxy C 1-4 Alkyl, cyclopropyl, halogenated C 1-4 Alkyl, deuterated C 1-4 Alkyl, deuterated C 1-4 Alkoxy and C 1-4 Alkoxy C 1-4 alkyl.
[0205] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), stereoisomers, isotopic derivatives, prodrugs, nitrogen oxides, solvates, or pharmaceutically acceptable salts thereof, wherein R is selected from halogenated C 1-4 Alkyl, deuterated C 1-4 Alkyl, C 1-4 Alkoxy C 1-4 Alkyl, C 1-4 Alkyl, C 1-4 Alkoxy and deuterated C 1-4 Alkoxy; preferably, R is selected from Ethyl, methyl, methoxy and
[0206] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), stereoisomers, isotopic derivatives, prodrugs, nitrogen oxides, solvates, or pharmaceutically acceptable salts thereof, wherein R is selected from C 1-4 Alkyl; preferably, R is selected from ethyl.
[0207] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), stereoisomers, isotopic derivatives, prodrugs, nitrogen oxides, solvates, or pharmaceutically acceptable salts thereof, wherein R is selected from deuterated C 1-4 Alkoxy; preferably, R is selected from
[0208] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), stereoisomers thereof, isotopic derivatives thereof, prodrugs thereof, nitrogen oxides thereof, solvates thereof, or pharmaceutically acceptable salts thereof, wherein R is selected from C 1-4 Alkyl, C 1-4 Alkoxy, deuterated C 1-4 Alkoxy, preferably ethyl, methoxy, deuterated methoxy, more preferably ethyl,
[0209] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), stereoisomers, isotopic derivatives, prodrugs, nitrogen oxides, solvates, or pharmaceutically acceptable salts thereof, wherein R n1 and R and the atoms to which it is attached together form an optionally C 1-6 Alkyl-substituted 3- to 8-membered heterocyclic group; wherein the 3- to 8-membered heterocyclic group is selected from a 5- to 6-membered monocyclic heterocyclic group, a 5- to 8-membered spiro heterocyclic group and a 5- to 8-membered fused heterocyclic group.
[0210] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), stereoisomers, isotopic derivatives, prodrugs, nitrogen oxides, solvates, or pharmaceutically acceptable salts thereof, wherein R n1 Together with R and the atoms it is connected to,
[0211] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), stereoisomers thereof, isotopic derivatives thereof, prodrugs thereof, nitrogen oxides thereof, solvates thereof, or pharmaceutically acceptable salts thereof, wherein R n1 and the atoms to which R is attached together form a 3- to 6-membered heterocyclic group or a 5- to 10-membered heteroaryl group; or R b and R and the atoms to which it is connected together form a 3- to 6-membered heterocyclic group, wherein the 3- to 6-membered heterocyclic group or the 5- to 10-membered heteroaryl group are each independently optionally selected from halogen, hydroxyl, hydroxyl, 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 More preferably, R n1 and the atoms to which R is attached together form a 5- to 6-membered heterocyclic group; or R b and R and the atoms to which it is connected together form a 5- to 6-membered heterocyclic group, wherein the 5- to 6-membered heterocyclic group is independently optionally selected from halogen, hydroxy, hydroxyl, 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 is substituted by one or more substituents in the alkoxy group; further preferably, R n1 Together with R and the atoms it is connected to, or R b Together with R and the atoms it is connected to, Each Rf and R g The same or different, and each independently selected from hydrogen atom, halogen, hydroxyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 Alkoxy, t is 0, 1, 2, 3 or 4, u is 0, 1, 2, 3, 4 or 5; More preferably, R n1 Together with R and the atoms it is connected to, or R b Together with R and the atoms it is connected to,
[0212] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), stereoisomers, isotopic derivatives, prodrugs, nitrogen oxides, solvates, or pharmaceutically acceptable salts thereof, wherein the structural unit Selected from
[0213] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), stereoisomers, isotopic derivatives, prodrugs, nitrogen oxides, solvates, or pharmaceutically acceptable salts thereof, wherein the structural unit Selected from
[0214] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), stereoisomers, isotopic derivatives, prodrugs, nitrogen oxides, solvates, or pharmaceutically acceptable salts thereof, wherein the structural unit Selected from
[0215] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (II), formula (III), formula (IV), and formula (V), their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates, or their pharmaceutically acceptable salts, wherein the structural unit Selected from
[0216] In some embodiments of the present disclosure, the compounds represented by the general formula (IV-1), general formula (V-1), general formula (Ia), their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates or their pharmaceutically acceptable salts, wherein the structural unit Selected from
[0217] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (II), formula (III), formula (IV), and formula (V), their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates, or their pharmaceutically acceptable salts, wherein the structural unit Selected from
[0218] In some embodiments of the present disclosure, the compounds represented by the general formula (IV-1), general formula (V-1), general formula (Ia), their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates or their pharmaceutically acceptable salts, wherein the structural unit Selected from
[0219] In some embodiments of the present disclosure, the compound represented by the general formula (I-1) or the general formula (I-2), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts, wherein ring C is selected from 5-8 membered monocyclic heterocyclic phenyl, 7-10 membered fused heterocyclic phenyl, 7-10 membered spiro heterocyclic phenyl, 5-8 membered monocyclic heterocyclic 5-6 membered heteroaryl, 7-10 membered fused heterocyclic 5-6 membered heteroaryl, 5-6 membered heteroaryl phenyl; each R c are the same or different and are independently selected from hydrogen, halogen, oxo, halogenated C 1-6 Alkyl, cyano, amino, C 1-6 Alkyl, 3 to 6 membered cycloalkyl, p is 0, 1, 2, 3 or 4; R b Selected from hydrogen atoms, halogens, C 1-6 Alkyl, n is 0 or 1; R is selected from halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy C1-6 Alkyl, C 1-6 Alkyl, C 1-6 Alkoxy and deuterated C 1-6 Alkoxy; R n1 Selected from hydrogen atoms, C 1-6 Alkyl and deuterated C 1-6 alkyl.
[0220] In some embodiments of the present disclosure, the compound represented by the general formula (I-1) or the general formula (I-2), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or its pharmaceutically acceptable salts, wherein ring C is selected from 5 to 8-membered monocyclic heterocyclic phenyl groups; each R c are the same or different and are independently selected from hydrogen, halogen, oxo, C 1-6 Alkyl, p is 0, 1, 2, 3 or 4; R b is selected from hydrogen atoms; R is selected from C 1-6 Alkyl and deuterated C 1-6 Alkoxy; R n1 Selected from hydrogen atoms.
[0221] In some embodiments of the present disclosure, the compound represented by the general formula (I-1) or the general formula (I-2), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or its pharmaceutically acceptable salts, wherein ring C is selected from 5 to 8-membered monocyclic heterocyclic phenyl groups; each R c are the same or different and are independently selected from hydrogen, halogen, oxo, C 1-6 Alkyl, p is 0, 1, 2 or 3; R b is selected from hydrogen atom; R is selected from ethyl group and -OCD3; R n1 Selected from hydrogen atoms.
[0222] In some embodiments of the present disclosure, the compound represented by general formula (Ia), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts, wherein X is selected from -CH2-, -O-; L is selected from -NHC(O)-, -NH-C(O)-NH-; bond a is a single bond or a double bond; when bond a is a single bond, Y and Z are the same or different and are each independently selected from -O- and -CH2-; when bond a is a double bond, Y and Z are the same and are both selected from CH; R c1 Selected from hydrogen atoms, C 1-6 Alkyl, halogenated C 1-6 alkyl, 3- to 6-membered heterocyclic group, and 3- to 6-membered cycloalkyl; R c2 、R c3 、R c4 are the same or different and are each independently selected from hydrogen atom, halogen, C 1-6 Alkyl and halogenated C1-6 Alkyl; R is selected from Ethyl, methyl, methoxy and The condition is: when X is -CH2-, It is not -CH2-CH2- at the same time, and -LR is not -NHC(O)-CH2CH3 at the same time.
[0223] In some embodiments of the present disclosure, the compound represented by the general formula (Ia), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts thereof, wherein X is selected from -CH2-, -O-; L is selected from -NHC(O)-; bond a is a double bond, Y and Z are the same and are both selected from CH; R c1 Selected from hydrogen atoms, C 1-6 Alkyl; R c2 、R c3 、R c4 are the same or different and are each independently selected from hydrogen atom, halogen, C 1-6 Alkyl; R is selected from Ethyl, methyl, methoxy and
[0224] In some embodiments of the present disclosure, the compound represented by the general formula (Ia), its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts thereof, wherein X is selected from -CH2-, -O-; L is selected from -NHC(O)-; bond a is a double bond, Y and Z are the same and are both selected from CH; R c1 Selected from methyl; R c2 Selected from hydrogen atoms, halogens, C 1-6 Alkyl; R c3 、R c4 are the same and are selected from hydrogen atoms; R is selected from Ethyl, methyl, methoxy and
[0225] The present disclosure also provides the following compounds, their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates, or their pharmaceutically acceptable salts, wherein typical compounds of the present disclosure include but are not limited to any one of the structures, their prodrugs, their nitrogen oxides, their solvates, or their pharmaceutically acceptable salts in Table 1 below:
[0226] Table 1
[0227] Another aspect of the present disclosure relates to a pharmaceutical composition, comprising compounds of the present disclosure represented by formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), and Table 1, stereoisomers thereof, isotopic derivatives thereof, prodrugs thereof, nitrogen oxides thereof, solvates thereof, or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable carriers.
[0228] The present disclosure further relates to the use of compounds of formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia) and shown in Table 1, their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates or their pharmaceutically acceptable salts, or pharmaceutical compositions containing the same in the preparation of drugs for inhibiting CYP11B2, preferably in the preparation of drugs for selectively inhibiting CYP11B2.
[0229] The present disclosure further relates to the use of compounds of formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia) and shown in Table 1, their stereoisomers, isotopic derivatives, prodrugs, nitrogen oxides, solvates or pharmaceutically acceptable salts thereof, or pharmaceutical compositions containing the same in the preparation of medicaments for treating and / or preventing CYP11B2-mediated diseases.
[0230] The present disclosure also relates to a method for inhibiting CYP11B2, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), and compounds shown in Table 1, stereoisomers thereof, isotopic derivatives thereof, prodrugs thereof, nitrogen oxides thereof, solvates thereof, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising the same.
[0231] The present disclosure also relates to a method for treating and / or preventing CYP11B2-mediated diseases, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia), and compounds shown in Table 1, stereoisomers thereof, isotopic derivatives thereof, prodrugs thereof, nitrogen oxides thereof, solvates thereof, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising the same.
[0232] The present disclosure further relates to a compound of formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia) and shown in Table 1, its stereoisomers, its isotopic derivatives, its prodrugs, its nitrogen oxides, its solvates or pharmaceutically acceptable salts, or pharmaceutical compositions containing the same, which are used as drugs.
[0233] The present disclosure further relates to compounds of formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia) and shown in Table 1, their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates or their pharmaceutically acceptable salts, or pharmaceutical compositions containing the same, which are used as CYP11B2 inhibitors, preferably as CYP11B2 selective inhibitors.
[0234] The present disclosure further relates to compounds of formula (IA), formula (I), formula (I-1), formula (I-2), formula (II), formula (III), formula (IV), formula (IV-1), formula (V), formula (V-1), formula (Ia) and shown in Table 1, their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates or their pharmaceutically acceptable salts, or pharmaceutical compositions containing the same, for use in treating and / or preventing CYP11B2-mediated diseases.
[0235] Preferably, the diseases described above in the present disclosure are selected from hypertension, chronic kidney disease, diabetic nephropathy, primary aldosteronism, chronic kidney disease, and diabetic nephropathy; the hypertension is preferably selected from refractory hypertension, uncontrolled hypertension, low renin hypertension, and essential hypertension.
[0236] The active compound may be formulated for administration by any appropriate route, preferably in a unit dosage form, or in a form that a patient can self-administer as a single dose. A unit dosage form of a compound or composition of the present disclosure may be in the form of a tablet, capsule, cachet, bottled solution, powder, granules, lozenge, suppository, reconstituted powder, or liquid formulation.
[0237] The pharmaceutical compositions of the present disclosure may contain, in addition to the active compound, one or more excipients selected from the group consisting of fillers (diluents), binders, wetting agents, disintegrants, and excipients. Depending on the method of administration, the composition may contain 0.1 to 99% by weight of the active compound; preferably, the composition may contain 1 to 95% by weight of the active compound.
[0238] Pharmaceutical compositions containing the active ingredient may be in a form suitable for oral administration, such as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Oral compositions may be prepared according to any method known in the art for preparing pharmaceutical compositions, and such compositions may contain one or more ingredients selected from the group consisting of sweeteners, flavoring agents, colorants, and preservatives to provide a pleasing and palatable pharmaceutical formulation. Tablets contain the active ingredient and, in admixture, nontoxic, pharmaceutically acceptable excipients suitable for tablet preparation. These excipients may include inert excipients, granulating agents, disintegrants, binders, and lubricants. These tablets may be uncoated or coated using known techniques that mask the taste of the drug or delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained-release effect over a longer period of time.
[0239] As is well known to those skilled in the art, the dosage of a drug depends on a variety of factors, including but not limited to the following: the activity of the specific compound used, the age of the patient, the weight of the patient, the health status of the patient, the behavior of the patient, the diet of the patient, the time of administration, the mode of administration, the rate of excretion, the combination of drugs, the severity of the disease, etc.; in addition, the optimal treatment method such as the mode of treatment, the daily dosage of the compound or the type of pharmaceutically acceptable salt can be verified according to traditional treatment regimens.
[0240] Terminology
[0241] Unless otherwise specified, the following terms and phrases used herein are intended to have the following meanings. A particular term or phrase should not be considered ambiguous or unclear without a specific definition, but should be understood according to its ordinary meaning.
[0242] "Optional" or "optionally" means that the event or circumstances described subsequently may but need not occur, and includes both situations in which the event or circumstances occur and do not occur. For example, "alkyl optionally (optionally) substituted with halogen or cyano" includes both situations in which the alkyl is substituted with halogen or cyano and situations in which the alkyl is not substituted with halogen and cyano.
[0243] Unless otherwise specified, the term "alkyl" refers to a group derived from a branched or straight chain saturated aliphatic alkane having the specified number of carbon atoms by removing one hydrogen. For example, "C 1-10 "Alkyl" refers to C1, C2, C3, C4, C5, C6, C7, C8, C9, C 10 Alkyl, "C 1-6 Alkyl", "C 1-4 Alkyl", "C 1-3 "Alkyl"; specific examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, sec-butyl, 2-methylbutyl, 1,1-dimethylbutyl, etc. The alkyl group may be substituted or unsubstituted. When substituted, it may be substituted at any available point of attachment, and the substituent is preferably selected from one or more of a D atom, a halogen, an alkoxy group, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclyloxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a cycloalkenyl group, a heterocyclyl group, an aryl group, and a heteroaryl group.
[0244] Unless otherwise specified, the term "haloalkyl" refers to an alkyl group in which one or more hydrogen atoms are replaced by a halogen atom, wherein alkyl is as defined above. 1-6 Examples of haloalkyl groups include, but are not limited to, monofluoromethyl, difluoromethyl, trifluoromethyl, trichloromethyl, tribromomethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl, and the like. Alkyl groups are as defined above.
[0245] Unless otherwise specified, the term "hydroxyalkyl" refers to a group derived from an alkyl group in which one or more hydrogen atoms are replaced by a hydroxyl group, wherein the definition of alkyl is as described above. The "hydroxyalkyl" described in the present disclosure includes "hydroxy C 1-6 Alkyl", "Hydroxy C 1-4 alkyl"; specific examples include but are not limited to -CH2OH, -CH2CH2OH, -CH(OH)CH3, -CH2CH2CH2OH, wait.
[0246] Unless otherwise specified, the term "alkoxy" refers to an alkyl group as defined herein attached to another group through an oxygen atom, i.e., "-O-(alkyl)", wherein alkyl is as defined above. 1-6 Alkoxy" (structure is C 1-6 Alkyl-O-), "C 1-4"alkoxy", specific examples include but are not limited to methoxy, ethoxy, propoxy, 1-methylethoxy, butoxy, 2-methylbutoxy, 3-methylbutoxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy, etc.; preferably, the "alkoxy" described in the present disclosure is preferably C 1-6 Alkoxy, more preferably C 1-4 Alkoxy. Alkoxy groups may be substituted or unsubstituted. When substituted, they may be substituted at any available point of attachment, and the substituents are preferably selected from one or more of a D atom, a halogen, an alkoxy group, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclyloxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a cycloalkenyl group, a heterocyclyl group, an aryl group, and a heteroaryl group.
[0247] Unless otherwise specified, the term "haloalkoxy" refers to a group obtained by replacing one or more hydrogen atoms in an alkoxy group with halogen atoms, wherein the definition of alkoxy is as described above. Preferably, the "haloalkoxy" described in the present disclosure is preferably a "haloC 1-6 Alkoxy", "halogenated C 1-4 Alkoxy". Specific examples of the present disclosure include: fluoromethoxy (including monofluoromethoxy, difluoromethoxy, trifluoromethoxy), -OCH2CF3, -OCHFCH3, etc.
[0248] Unless otherwise specified, the term "alkenyl" refers to a group derived from a straight-chain or branched alkene (or an alkyl group containing at least one carbon-carbon double bond, wherein the definition of alkyl is as described above) by removing a hydrogen atom, including "C 2-6 Alkenyl", "C 2-5 Alkenyl", "C 2-4 Alkenyl", "C 2-3 "Alkenyl", specific examples include but are not limited to: -CH=CH2, -CH=CHCH3, -C(CH2)=CH2, -CH=CHCH2CH3, -CH2CH=CHCH3, etc. Alkenyl can be substituted or unsubstituted. When substituted, it can be substituted at any available connection point. The substituent is preferably selected from one or more of D atom, alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, cycloalkenyl, heterocyclyl, aryl and heteroaryl.
[0249] Unless otherwise specified, the term "alkynyl" refers to a radical derived from a straight-chain or branched alkyne (or an alkyl group containing at least one carbon-carbon triple bond, wherein alkyl is as defined above) by removing a hydrogen atom, including "C 2-5 Alkynyl", "C 2-4 Alkynyl", "C 2-3"Alkynyl", specific examples include but are not limited to: -C≡CH, -C≡CHCH3, CH≡CHCH2-, CH≡CC≡C-, etc. Alkynyl can be substituted or unsubstituted. When substituted, it can be substituted at any available connection point, and the substituent is preferably selected from one or more of D atom, alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, cycloalkenyl, heterocyclyl, aryl and heteroaryl.
[0250] Unless otherwise specified, the term "hetero" refers to substituted or unsubstituted heteroatoms and oxidized forms of heteroatoms (also known as heteroatoms). The heteroatoms are generally selected from N, O, S, and P. Oxidized forms generally include NO, SO, S(O)2, and P(O). The nitrogen atom can be substituted, i.e., NR (R is H or other substituents defined herein). The number of atoms in the ring is generally defined as the number of ring members. For example, "3-6 membered heterocycloalkyl" refers to a ring of 3-6 atoms arranged around, each ring optionally containing 1 to 3 heteroatoms and / or heteroatoms, i.e., N, O, S, NO, SO, S(O)2, P(O) or NR, each ring optionally substituted by an R group, where R is a group defined herein.
[0251] Unless otherwise specified, the term "cycloalkyl" refers to a saturated cyclic alkyl group derived from a cycloalkane by removing a hydrogen atom, including monocyclic or polycyclic saturated hydrocarbon groups. Polycyclic saturated hydrocarbon groups refer to polycyclic groups formed by two or more cyclic alkyl structures connected by spiro, bridged, or fused structures. Carbon atoms in the cycloalkyl group may be further oxidized, forming C(O). Unless otherwise specified, "one-membered cycloalkyl" as used herein refers to a monocyclic cycloalkyl group. When polycyclic, it will be specifically indicated as a spiro, fused, or bridged ring group. Cycloalkyl groups include "3- to 8-membered cycloalkyl," "3- to 8-membered monocyclic cycloalkyl," "3- to 6-membered cycloalkyl," and "3- to 5-membered cycloalkyl." Preferably, the cycloalkyl group is a monocyclic, saturated structure; specific examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
[0252] Unless otherwise specified, "cycloalkenyl" means that one or more of the ring bonds in a "cycloalkyl" is a double bond and the cycloalkenyl is not aromatic. The carbon atoms in the cycloalkenyl may be further oxidized, i.e., to form C(O). The cycloalkenyl includes "3- to 8-membered cycloalkenyl", "3- to 8-membered monocyclic cycloalkenyl", "3- to 6-membered cycloalkenyl", "3- to 5-membered cycloalkenyl", and "5- to 6-membered cycloalkenyl". Specific examples include, but are not limited to
[0253] The term "spirocyclyl" refers to a polycyclic ring system in which the rings share a carbon atom (called a spiro atom), which may contain one or more double bonds within the ring, or one or more heteroatoms selected from nitrogen, oxygen, and sulfur (the nitrogen may be optionally oxidized to form a nitrogen oxide; the sulfur may be optionally oxidized to form a sulfoxide or sulfone, but does not include -OO-, -OS-, or -SS-), provided that it contains at least one all-carbon non-aromatic ring and the point of attachment is on the all-carbon non-aromatic ring, and has 5 to 10 (e.g., 5, 6, 7, 8, 9, 10) ring atoms (i.e., a 5- to 10-membered spirocyclyl). The spirocyclyl is preferably a spirocyclyl having 6 to 10 ring atoms (i.e., a 6- to 10-membered spirocyclyl), and more preferably a spirocyclyl having 7 to 10 ring atoms (i.e., a 7- to 10-membered spirocyclyl). The spirocyclic radical includes a monospirocyclic radical and a polyspirocyclic radical (such as a bispirocyclic radical, etc.), preferably a monospirocyclic radical or a bispirocyclic radical, more preferably a 3-membered / 4-membered, 3-membered / 5-membered, 3-membered / 6-membered, 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 3-membered, 5-membered / 4-membered, 5-membered / 5-membered, 5-membered / 6-membered, 5-membered / 7-membered, 6-membered / 3-membered, 6-membered / 4-membered, 6-membered / 5-membered, 6-membered / 6-membered, 6-membered / 7-membered, 7-membered / 5-membered or 7-membered / 6-membered monospirocyclic radical. Non-limiting examples include:
[0254] Its connection point can be at any position;
[0255] wait.
[0256] The term "fused cyclyl" refers to a polycyclic ring system in which two adjacent carbon atoms are shared between the rings, and is a monocyclic cycloalkyl fused to one or more monocyclic cycloalkyls, or a monocyclic cycloalkyl fused to one or more of a cycloalkenyl, heterocyclyl, aryl or heteroaryl, wherein the point of attachment is on an all-carbon non-aromatic ring, which may contain one or more double bonds within the ring and has 5 to 14 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14) ring atoms (i.e., a 5- to 14-membered fused cyclyl). The fused cyclyl is preferably a fused cyclyl having 6 to 14 ring atoms (i.e., a 6- to 14-membered fused cyclyl), preferably a fused cyclyl having 6 to 10 ring atoms (i.e., a 6- to 10-membered fused cyclyl), more preferably a fused cyclyl having 7 to 10 ring atoms (i.e., a 7- to 10-membered fused cyclyl, including a 7-membered fused cyclyl). The fused ring group includes a bicyclic fused ring group and a polycyclic fused ring group (such as a tricyclic fused ring group, a tetracyclic fused ring group, etc.), preferably a bicyclic fused ring group or a tricyclic fused ring group, more preferably a 3-membered / 4-membered, 3-membered / 5-membered, 3-membered / 6-membered, 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 3-membered, 5-membered / 4-membered, 5-membered / 5-membered, 5-membered / 6-membered, 5-membered / 7-membered, 6-membered / 3-membered, 6-membered / 4-membered, 6-membered / 5-membered, 6-membered / 6-membered, 6-membered / 7-membered, 7-membered / 5-membered or 7-membered / 6-membered bicyclic fused ring group. Non-limiting examples include:
[0257] Its connection point can be at any position; wait.
[0258] The term "bridged ring group" refers to a full carbon polycyclic ring system that shares two carbon atoms that are not directly connected between the rings, which may contain one or more double bonds in the ring and has 5 to 10 (e.g., 5, 6, 7, 8, 9, 10) carbon atoms (i.e., 5 to 10-membered bridged ring groups). The bridged ring group preferably has a bridged ring group of 6 to 10 carbon atoms (i.e., 6 to 10-membered bridged ring groups), and more preferably has a bridged ring group of 7 to 10 carbon atoms (i.e., 7 to 10-membered bridged ring groups, including 7-membered bridged ring groups). The bridged ring group includes a bicyclic bridged ring group and a polycyclic bridged ring group (such as a tricyclic bridged ring group, a tetracyclic bridged ring group, etc.), preferably a bicyclic bridged ring group or a tricyclic bridged ring group. Non-limiting examples include:
[0259] Its connection point can be at any position.
[0260] Unless otherwise specified, the term "heterocyclyl" refers to a saturated or unsaturated cyclic group (heterocyclyl includes heterocycloalkenyl, the same below) derived from one or more ring carbon atoms in a cycloalkyl group being replaced by a heteroatom and / or a heteroatom group. The heteroatom and / or heteroatom group is generally selected from N, O, S, NO, SO, S(O)2, P(O), and NR, wherein the carbon atoms in the heterocyclic ring are optionally oxoed, i.e., forming -C(O); preferably, the heteroatom is independently selected from 1-3 N and / or O. The heterocyclyl may be a monocyclic heterocyclyl or a polycyclic heterocyclyl, and the polycyclic heterocyclyl includes a spiro heterocyclyl, a fused heterocyclyl, and a bridged heterocyclyl. Non-limiting examples include "3 to 8-membered heterocyclyl", "3 to 8-membered monocyclic heterocyclyl", "3 to 6-membered heterocyclyl", "3 to 5-membered heterocyclyl", "4 to 6-membered heterocyclyl", "5 to 6-membered heterocyclyl", "6-membered heterocyclyl", "5 to 6-membered monocyclic heterocyclyl", 5 to 8-membered spiroheterocyclyl, 5 to 8-membered fused heterocyclyl, 5 to 8-membered monocyclic heterocyclyl. Specific examples include, but are not limited to, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, and the like. When the heterocyclyl contains an unsaturated structure, the heterocyclyl is also called "heterocycloalkenyl", which means that one or more ring bonds in the "heterocyclyl" are double bonds and the heterocycle is not aromatic. Preferably, the heteroatoms are independently selected from 1-3 N and / or O. The heterocyclyl includes "3 to 8-membered heterocycloalkenyl", "3 to 6-membered heterocycloalkenyl", "3 to 5-membered heterocycloalkenyl", and "5 to 6-membered heterocycloalkenyl". Specific examples include but are not limited to: wait.
[0261] The term "fused heterocyclyl" refers to a polycyclic heterocyclic ring system that shares two adjacent atoms between the rings, which may contain one or more double bonds in the ring and at least one (e.g., 1, 2, 3, or 4) heteroatom selected from nitrogen, oxygen, and sulfur (the nitrogen may be optionally oxidized, i.e., to form nitrogen oxides; the sulfur may be optionally oxidized, i.e., to form sulfoxides or sulfones, but excluding -OO-, -OS-, or -SS-), which is a monocyclic heterocyclyl fused to one or more monocyclic heterocyclyls, or a monocyclic heterocyclyl fused to one or more cycloalkyl, cycloalkenyl, aryl, or heteroaryl groups, wherein the point of attachment is on the monocyclic heterocyclyl, and has 6 to 14 (e.g., 6, 7, 8, 9, 10, 11, 12, 13, 14) ring atoms (i.e., a 6- to 14-membered fused heterocyclyl). The fused heterocyclic radical preferably has a fused heterocyclic radical of 7 to 10 ring atoms (i.e. 7 to 10 yuan fused heterocyclic radical) or preferably has a fused heterocyclic radical of 5 to 8 ring atoms (i.e. 5 to 8 yuan fused heterocyclic radical). The fused heterocyclic radical includes bicyclic and polycyclic fused heterocyclic radicals (such as tricyclic fused heterocyclic radicals, tetracyclic fused heterocyclic radicals, etc.), preferably bicyclic fused heterocyclic radicals or tricyclic fused heterocyclic radicals, more preferably 3 yuan / 4 yuan, 3 yuan / 5 yuan, 3 yuan / 6 yuan, 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 3 yuan, 5 yuan / 4 yuan, 5 yuan / 5 yuan, 5 yuan / 6 yuan, 5 yuan / 7 yuan, 6 yuan / 3 yuan, 6 yuan / 4 yuan, 6 yuan / 5 yuan, 6 yuan / 6 yuan, 6 yuan / 7 yuan, 7 yuan / 5 yuan or 7 yuan / 6 yuan bicyclic fused heterocyclic radicals. Non-limiting examples include:
[0262] wait.
[0263] The term "spiroheterocyclyl" refers to a polycyclic heterocyclic ring system in which the rings share one atom (called a spiro atom), which may contain one or more double bonds in the ring and at least one (e.g., 1, 2, 3, or 4) heteroatom selected from nitrogen, oxygen, and sulfur (the nitrogen may be optionally oxidized, i.e., to form nitrogen oxides; the sulfur may be optionally oxoed, i.e., to form sulfoxides or sulfones, but excluding -OO-, -OS-, or -SS-), provided that it contains at least one monocyclic heterocyclic group and the point of attachment is on the monocyclic heterocyclic group, preferably a spiroheterocyclyl having 6 to 14 ring atoms (i.e., a 6- to 14-membered spiroheterocyclyl), more preferably a spiroheterocyclyl having 7 to 10 ring atoms (i.e., a 7- to 10-membered spiroheterocyclyl), or preferably a spiroheterocyclyl having 5 to 8 ring atoms (i.e., a 5- to 8-membered spiroheterocyclyl). Non-limiting examples include:
[0264] wait.
[0265] The term "aryl" refers to a monocyclic all-carbon aromatic ring (i.e., monocyclic aryl) or a polycyclic aromatic ring system (i.e., polycyclic aryl) having a conjugated π electron system, which has 6 to 14 (e.g., 6, 7, 8, 9, 10, 11, 12, 13, or 14) ring atoms (i.e., a 6- to 14-membered aryl). The aryl group is preferably an aryl group having 6 to 10 ring atoms (i.e., a 6- to 10-membered aryl group). The monocyclic aryl group is, for example, phenyl. Non-limiting examples of the polycyclic aryl group include naphthyl, anthracenyl, phenanthrenyl, and the like. The polycyclic aromatic group also includes a phenyl group fused to one or more heterocyclic groups or cycloalkyl groups, or a naphthyl group fused to one or more heterocyclic groups or cycloalkyl groups, wherein the point of attachment is on the phenyl group or naphthyl group, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic aromatic ring system and preferably has 7 to 14 (e.g., 7, 8, 9, 10, 11, 12, 13 or 14) ring atoms (i.e., a 7 to 14-membered fused aromatic group). Non-limiting examples include:
[0266] wait.
[0267] The term "heteroaryl" refers to a monocyclic heteroaromatic ring (i.e., a monocyclic heteroaryl) or a polycyclic heteroaromatic ring system (i.e., a polycyclic heteroaryl) having a conjugated π electron system, which contains at least one (e.g., 1, 2, 3, or 4) heteroatoms selected from nitrogen, oxygen, and sulfur (the nitrogen may be optionally oxidized, i.e., to form a nitrogen oxide; the sulfur may be optionally oxidized, i.e., to form a sulfoxide or sulfone, but excluding -OO-, -OS-, or -SS-), and has 5 to 14 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14) ring atoms (i.e., a 5- to 14-membered heteroaryl). The heteroaryl is preferably a heteroaryl having 5 to 10 ring atoms (i.e., a 5- to 10-membered heteroaryl), more preferably a heteroaryl having 5 or 6 ring atoms (i.e., a 5- to 6-membered heteroaryl). The polycyclic heteroaryl group preferably has 6 to 14 (eg, 6, 7, 8, 9, 10, 11, 12, 13, or 14) ring atoms (ie, a 6- to 14-membered fused heteroaryl group).
[0268] The monocyclic heteroaryl groups include, but are not limited to, furyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furazanyl, pyrrolyl, N-alkylpyrrolyl, pyridyl, pyrimidinyl, pyridonyl, N-alkylpyridone (e.g. etc.), pyrazinyl, pyridazinyl, etc.
[0269] The polycyclic heteroaryl, non-limiting examples include: indolyl, indazolyl, quinolyl, isoquinolyl, quinoxalinyl, phthalazinyl, benzimidazolyl, benzothiophenyl, quinazolinyl, benzothiazolyl, carbazolyl and the like. The polycyclic heteroaryl also includes a monocyclic heteroaryl fused with one or more aromatic groups, wherein the point of attachment is on the aromatic ring, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic heteroaromatic ring system. The polycyclic heteroaryl also includes a monocyclic heteroaryl fused with one or more cycloalkyl or heterocyclic groups, wherein the point of attachment is on the monocyclic heteroaromatic ring, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic heteroaromatic ring system and preferably has 6 to 14 (e.g., 6, 7, 8, 9, 10, 11, 12, 13 or 14) ring atoms (i.e., 6 to 14-membered fused heteroaryl). Non-limiting examples include:
[0270]
[0271] wait.
[0272] The term "halogen" refers to fluorine, chlorine, bromine or iodine.
[0273] The term "hydroxy" refers to -OH.
[0274] The term "amino" refers to -NH2.
[0275] The term "cyano" refers to -CN.
[0276] The term "oxo" or "oxo" refers to "=0".
[0277] The disclosed compounds may exist in specific stereoisomeric forms. The term "stereoisomer" refers to isomers having identical structures but different arrangements of atoms in space. It includes cis and trans (or Z and E) isomers, (-)- and (+)-isomers, (R)- and (S)-enantiomers, diastereomers, (D)- and (L)-isomers, tautomers, atropisomers, conformers and mixtures thereof (such as racemates, mixtures of diastereomers). The substituents in the disclosed compounds may have additional asymmetric atoms. All of these stereoisomers and their mixtures are included within the scope of the present disclosure. Optically active (-)- and (+)-isomers, (R)- and (S)-enantiomers and (D)- and (L)-isomers can be prepared by chiral synthesis, chiral reagents or other conventional techniques. An isomer of a compound disclosed herein can be prepared by asymmetric synthesis or chiral auxiliary, or, when the molecule contains a basic functional group (e.g., amino) or an acidic functional group (e.g., carboxyl), by forming a diastereomeric salt with an appropriate optically active acid or base, followed by diastereomeric resolution by conventional methods known in the art to obtain the pure isomer. Furthermore, separation of enantiomers and diastereomers is typically accomplished by chromatography.
[0278] The absolute stereo configuration of the compound can be confirmed by conventional technical means in the art. For example, single crystal X-ray diffraction, the absolute configuration of the compound can also be confirmed by the chiral structure of the raw material and the reaction mechanism of asymmetric synthesis. Or after splitting, its stereo configuration is determined by comparing it with the product with determined absolute configuration. For example, by comparing it with the compound of Reference Example 1 with determined absolute configuration (reference patent WO2013041591A1), its stereo configuration is determined by the difference in activity. The compounds marked as "absolute configuration unknown / undetermined" herein are usually split into single isomers by chiral preparative SFC from racemic compounds, and then characterized and tested.
[0279] The compounds of the present disclosure include all suitable isotopic derivatives of the compounds thereof. The term "isotopic derivative" refers to a compound in which at least one atom is replaced by an atom having the same atomic number but a different atomic mass. Examples of isotopes that can be introduced into the compounds of the present disclosure include stable and radioactive isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine, and iodine, for example, 2 H (deuterium, D), 3 H (tritium, T), 11 C. 13 C. 14 C. 15 N. 17 O. 18 O. 32 p、 33 p、33 S. 34 S. 35 S. 36 S. 18 F. 36 Cl, 82 Br, 123 I. 124 I. 125 I. 129 I and 131 I, etc., preferably deuterium. Compared to non-deuterated drugs, deuterated drugs have advantages such as reduced toxic side effects, increased drug stability, enhanced therapeutic efficacy, and extended drug biological half-life. All isotopic composition changes of the compounds disclosed herein, whether radioactive or not, are included in the scope of this disclosure. Each available hydrogen atom attached to a carbon atom can be independently replaced by a deuterium atom, wherein the deuterium replacement can be partial or complete, and partial deuterium replacement means that at least one hydrogen is replaced by at least one deuterium.
[0280] The term "prodrug" refers to certain derivatives of the disclosed compounds that have little or no pharmacological activity themselves, which have cleavable groups and decompose into the disclosed compounds through solvent decomposition or under physiological conditions. The types of prodrugs include, but are not limited to, amides, esters, anhydrides, salts, and the like. The "ester" refers to a derivative formed with a suitable alcohol when the disclosed compound contains an acidic group (such as a carboxylic acid); or a derivative formed with a suitable acid (including an organic acid or an inorganic acid) when the disclosed compound contains a hydroxyl group. Methods for preparing prodrugs are well known to those skilled in the art.
[0281] The term "solvate" refers to an association or complex of one or more solvent molecules with a compound of the present disclosure. The term "hydrate" may be used when the solvent is water. The solvent molecules may be present in stoichiometric or non-stoichiometric amounts.
[0282] The term "nitrogen oxide" or "N-oxide" refers to a derivative formed by further oxidation of the nitrogen atom in a nitrogen-containing group. Common N-oxides include N-oxides of tertiary amines or nitrogen atoms in nitrogen-containing heterocycles. Synthesis methods of N-oxides are well known to those skilled in the art and include oxidation of heterocycles and tertiary amines using peroxyacids such as peracetic acid and m-chloroperbenzoic acid, hydrogen peroxide, alkyl hydroperoxides such as tert-butyl hydroperoxide, sodium perborate, and dioxiranes such as dimethyldioxirane.
[0283] In the chemical structures of the compounds disclosed herein, the bond Indicates that the configuration is not specified, that is, if chiral isomers exist in the chemical structure, the bond Can be or include both For all carbon-carbon double bonds, even if only one configuration is named, both the Z and E configurations are included.
[0284] When a substituent's bond can cross-link to a ring, it means that the substituent can be bonded to any atom on the ring. Represents the substituent R b Substitution can occur at any position on ring B (including NH), and R b The number of atoms is n; when the ring contains NH, it means that NH and other ring atoms can be R b Replaced by R b H may or may not be substituted, for example, the structural unit Including R b There are two situations: replacing the H on N or not replacing the H on N.
[0285] When any variable (such as R b ) appears more than once in the composition or structure of a compound, its definition in each instance is independent. For example, a structural unit Indicates that ring B is surrounded by n R b is replaced, and each R b There are independent options.
[0286] When a substituent is listed without specifying the atom through which the substituent is attached to a given group or a given structural formula, the substituent may be attached via any bondable atom. For example, pyrimidine as a substituent means that any carbon atom or nitrogen atom on the pyrimidine ring is attached to the substituted group. For example, in the present disclosure, ring B is selected from There is no limitation on the connection site in the structural unit, which means that any carbon atom on the tetrahydropyran ring can be connected to a given group or a given structural formula.
[0287] When the term "and" appears between two chemical structure names, it means that the two chemical structures are connected in a fused manner, but it does not limit the direction of connection with a given group or a given structural formula. For example, the structural unit described in this disclosure: In the above, "ring C is selected from 5- to 8-membered monocyclic heterocyclic groups and phenyl groups" means a condensed structure in which ring C is selected from 5- to 8-membered monocyclic heterocyclic groups and phenyl groups, but The directly connected structural fragment may be a 5- to 8-membered monocyclic heterocyclic group or a phenyl group.
[0288] When the structure appears When The atoms that are connected are bonding atoms, e.g. Indicates that the carbon atoms on the pyrimidine ring are bonding atoms.
[0289] When the structure appears When The atoms that are connected are bonding atoms, and It may be a single bond or a double bond; for example Contains two bonded atoms, The bond between two atoms can be either a single bond or a double bond, depending on the Condensed specific structure.
[0290] The presence of a dash "-" in a substituent structure or any structural unit mentioned in this disclosure indicates the point of attachment for the substituent, for example, -CH3 is attached through a C atom. When two dashes "-" appear in a substituent structure, such as the L group in this disclosure, unless otherwise specified, the dash "-" on the right end of the substituent is attached to the right side of the corresponding general formula, for example, L is selected from -NHC(O)-, where the dash "-" on the right end indicates the position of attachment to R, and the same applies to the left side.
[0291] Specifically, all combinations of substituents and / or variations thereof are permissible only if such combinations result in stable compounds.
[0292] "Substitution" or "substituted" means that one or more hydrogen atoms, preferably 1 to 6, more preferably 1 to 3 hydrogen atoms, in a group are independently replaced by a corresponding number of substituents. Those skilled in the art will be able to determine (by experiment or theory) whether substitution is possible or not without undue effort. For example, an amino or hydroxyl group having free hydrogens may be unstable when combined with a carbon atom having an unsaturated (e.g., olefinic) bond.
[0293] A "pharmaceutical composition" refers to a mixture containing one or more compounds described herein, or their physiologically / pharmaceutically acceptable salts or prodrugs, together with other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitating absorption of the active ingredient and thereby exerting its biological activity.
[0294] The term "pharmaceutically acceptable salt" refers to derivatives of the disclosed compounds prepared with relatively nontoxic acids or bases. These salts can be prepared during compound synthesis, isolation, and purification, or by reacting the purified free form of the compound with a suitable acid or base. When the compound contains relatively acidic functional groups, base addition salts are obtained by reaction with alkali metal or alkaline earth metal hydroxides or organic amines. These salts include cations based on alkali and alkaline earth metals, as well as nontoxic ammonium, quaternary ammonium, and amine cations, and also encompass salts of amino acids. When the compound contains relatively basic functional groups, acid addition salts are obtained by reaction with organic or inorganic acids.
[0295] The term "pharmaceutically acceptable" refers to those compounds, materials, compositions and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications, commensurate with a reasonable benefit / risk ratio.
[0296] The term "pharmaceutically acceptable carrier" refers to a medium generally accepted in the art for delivering biologically active agents to animals, particularly mammals, and includes, for example, adjuvants, excipients, or vehicles, such as diluents, preservatives, fillers, flow regulators, disintegrants, wetting agents, emulsifiers, suspending agents, sweeteners, flavoring agents, fragrances, antibacterial agents, antifungal agents, lubricants, and dispersants, depending on the mode of administration and the nature of the dosage form. Pharmaceutically acceptable carriers are formulated within the purview of those skilled in the art based on a wide range of factors. These include, but are not limited to, the type and nature of the active agent being formulated, the subject to whom the composition containing the agent is to be administered, the intended route of administration of the composition, and the intended therapeutic indication. Pharmaceutically acceptable carriers include both aqueous and non-aqueous media, as well as a variety of solid and semisolid dosage forms. In addition to the active agent, such carriers include a variety of different ingredients and additives, and the inclusion of such additional ingredients in a formulation for various reasons (e.g., to stabilize the active agent, binders, etc.) is well known to those skilled in the art.
[0297] The term "therapeutically effective amount" refers to a sufficient amount of a compound of the present disclosure, a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or an isotopic derivative thereof to treat a disorder at a reasonable benefit / risk ratio applicable to any medical treatment and / or prevention. However, it should be understood that the total daily dosage of all formulae described herein, including but not limited to formula (IA), formula (I), formula (II), and the compounds shown in Table 1 thereof, their stereoisomers, their isotopic derivatives, their prodrugs, their nitrogen oxides, their solvates, or their pharmaceutically acceptable salts and compositions, must be determined by the attending physician within the scope of sound medical judgment. For any particular patient, the specific therapeutically effective dosage level must be determined based on a variety of factors, including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the patient's age, weight, general health, sex, and diet; the administration time, route of administration, and excretion rate of the specific compound employed; the duration of treatment; drugs used in combination with or concurrently with the specific compound employed; and similar factors well known in the medical field. With respect to a drug or pharmacologically active agent, the term "therapeutically effective amount" refers to a non-toxic amount of the drug or agent sufficient to achieve the desired effect. The determination of an effective amount varies from person to person, depending on the age and general condition of the recipient, as well as the specific active agent. The appropriate effective amount in each individual case can be determined by those skilled in the art through routine experimentation.
[0298] As used herein, the singular form "a," "an," and "the" include plural references and vice versa unless the context clearly dictates otherwise.
[0299] When the term "about" is applied to a parameter such as pH, concentration, temperature, etc., it indicates that the parameter can vary by ±10%, and sometimes more preferably within ±5%. As will be understood by those skilled in the art, when a parameter is not critical, numbers are generally given for illustration purposes only and are not limiting.
[0300] Technical Effects
[0301] The disclosed compounds have a significant inhibitory effect on CYP11B2 and are significantly superior to the reference compound in terms of in vitro activity, selectivity, and pharmacokinetic properties (the reference compound is compound 3-1 on page 95 of patent WO2013041591A1). The structure of the reference compound is as follows:
[0302] In addition, the disclosed compounds exhibited significant in vivo efficacy in monkeys at multiple doses (e.g., 0.03 mpk, 0.1 mpk, and 0.3 mpk) without causing significant changes in hormones such as cortisol (e.g., 11-deoxycorticosterone, 11-deoxycortisol, 17-hydroxyprogesterone, and corticosterone). BRIEF DESCRIPTION OF THE DRAWINGS
[0303] The drawings described herein are used to provide further understanding of the present disclosure and constitute a part of the present disclosure. The exemplary embodiments of the present disclosure and their descriptions are used to explain the present disclosure and do not constitute improper limitations on the present disclosure.
[0304] FIG1 is a diagram showing the pharmacodynamic results of Example Compound C44 in monkeys;
[0305] FIG2 is a graph showing the pharmacodynamic results of Example Compound A09 in monkeys;
[0306] FIG3 is a graph showing the pharmacodynamic results of Example Compound A50 in monkeys;
[0307] FIG4 is a graph showing the pharmacodynamic results of Example Compound C43 in monkeys;
[0308] FIG5 is a graph showing the pharmacodynamic results of Example Compound A02-P2 in monkeys. DETAILED DESCRIPTION
[0309] The present disclosure is described in detail below by way of examples, but is not intended to limit the present disclosure in any way. While the present disclosure has been described in detail herein, including specific embodiments thereof, it will be apparent to those skilled in the art that various changes and modifications may be made to the specific embodiments of the present disclosure without departing from the spirit and scope of the invention.
[0310] In the embodiments of the present disclosure, the naming of the compounds is converted from the compound structure with the help of Chemdraw. If there is an inconsistency between the compound name and the compound structure, it can be determined by integrating relevant information and reaction routes. The preparation methods of some compounds in the present disclosure quote the preparation methods of the aforementioned similar compounds. Those skilled in the art should know that when using or referring to the preparation methods cited, the feed ratio of the reactants, the reaction solvent, the reaction temperature, etc. can be appropriately adjusted according to the different reactants. The compounds of the present disclosure can be prepared by a variety of synthesis methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by combining them with other chemical synthesis methods, and equivalent replacement methods well known to those skilled in the art. Preferred embodiments include but are not limited to the embodiments of the present disclosure.
[0311] 1. Summary of experimental instruments
[0312] The structures of the compounds disclosed herein are confirmed by nuclear magnetic resonance (NMR) and / or liquid chromatography-mass spectrometry (LC-MS), or ultra-performance liquid chromatography-mass spectrometry (UPLC-MS).
[0313] NMR measurements were performed using a Bruker AVANCE III HD 400 MHz or Bruker AVANCE NEO 400 MHz NMR instrument. The solvents used were deuterated dimethyl sulfoxide (DMSO-d6), deuterated methanol (CD3OD), deuterated chloroform (CDCl3), and deuterated water (D2O). The internal standard was tetramethylsilane (TMS). NMR chemical shifts (δ) are given in parts per million (ppm).
[0314] Liquid chromatography-mass spectrometry (LC-MS) was performed using a Shimadzu LC-20AD & MS 2020, Shimadzu LC-20AD XR & MS 2020, or Agilent 1260 & MS 6125B mass spectrometer (electrospray ionization as the ion source).
[0315] HPLC analysis was performed using Agilent 1200, Agilent 1100, Shimadzu LC-20AD, or Shimadzu LC-20AD high performance liquid chromatography.
[0316] Preparative HPLC was performed using Gilson (GX281), Waters (2767), or Waters (2767 / QDA).
[0317] Chiral HPLC was performed using a Waters Arc 2998 with QDA.
[0318] Supercritical fluid chromatography (SFC) was performed using a Waters SFC150 MGM.
[0319] The starting materials and intermediates used in this disclosure can be synthesized according to methods known in the art or purchased commercially. Experimental procedures in the examples where specific conditions are not specified were generally performed under conventional conditions or as recommended by the raw material or product manufacturer. Reagents where the specific sources are not specified were purchased commercially.
[0320] The reaction progress in the examples can be monitored by conventional methods such as thin layer chromatography (TLC) and LC-MS. The eluent system of the column chromatography (which can be conventional column chromatography or flash column chromatography) and the developing solvent system of the thin layer chromatography used for purification can be composed of one or more of the following solvents: dichloromethane, methanol, n-hexane, ethyl acetate, petroleum ether, ethyl acetate, acetone, dichloromethane, etc. The volume ratio of the solvent is adjusted according to the polarity of the compound, and a small amount of alkaline or acidic reagents such as triethylamine, acetic acid, trifluoroformic acid, etc. can also be added for adjustment.
[0321] Unless otherwise specified, the percentage contents (%) referred to in the present disclosure refer to mass percentages for solid-liquid mixtures and solid-solid mixtures, and refer to volume percentages for liquid-liquid mixtures.
[0322] 2. Synthesis Example
[0323] Reference Example 1 (Comparative Example Compound):
[0324] The preparation method refers to patent WO2013041591A1.
[0325] The synthetic routes of some compounds disclosed in this disclosure are described as follows:
[0326] Option 1:
[0327] Int1 synthesis scheme:
[0328] Option 2:
[0329] Option 3:
[0330] Option 4:
[0331] The syntheses of the compounds other than TM1 to TM4 in Table 1 of the present disclosure were prepared by referring to any one of Schemes 1 to 4 above. The structures of the target compounds prepared according to the above synthetic routes were confirmed by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS).
[0332] The compounds shown in Table 2 below can be synthesized according to the synthesis schemes of Schemes 1 to 4 above, or according to the synthesis schemes of specific compounds described in this disclosure, or according to methods in existing literature.
[0333] Table 2
[0334] Synthesis of specific compounds:
[0335] Synthesis of intermediates:
[0336] Intermediates INT-1A, INT-1B, INT-1C, INT-1D, INT-1E, INT-1F
[0337] Step 1: Synthesis of compound INT-1-2
[0338] To a solution of compound INT-1-1 (2.0 g, 8.85 mmol) in methanol (13 mL) were added a methanolic amine solution (7 M, 6.32 mL, 44.25 mmol) and tetraisopropyl titanate (5.03 g, 17.70 mmol) at 25°C. The resulting mixed reaction solution was stirred at 25°C for 16 hours under nitrogen. Sodium borohydride (502 mg, 13.27 mmol) was added to the above reaction solution at 0°C. The resulting mixed reaction solution was stirred at 25°C for 2 hours under nitrogen. The resulting mixed reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound INT-1-2 (1.45 g).
[0339] MS(ESI)M / Z:210.0,212.0[M+H-17] + .
[0340] Step 2: Synthesis of Compound INT-1-3 and Compound INT-1-3'
[0341] Compound INT-1-2 (1.45 g) was purified by supercritical fluid chromatography (chromatographic conditions: system: Waters SFC 150; column name: Chromatographic column size: 250×25mm 10μm; mobile phase A; supercritical CO2; mobile phase B: methanol (+0.1% 7.0mol / L ammonia methanol), A:B=75:25; wavelength: 214nm; flow rate: 120mL / min; column temperature: room temperature; column pressure: 100bar, injection volume: 8.0mL; cycle time: 6.58min) was purified to obtain compound INT-1-3' (peak1 (peak 1), ee (purity) = 100%, 675mg) and compound INT-1-3 (peak2 (peak 2), ee = 99.4%, 665mg).
[0342] Compound INT-1-3': Peak 1, by supercritical fluid chromatography (chromatographic conditions: system: Waters UPCC (CA352); column name: Chromatographic column dimensions: 100×3.0 mm 3.0 μm; mobile phase A: supercritical CO2; mobile phase B: methanol (0.1% DEA (diethanolamine)), A:B = 80:20; wavelength: 214 nm; flow rate: 1.5 mL / min; column temperature: 35°C; column pressure: 1800 psi, injection volume: 1.0 μL; cycle time: 8.0 min) analysis, retention time RT: 2.020 min, ee = 100%.
[0343] 1 H NMR (400MHz, DMSO-d6) δ8.59 (s, 1H), 8.47 (s, 1H), 3.89 (t, J = 6.0Hz, 1H), 2.68-2.56 (m,2H),1.99-1.90(m,3H),1.87-1.80(m,1H),1.73-1.67(m,1H),1.62-1.55(m,1H).
[0344] MS(ESI)M / Z:210.0,212.0[M+H-17] + .
[0345] Compound INT-1-3: Peak 2, by supercritical fluid chromatography (chromatographic conditions: system: Waters UPCC (CA352); column name: Column dimensions: 100 × 3.0 mm, 3.0 μm; mobile phase A: supercritical CO2; mobile phase B: methanol (0.1% DEA), A:B = 80:20; wavelength: 214 nm; flow rate: 1.5 mL / min; column temperature: 35°C; column pressure: 1800 psi, injection volume: 1.0 μL; cycle time: 8.0 min) analysis, retention time (RT): 2.826 min, ee = 99.4%.
[0346] 1 H NMR (400MHz, DMSO-d6) δ8.60 (s, 1H), 8.48 (s, 1H), 3.93 (t, J = 6.0Hz, 1H), 2.69-2.55 (m,2H),1.97-1.91(m,1H),1.88-1.81(m,1H),1.74-1.68(m,1H),1.64-1.58(m,1H).
[0347] MS(ESI)M / Z:210.0,212.0[M+H-17] + .
[0348] Step 3: Synthesis of compound INT-1A
[0349] To a solution of compound INT-1-3 (665 mg, 2.93 mmol) and triethylamine (1.48 g, 14.65 mmol) in dichloromethane (20 mL) was added dropwise propionyl chloride (271 mg, 2.93 mmol) under nitrogen at 0°C. The resulting mixture was stirred at 0°C for 1 hour. The reaction mixture was quenched with water (20 mL) and extracted with ethyl acetate (20 mL x 2). The combined organic phases were concentrated under reduced pressure. The residue was purified by silica gel column chromatography to afford compound INT-1A (650 mg).
[0350] Compound INT-1A: analyzed by supercritical fluid chromatography (chromatographic conditions: system: Waters UPCC (CA352); column name: Column dimensions: 100 × 3.0 mm, 3.0 μm; mobile phase A: supercritical CO2; mobile phase B: methanol (0.1% DEA), gradient: 5% B-40% B; wavelength: 214 nm; flow rate: 1.5 mL / min; column temperature: 35°C; column pressure: 1800 psi, injection volume: 0.5 μL; cycle time: 8.0 min); retention time (RT): 3.961 min.
[0351] 1H NMR (400MHz, DMSO-d6) δ8.54(s,1H),8.29(s,1H),8.23(d,J=8.4Hz,1H),5.04-5.01(m ,1H),2.69-2.64(m,2H),2.17-2.10(m,2H),1.91-1.68(m,4H),1.04(d,J=7.2Hz,3H).
[0352] MS (ESI) M / Z: 283.0, 285.0 [M+H] + .
[0353] Step 4: Synthesis of compound INT-1B
[0354] At room temperature, N,N'-carbonyldiimidazole (115 mg, 0.71 mmol) and N,N'-diisopropylethylamine (454 mg, 3.5 mmol) were added to ultra-dry tetrahydrofuran (5 mL) containing compound INT-1-3 (80 mg, 0.35 mmol). The mixture was stirred at room temperature for 2 hours, followed by the addition of deuterated methylamine hydrochloride (100 mg, 1.41 mmol). The mixture was stirred at room temperature for 16 hours. After completion of the reaction, the mixture was diluted with water (5 mL) and concentrated. The residue was separated and purified by reverse-phase column chromatography (0.1% formic acid-acetonitrile, 15% acetonitrile) to give compound INT-1B (50 mg).
[0355] MS(ESI)M / Z: 287.0, 289.0[M+H] + .
[0356] Step 5: Synthesis of compound INT-1C
[0357] To a solution of compound INT-1-3 (90 mg, 0.40 mmol) in tetrahydrofuran (5 mL) was added N,N'-carbonyldiimidazole (129.72 mg, 0.80 mmol) and ethyldiisopropylamine (1033.92 mg, 8 mmol) under nitrogen at 25°C. The resulting mixed reaction solution was stirred at 25°C for 2 hours. Methylamine hydrochloride (270.08 mg, 4 mmol) was added to the above reaction solution, and the resulting mixed reaction solution was stirred at 25°C for 16 hours under nitrogen. The mixed reaction solution was quenched with saturated aqueous ammonium chloride (10 mL) and extracted with ethyl acetate (10 mL × 2). The combined organic phases were washed with saturated brine (10 mL × 3) and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound INT-1C (50 mg).
[0358] 1H NMR(400MHz,DMSO-d6)δ8.52(s,1H),8.37(s,1H),6.41(d,J=8.8Hz,1H),5.70-5.69(m ,1H),4.88-4.83(m,1H),2.68-2.63(m,2H),2.59(d,J=4.4Hz,3H),1.87-1.68(m,4H).
[0359] MS (ESI) M / Z: 284.0, 286.0 [M+H] + .
[0360] Step 6: Synthesis of compound INT-1D
[0361] Compound INT-1-3 (50 mg, 0.22 mmol) was dissolved in dichloromethane (5 mL), and triethylamine (67 mg, 0.66 mmol) and methyl chloroformate (21 mg, 0.22 mmol) were added at room temperature. The reaction was stirred at room temperature for 1 hour. The reaction solution was added with water (100 mL) and extracted twice with ethyl acetate (30 mL). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound INT-1D (30 mg).
[0362] MS (ESI) M / Z: 285.1, 287.1 [M+H] + .
[0363] Step 7: Synthesis of compound INT-1E
[0364] To a solution of compound INT-1-3 (60 mg, 0.26 mmol) in tetrahydrofuran (2 mL) under nitrogen at 25°C was added N,N'-carbonyldiimidazole (84.32 mg, 0.52 mmol) and ethyldiisopropylamine (336.02 mg, 2.60 mmol). The resulting mixture was stirred at 25°C under nitrogen for 2 hours. A solution of dimethylamine in tetrahydrofuran (2.0 M in THF, 0.65 mL, 1.30 mmol) was added to the above reaction mixture, and the resulting mixture was stirred at 25°C under nitrogen for 16 hours. The mixture was quenched with saturated aqueous ammonium chloride (10 mL) and extracted with ethyl acetate (10 mL x 2). The combined organic phases were washed with saturated brine (10 mL x 3) and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound INT-1E (50 mg).
[0365] 1HNMR(400MHz,DMSO-d6)δ8.51(s,1H),8.34(s,1H),6.63(d,J=8.4Hz,1H),4.95-4.8 9(m,1H),2.81(s,6H),2.65(d,t=6.0Hz,2H),1.97-1.91(m,1H),1.85-1.72(m,3H).
[0366] MS (ESI) M / Z: 298.0, 300.0 [M+H] + .
[0367] Step 8: Synthesis of compound INT-1F
[0368] To a solution of compound INT-1-3 (20 mg, 0.088 mmol) in tetrahydrofuran (4 mL) was added N,N'-carbonyldiimidazole (28.54 mg, 0.18 mmol) and ethyldiisopropylamine (227.46 mg, 1.76 mmol) under nitrogen at 25°C. The resulting mixed reaction solution was stirred at 25°C under nitrogen for 2 hours. Deuterated methanol (3 mL) was added to the above reaction solution, and the resulting mixed reaction solution was stirred at 60°C under nitrogen for 16 hours. The mixed reaction solution was quenched with saturated aqueous ammonium chloride (10 mL) and extracted with ethyl acetate (10 mL x 2). The combined organic phases were washed with saturated brine (10 mL x 3), dried, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound INT-1F (26 mg).
[0369] MS (ESI) M / Z: 288.0, 290.0 [M+H] + .
[0370] Intermediate INT-2
[0371] Step 1: Synthesis of compound INT-2-2
[0372] First, the compound INT-2-1 (2g, 8.93mmol) was dissolved in N,N-dimethylformamide solution (20mL), and the reaction solution was placed in an ice bath at 0°C. Potassium tert-butoxide (2g, 17.86mmol) was then added and stirred in an ice bath for 15 minutes. Then, iodomethane (1.65g, 11.61mmol) was added and the atmosphere was replaced with N2 three times. The system was naturally warmed to room temperature and stirred for 16 hours. Ethyl acetate (200mL) and water (100mL) were used for extraction, and the organic phase was washed with saturated sodium chloride (100mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated in vacuo to obtain a crude product, which was separated and purified by column chromatography to obtain compound INT-2-2 (1.5g).
[0373] MS(ESI)M / Z: 238.0, 240.0[M+H] + .
[0374] Step 2: Synthesis of compound INT-2
[0375] Compound INT-2-2 (0.2 g, 0.84 mmol) and pinacol diboronate (0.32 g, 1.26 mmol) were dissolved in 1,4-dioxane (10 mL). Potassium acetate (0.25 g, 2.52 mmol) and 1,1'-bis(diphenylphosphino)ferrocenepalladium(II) chloride (0.061 g, 0.084 mmol) were then added. The atmosphere was fully purged with nitrogen, and the reaction was continued at 80°C for 2 hours. The reaction solution was cooled to room temperature, diluted with water (60 mL), and extracted with ethyl acetate (80 mL x 2). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to yield a crude product. The crude product was separated and purified by column chromatography to yield compound INT-2 (0.24 g).
[0376] 1 H NMR (400MHz, CDCl3) δ8.02(d,J=1.2Hz,1H),7.97(dd,J=8.4Hz,1.2Hz,1H),7.70(d,J =9.6Hz, 1H), 7.35 (d, J = 8.4Hz, 1H), 6.71 (d, J = 9.2Hz, 1H), 3.73 (s, 3H), 1.37 (s, 12H).
[0377] MS (ESI) M / Z: 286.10 [M+H] + .
[0378] Intermediate INT-3
[0379] Step 1: Synthesis of compound INT-3-2
[0380] Compound INT-3-1 (7.0 g, 35.53 mmol) was dissolved in N,N-dimethylacetamide (70 mL), followed by the addition of potassium tert-butoxide solution (4.98 g, 44.41 mmol, 1 mol / L) and dimethyl oxalate (6.29 g, 53.30 mmol). The atmosphere was fully N2-displaced, and the reaction was continued at 130°C for 16 hours. The mixture was diluted with water (150 mL) and extracted with ethyl acetate (100 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to yield the crude product. The crude product was isolated and purified by column chromatography to yield compound INT-3-2 (1.26 g).
[0381] MS (ESI) M / Z: 211.1 [M+H] +.
[0382] Step 2: Synthesis of compound INT-3-3
[0383] Compound INT-3-2 (0.2 g, 0.95 mmol) was dissolved in ultra-dry tetrahydrofuran (5 mL) and thoroughly purged with nitrogen. The reaction mixture was then placed in an ice bath at 0°C and slowly added dropwise with lithium aluminum hydride (0.18 g, 4.75 mmol, 2.5 mol / L). The reaction mixture was allowed to react at room temperature for 2 hours. Water (10 mL), 15% aqueous sodium hydroxide solution (10 mL), and water (30 mL) were added sequentially in an ice bath. The mixture was then filtered through celite and washed with ethyl acetate (20 mL x 3). The filtrate was concentrated in vacuo to yield the crude product. The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was separated and purified by column chromatography to yield compound INT-3-3 (0.16 g).
[0384] MS (ESI) M / Z: 215.1 [M+H] + .
[0385] Step 3: Synthesis of compound INT-3-4
[0386] Compound INT-3-3 (0.16 g, 0.74 mmol) was dissolved in tetrahydrofuran (5 mL), and then N,N'-carbonyldiimidazole (0.06 g, 0.37 mmol) was added. The atmosphere was fully replaced with nitrogen, and the system was reacted at 60°C for 2 hours. The reaction solution was cooled to room temperature, diluted with water (80 mL), and extracted with ethyl acetate (80 mL × 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was separated and purified by column chromatography to obtain compound INT-3-4 (0.1 g).
[0387] MS (ESI) M / Z: 241.0 [M+H] + .
[0388] Step 4: Synthesis of compound INT-3
[0389] Compound INT-3-4 (0.1 g, 0.41 mmol) and pinacol diboronate (120 mg, 0.49 mmol) were dissolved in 1,4-dioxane (10 mL). DPPF palladium dichloride (1,1'-bis(diphenylphosphinoferrocene)palladium dichloride, 33 mg, 0.041 mmol) and potassium acetate (120 mg, 1.23 mmol) were then added. The atmosphere was fully purged with nitrogen. The reaction mixture was heated at 80°C under nitrogen for 12 hours. The reaction mixture was cooled to room temperature, filtered through celite, and washed with ethyl acetate (20 mL x 3). The filtrate was extracted with water (40 mL). The organic phases were combined, washed with saturated sodium chloride (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to remove the solvent to yield the crude product. The crude product was purified by column chromatography to yield compound INT-3 (80 mg).
[0390] MS (ESI) M / Z: 289.2 [M+H] + .
[0391] Intermediate INT-4
[0392] Step 1: Synthesis of compound INT-4-2
[0393] Compound INT-4-1 (0.8 g, 3.51 mmol) was dissolved in N,N-dimethylformamide (10 mL), followed by the addition of potassium carbonate (0.97 g, 7.02 mmol) and iodomethane (0.75 g, 5.26 mmol). The atmosphere was replaced with nitrogen, and the reaction was continued at 50°C under nitrogen for 16 hours. The reaction solution was cooled to room temperature, diluted with water (80 mL), and extracted with ethyl acetate (80 mL × 3). The organic phase was washed with saturated sodium chloride (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated in vacuo to obtain the crude product. The crude product was separated and purified by column chromatography to obtain compound INT-4-2 (0.7 g).
[0394] MS(ESI)M / Z: 242.0, 244.0[M+H] + .
[0395] Step 2: Synthesis of compound INT-4
[0396] Compound INT-4-2 (0.2 g, 0.83 mmol) and pinacol diboron (0.25 g, 1.00 mmol) were dissolved in 1,4-dioxane (10 mL). DPPF palladium dichloride (0.0068 g, 0.083 mmol) and potassium acetate (0.24 g, 2.49 mmol) were then added. The atmosphere was fully purged with nitrogen, and the reaction was continued at 80°C for 12 hours. The reaction mixture was cooled to room temperature, filtered through celite, and extracted with ethyl acetate (50 mL x 2) and water (60 mL). The organic phase was washed with saturated sodium chloride (60 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated in vacuo to obtain the crude product. The crude product was separated and purified by column chromatography to obtain compound INT-4 (0.2 g).
[0397] 1 H NMR (400MHz, CDCl3): δ7.79(d,J=7.6Hz,1H),7.57(s,1H),6.93(d,J=8.0Hz,1H),5.20(s,2H),3.39(s,3H),1.35(s,12H).
[0398] MS (ESI) M / Z: 290.2 [M+H] + .
[0399] Intermediate INT-5A
[0400] Step 1: Synthesis of Compound INT-5A and Compound INT-5A'
[0401] Compound A02-8 (168 mg) was purified by supercritical fluid chromatography (chromatographic conditions: system: Waters SFC 150; column name: Chromatographic column size: 250×30mm 10μm; mobile phase A; supercritical CO2; mobile phase B: ethanol (+0.1% 7.0mol / L ammonia methanol), A:B=75:25; wavelength: 214nm; flow rate: 120mL / min; column temperature: room temperature; column pressure: 100bar, injection volume: 7.0mL; cycle time: 5.21min) was purified to obtain compound INT-5A' (peak 1, 66mg) and compound INT-5A (peak 2, 62mg).
[0402] Compound INT-5A': Peak 1, analyzed by supercritical fluid chromatography (chromatographic conditions: system: Waters UPCC (CA-060); column name: Column dimensions: 100 × 3.0 mm (3.0 μm); mobile phase A: supercritical CO2; mobile phase B: methanol (0.1% DEA), A:B = 85:15; wavelength: 214 nm; flow rate: 1.5 mL / min; column temperature: 35°C; column pressure: 1800 psi, injection volume: 0.2 μL; cycle time: 8.0 min); retention time (RT): 1.799 min, ee > 99%.
[0403] Compound INT-5A: Peak 2, analyzed by supercritical fluid chromatography (chromatographic conditions: system: Waters UPCC (CA-060); column name: Column dimensions: 100 × 3.0 mm (3.0 μm); mobile phase A: supercritical CO2; mobile phase B: methanol (0.1% DEA), A:B = 85:15; wavelength: 214 nm; flow rate: 1.5 mL / min; column temperature: 35°C; column pressure: 1800 psi, injection volume: 0.2 μL; cycle time: 8.0 min); retention time (RT): 3.949 min, ee > 99%.
[0404] Intermediates INT-5B, INT-5C, INT-5D, INT-5E
[0405] Step 1: Synthesis of Compound INT-5-1 and Compound INT-5-1'
[0406] Compound A02-7 (2.3 g) was purified by supercritical fluid chromatography (chromatographic conditions: system: Waters SFC 150; column name: Chromatographic column size: 250×30mm 10μm; mobile phase A; supercritical CO2; mobile phase B: methanol (+0.1% 7.0mol / L ammonia methanol), A:B=70:30; wavelength: 214nm; flow rate: 120mL / min; column temperature: room temperature; column pressure: 100bar, injection volume: 2.0mL; cycle time: 11.00min) was purified to obtain compound INT-5-1' (peak 1, 490mg) and compound INT-5-1 (peak 2, 568mg).
[0407] Compound INT-5-1': Peak 1, analyzed by supercritical fluid chromatography (chromatographic conditions: system: Waters UPCC (CA060); column name: Column dimensions: 100 × 3.0 mm (3.0 μm); mobile phase A: supercritical CO2; mobile phase B: methanol (0.1% DEA), A:B = 75:25; wavelength: 214 nm; flow rate: 1.5 mL / min; column temperature: 35°C; column pressure: 1800 psi, injection volume: 0.10 μL; cycle time: 8.0 min); retention time (RT): 1.376 min; ee = 98.4%.
[0408] 1 H NMR(400MHz,DMSO-d6)δ8.41(s,1H),8.38(s,1H),4.50-4.33(m,2H),3.99 (t,J=5.2Hz,1H),2.41-2.14(m,2H),2.09-1.94(m,1H),1.88-1.75(m,1H).
[0409] MS (ESI) M / Z: 229.0, 231.0 [M+H] + .
[0410] Compound INT-5-1: Peak 2, analyzed by supercritical fluid chromatography (chromatographic conditions: system: Waters UPCC (CA060); column name: Column dimensions: 100 × 3.0 mm (3.0 μm); mobile phase A: supercritical CO2; mobile phase B: methanol (0.1% DEA), A:B = 75:25; wavelength: 214 nm; flow rate: 1.5 mL / min; column temperature: 35°C; column pressure: 1800 psi, injection volume: 0.10 μL; cycle time: 8.0 min); retention time (RT): 2.915 min, ee = 99.8%.
[0411] 1 H NMR(400MHz,DMSO-d6)δ8.41(s,1H),8.38(s,1H),4.50-4.33(m,2H),3.98( t,J=5.2Hz,1H),2.32-2.09(m,2H),2.08-1.956(m,1H),1.86-1.75(m,1H).
[0412] MS (ESI) M / Z: 229.0, 231.0 [M+H] + .
[0413] Step 2: Synthesis of compound INT-5B
[0414] At room temperature, N,N'-carbonyldiimidazole (210 mg, 1.31 mmol) and N,N-diisopropylethylamine (845 mg, 6.55 mmol) were added to ultra-dry tetrahydrofuran (4 mL) containing compound INT-5-1 (150 mg, 0.66 mmol). The mixture was stirred at room temperature for 2 hours. After LCMS detected the disappearance of the starting material, deuterated methylamine hydrochloride (92 mg, 1.31 mmol) was added and the mixture was stirred at room temperature for 16 hours. After the reaction was completed, the mixture was diluted with water (5 mL) and concentrated. The residue was separated and purified by reverse column chromatography (0.1% formic acid-acetonitrile, 15% acetonitrile) to obtain compound INT-5B (120 mg).
[0415] MS (ESI) M / Z: 289.1, 291.1 [M+H] + .
[0416] Step 3: Synthesis of compound INT-5C
[0417] To a solution of compound INT-5-1 (30 mg, 0.13 mmol) in tetrahydrofuran (3 mL) was added N,N'-carbonyldiimidazole (42.16 mg, 0.26 mmol) and ethyldiisopropylamine (336.02 mg, 2.60 mmol) under nitrogen at 25°C. The resulting mixed reaction solution was stirred at 25°C under nitrogen for 2 hours. Deuterated methanol (3 mL) was added to the above reaction solution, and the resulting mixed reaction solution was stirred at 60°C under nitrogen for 16 hours. The mixed reaction solution was quenched with saturated aqueous ammonium chloride (10 mL) and extracted with ethyl acetate (10 mL × 2). The combined organic phases were washed with saturated brine (10 mL × 3), dried, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound INT-5C (30 mg).
[0418] MS (ESI) M / Z: 289.9, 291.9 [M+H] + .
[0419] Step 4: Synthesis of compound INT-5D
[0420] To a solution of INT-5-1 (30 mg, 0.13 mmol) in tetrahydrofuran (3 mL) was added N,N'-carbonyldiimidazole (42.16 mg, 0.26 mmol) and ethyldiisopropylamine (336.02 mg, 2.60 mmol) under nitrogen at 25°C. The resulting mixed reaction solution was stirred at 25°C under nitrogen for 2 hours. Anhydrous methanol (2 mL) was added to the above reaction solution, and the resulting mixed reaction solution was stirred at 60°C under nitrogen for 16 hours. The mixed reaction solution was quenched with saturated aqueous ammonium chloride (10 mL) and extracted with ethyl acetate (10 mL × 2). The combined organic phases were washed with saturated brine (10 mL × 3), dried, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give INT-5D (25 mg).
[0421] MS (ESI) M / Z: 288.8 [M+H] + .
[0422] Step 5: Synthesis of compound INT-5E
[0423] To a solution of INT-5-1 (30 mg, 0.13 mmol) in tetrahydrofuran (3 mL) was added N,N'-carbonyldiimidazole (42.16 mg, 0.26 mmol) and ethyldiisopropylamine (336.02 mg, 2.60 mmol) under nitrogen at 25°C. The resulting mixed reaction solution was stirred at 25°C under nitrogen for 2 hours. Methylamine hydrochloride (180 mg, 2.60 mmol) was added to the above reaction solution, and the resulting mixed reaction solution was stirred at 60°C under nitrogen for 16 hours. The mixed reaction solution was quenched with saturated aqueous ammonium chloride (10 mL) and extracted with ethyl acetate (10 mL x 2). The combined organic phases were washed with saturated brine (10 mL x 3), dried, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield INT-5E (25 mg).
[0424] MS (ESI) M / Z: 285.9, 287.9 [M+H] + .
[0425] Intermediate INT-6
[0426] The intermediate INT-6 is a commercial reagent with CAS number: 1427587-32-3, which was purchased.
[0427] Intermediate INT-7
[0428] Step 1: Synthesis of compound INT-7-2
[0429] Compound INT-7-1 (520 mg, 2.15 mmol) was dissolved in N,N-dimethylformamide (10 mL), and 60% sodium hydride (300 mg, 8.6 mmol) was slowly added at 0°C. The mixture was stirred at room temperature for 30 minutes, and then iodomethane (366 mg, 2.58 mmol) was added. The system was reacted at 25°C for 5 hours. After TLC monitoring, the reaction was diluted with water (50 mL) and extracted twice with ethyl acetate (20 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was chromatographed on a silica gel column to obtain compound INT-7-2 (350 mg).
[0430] MS (ESI) M / Z: 256.0 [M+H] + .
[0431] Step 2: Synthesis of compound INT-7
[0432] Compound INT-7-2 (350 mg, 1.37 mmol), bis-pinacol borate (696 mg, 2.74 mmol), potassium acetate (404 mg, 4.11 mmol) and [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane complex (112 mg, 0.14 mmol) were added to 1,4-dioxane (15 mL). After nitrogen substitution three times, the mixture was reacted at 90°C for 16 hours. LCMS monitored the reaction completion. The reaction solution was directly concentrated under reduced pressure and purified by silica gel column chromatography to obtain compound INT-7 (256 mg).
[0433] MS (ESI) M / Z: 304.1 [M+H] + .
[0434] Intermediate INT-8
[0435] Step 1: Synthesis of compound INT-8-2
[0436] Compound INT-8-1 (1.0 g, 4.51 mmol) was dissolved in dimethyl sulfate (5 mL) at room temperature, and the mixture was stirred at 60°C for 16 hours to precipitate a white solid. LCMS monitored the reaction until completion, and the reaction solution was filtered. The white solid was rinsed with tetrahydrofuran and dried to obtain compound INT-8-2 (1.0 g).
[0437] MS (ESI) M / Z: 238.0 [M+H] + .
[0438] Step 2: Synthesis of compound INT-8-3
[0439] At room temperature, potassium hydroxide (708 mg, 12.66 mmol) and potassium ferricyanide (2.78 g, 8.44 mmol) were added to acetonitrile and water (8 / 8 mL) containing compound INT-8-2 (1.2 g), and the mixture was stirred at room temperature for 2 hours. LCMS detected the completion of the reaction, and the mixture was diluted with water (20 mL), extracted with ethyl acetate (30 mL × 3), and the combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was separated and purified by column chromatography to give compound INT-8-3 (1.0 g).
[0440] MS (ESI) M / Z: 252.1 [M+H] + .
[0441] Step 3: Synthesis of compound INT-8
[0442] At room temperature, to a solution of compound INT-8-3 (300 mg, 1.19 mmol) in dioxane (10 mL), diboronic acid pinacol ester (756 mg, 2.98 mmol), potassium acetate (350 mg, 3.57 mmol) and [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium (II) dichloromethane complex (87 mg, 0.119 mmol) were added. The resulting mixed reaction liquid was heated at 90 ° C under nitrogen protection and stirred for 16 hours. The obtained mixed reaction liquid was filtered, the mother liquor was concentrated under reduced pressure, and the residue was purified by column chromatography to obtain compound INT-8 (300 mg).
[0443] MS (ESI) M / Z: 300.1 [M+H] + .
[0444] Intermediate INT-9
[0445] Step 1: Synthesis of compound INT-9-2
[0446] Compound INT-9-1 (1 g, 4.24 mmol) was dissolved in N-methylpyrrolidone (3 mL), and a methylamine tetrahydrofuran solution (2 M, 5 mL, 10 mmol) was added at room temperature. The mixture was heated to 110° C. in a sealed tube and reacted for 16 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by reverse phase flash chromatography (80 g; mobile phase A: pure water; mobile phase B: acetonitrile; flow rate: 70 mL / min). When the mobile phase B content reached 15%, compound INT-9-2 (610 mg) was collected.
[0447] MS (ESI) M / Z: 249.9 [M+H] + .
[0448] Step 2: Synthesis of compound INT-9-3
[0449] Compound INT-9-2 (550 mg, 2.21 mmol) was dissolved in tetrahydrofuran (10 mL) and borane tetrahydrofuran solution (1 M, 13.32 mL) was added dropwise at 0 ° C. The system was reacted at room temperature for 16 hours under nitrogen protection. The mixed reaction solution was quenched by adding methanol (4 mL) under ice bath, diluted with water, and then extracted twice with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was chromatographed on a silica gel column to give compound INT-9-3 (330 mg).
[0450] MS (ESI) M / Z: 234.0 [M+H] + .
[0451] Step 3: Synthesis of compound INT-9-4
[0452] Compound INT-9-3 (270 mg, 1.15 mmol) was dissolved in tetrahydrofuran (6 mL), and triethylamine (349.11 mg, 3.45 mmol) and triphosgene (341.26 mg, 1.15 mmol) were added at -60 ° C. After completion, the temperature was raised to -40 ° C and stirred for 2 hours. TLC and LCMS monitored the disappearance of the starting material. The reaction solution was diluted with water (10 mL) and extracted with ethyl acetate (10 mL × 2). The organic phase was washed twice with saturated brine and dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was chromatographed on a silica gel column to give compound INT-9-4 (116 mg).
[0453] MS (ESI) M / Z: 302.9 [M+41+H] + .
[0454] Step 4: Synthesis of compound INT-9
[0455] Potassium acetate (55.94 mg, 0.57 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride dichloromethane complex (15.52 mg, 0.019 mmol) were added to a mixture of compound INT-9-4 (50 mg, 0.19 mmol) and pinacol diboron (96.50 mg, 0.38 mmol) in 1,4-dioxane (5.0 mL). The resulting mixed reaction solution was heated at 90°C and stirred for 16 hours under nitrogen. LCMS monitoring showed the disappearance of the starting material. The reaction solution was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound INT-9 (30 mg).
[0456] MS (ESI) M / Z: 308.0 [M+H] +.
[0457] Examples A02-P1 and A02-P2
[0458] Step 1: Synthesis of Compound A02-2
[0459] To a tetrahydrofuran solution (100 mL) of compound A02-1 (10.0 g, 39.53 mmol), but-3-en-1-ol (3.4 g, 47.22 mmol), and triphenylphosphine (15.55 g, 59.35 mmol) was added diisopropyl azodicarboxylate (11.99 g, 59.35 mmol) at 0°C under nitrogen. The mixture was stirred at room temperature for 16 hours. After the reaction, the mixture was concentrated, and the residue was isolated and purified by column chromatography to obtain compound A02-2 (7.00 g).
[0460] MS(ESI)M / Z:305.9,307.9,309.9[M+H] + .
[0461] Step 2: Synthesis of Compound A02-3
[0462] At room temperature, under nitrogen, triphenylphosphine (1.28 g, 4.89 mmol), palladium acetate (0.37 g, 1.63 mmol), tetraethylammonium bromide (2.16 g, 13.03 mmol), and potassium acetate (7.99 g, 81.45 mmol) were added to ultra-dry N,N-dimethylformamide (220 mL) containing compound A02-2 (5.00 g, 16.29 mmol). The mixture was stirred at 105°C for 16 hours. After the reaction, the mixture was diluted with water (100 mL) and extracted with ethyl acetate (200 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was separated and purified by column chromatography to yield compound A02-3 (2.00 g).
[0463] MS (ESI) M / Z: 226.0, 228.0 [M+H] + .
[0464] Step 3: Synthesis of Compound A02-4
[0465] To a solution of compound A02-3 (2.00 g, 8.85 mmol) in tetrahydrofuran (15 mL) / water (15 mL) were added sodium periodate (9.46 g, 44.25 mmol) and potassium osmate dihydrate (0.33 g, 0.89 mmol) at room temperature. The mixture was stirred at room temperature for 16 hours. After the reaction, the mixture was diluted with water (200 mL) and extracted with ethyl acetate (200 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was isolated and purified by column chromatography to yield compound A02-4 (1.19 g).
[0466] MS (ESI) M / Z: 228.0, 230.0 [M+H] + .
[0467] Step 4: Synthesis of Compound A02-5
[0468] To a solution of compound A02-4 (500 mg, 2.19 g) and tert-butylsulfenamide (400 mg, 0.328 mmol) in tetrahydrofuran (10 mL) at room temperature was added tetraethyl titanate (1.00 g, 4.38 mmol). The resulting mixed reaction solution was heated at 65°C under nitrogen and stirred for 16 hours. After the reaction, the mixed reaction solution was concentrated under reduced pressure. The residue was purified by column chromatography to yield compound A02-5 (545 mg).
[0469] MS (ESI) M / Z: 330.9, 332.9 [M+H] + .
[0470] Step 5: Synthesis of Compound A02-6
[0471] To compound A02-5 (500 mg, 1.51 mmol) dissolved in tetrahydrofuran (10 mL) at 0°C under nitrogen was added a borane-tetrahydrofuran solution (1 M, 7.5 mL, 7.5 mmol). The resulting mixed reaction solution was stirred at 0°C under nitrogen for 4 hours. After completion of the reaction, the mixed reaction solution was quenched with methanol (20 mL). The mixed solution was concentrated, and the residue was purified by column chromatography to afford crude compound A02-6 (495 mg).
[0472] MS (ESI) M / Z: 333.0, 335.0 [M+H] + .
[0473] Step 6: Synthesis of Compound A02-7
[0474] To a solution of compound A02-6 (445 mg, 0.64 mmol) in dioxane (18 mL) was added a 4 M solution of hydrochloric acid in methanol (6.2 mL, 24.80 mmol) at room temperature. The resulting mixed reaction solution was stirred at room temperature for 5 hours. After the reaction was completed, the mixed reaction solution was quenched with amine-methanol (200 mL). The mixed solution was concentrated, and the residue was purified by column chromatography to obtain compound A02-7 (230 mg). MS (ESI) M / Z: 229.0, 231.0 [M+H] + .
[0475] Step 7: Synthesis of Compound A02-8
[0476] To compound A02-7 (190 mg, 0.83 mmol) dissolved in DMF (3 mL) at room temperature under nitrogen was added propionic acid (120 mg, 1.66 mmol), 2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethylbromohexafluorophosphate (630 mg, 1.66 mmol), and ethyldiisopropylamine (540 mg, 4.15 mmol). The resulting reaction mixture was stirred at room temperature under nitrogen for 2 hours. After the reaction, the mixed reaction solution was poured into water (50 mL) and extracted with ethyl acetate (50 mL×2). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was purified by reverse phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 25 g; mobile phase A: containing pure water; mobile phase B: acetonitrile; flow rate: 35 mL / min; gradient: 5% B-95% B in 30 minutes; detector: 214 nm) to obtain compound A02-8 (140 mg).
[0477] MS (ESI) M / Z: 285.0, 287.0 [M+H] + .
[0478] Step 8: Synthesis of Compound A02
[0479] Under nitrogen at room temperature, to a solution of compound A02-8 (70 mg, 0.25 mmol) in anhydrous ethanol (3 mL) / water (1 mL) was added 1-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroquinolin-2(1H)-one (140 mg, 0.50 mmol), anhydrous potassium carbonate (69 mg, 0.50 mmol), and tetrakis(triphenylphosphine)palladium (29 mg, 0.025 mmol). The resulting mixed reaction solution was stirred at 85°C under nitrogen for 16 hours. After completion of the reaction, the mixed reaction solution was filtered through a filter membrane and concentrated. The residue was separated and purified by column chromatography to obtain a brown crude product of A02. The crude product was purified by reverse phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 25 g; mobile phase A: containing pure water; mobile phase B: acetonitrile; flow rate: 35 mL / min; gradient: 5% B-95% B in 30 minutes; detector: 214 nm) to give compound A02 (56 mg).
[0480] Step 9: Synthesis of compounds A02-P1 and A02-P2
[0481] Compound A02 (56 mg) was purified by supercritical fluid chromatography (chromatographic conditions: system: Waters SFC 80; column name: Chromatographic column size: 250×25mm 10μm; mobile phase A; supercritical CO2; mobile phase B: methanol (+0.1% 7.0mol / L ammonia methanol), A:B=70:30; wavelength: 214nm; flow rate: 50mL / min; column temperature: room temperature; column pressure: 100bar, injection volume: 2.0mL; cycle time: 4.00min) was purified to obtain compound A02-P1 (peak 1, 20.51mg) and compound A02-P2 (peak 2, 22.34mg).
[0482] Compound A02-P1: Peak 1, analyzed by supercritical fluid chromatography (chromatographic conditions: system: Waters UPCC (CA 415); column name: Column dimensions: 100 × 3.0 mm × 3.0 μm; mobile phase A: supercritical CO2; mobile phase B: methanol (0.1% DEA), A:B = 80:20; wavelength: 214 nm; flow rate: 1.5 mL / min; column temperature: 35°C; column pressure: 1800 psi, injection volume: 1.0 μL; cycle time: 10.0 min); retention time RT: 2.279 min, ee = 100%.
[0483] 1H NMR (400MHz, DMSO-d6): δ8.36(d,J=8.0Hz,1H),8.26(s,1H),8.22(s,1H),7.40(d,J=8.4Hz,2.0Hz,1H),7.37(s,1H),7.15(d,J=8.4Hz,1H),5.12-5. 07(m,1H),4.37-4.23(m,2H),3.28(s,3H),2.91(t,J=6.4Hz,2H),2.58(t, J=8.0Hz,2H),2.21-2.04(m,3H),1.97-1.90(m,1H),1.05(t,J=7.6Hz,3H).
[0484] MS (ESI) M / Z: 366.1 [M+H] +
[0485] A02-P2: Peak 2, analyzed by supercritical fluid chromatography (chromatographic conditions: system: Waters UPCC (CA 415); column name: Column dimensions: 100 × 3.0 mm × 3.0 μm; mobile phase A: supercritical CO2; mobile phase B: methanol (0.1% DEA), A:B = 80:20; wavelength: 214 nm; flow rate: 1.5 mL / min; column temperature: 35°C; column pressure: 1800 psi, injection volume: 1.0 μL; cycle time: 10.0 min); retention time RT: 2.959 min, ee = 98.6%.
[0486] 1 H NMR (400MHz, DMSO-d6): δ8.36(d,J=8.0Hz,1H),8.26(s,1H),8.22(s,1H),7.40(d,J=8.4Hz,2.0Hz,1H),7.36(s,1H),7.15(d,J=8.4Hz,1H),5.12-5. 07(m,1H),4.37-4.23(m,2H),3.28(s,3H),2.91(t,J=6.8Hz,2H),2.58(t, J=8.0Hz,2H),2.21-2.05(m,3H),1.97-1.91(m,1H),1.05(t,J=7.6Hz,3H).
[0487] MS (ESI) M / Z: 366.1 [M+H] + .
[0488] Example A08
[0489] Step 1: Synthesis of Compound A08
[0490] Compound INT-4 (64 mg, 0.22 mmol), INT-5A (30 mg, 0.11 mmol), potassium carbonate (45.61 mg, 0.33 mmol) and 1,1-bis(diphenylphosphino)diphenylferric palladium chloride (8.05 mg, 0.011 mmol) were dissolved in 1,4-dioxane (5 mL) and water (0.5 mL). After nitrogen replacement three times, the mixture was reacted at 90°C for 4 hours. The reaction solution was directly concentrated under reduced pressure and purified by silica gel column chromatography to obtain a crude product. The crude product was purified by reverse phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 40 g; mobile phase A: pure water; mobile phase B: acetonitrile; flow rate: 40 mL / min; gradient: 5% B-95% B in 20 minutes; detector: 214 nm) to obtain compound A08 (32.17 mg).
[0491] Compound A08: analyzed by supercritical fluid chromatography (chromatographic conditions: system: Waters UPCC (CA352); column name: Column dimensions: 100 × 3.0 mm (3.0 μm); mobile phase A: supercritical CO2; mobile phase B: methanol (0.1% DEA), A:B = 70:30; wavelength: 214 nm; flow rate: 1.5 mL / min; column temperature: 35°C; column pressure: 1800 psi, injection volume: 1.0 μL; cycle time: 8.0 min); retention time (RT): 2.404 min, ee = 100%.
[0492] 1 H NMR (400MHz, DMSO-d6): δ8.35 (d, J = 8.0Hz, 1H), 8.26 (s, 1H), 8.23 (s, 1H), 7.5 1(dd,J=8.4Hz,1.6Hz,1H), 7.42(d,J=2.0Hz,1H), 7.16(d,J=8.4Hz,1H), 5.29( s,2H), 5.12-5.08(m,1H), 4.38-4.33(m,1H), 4.29-4.24(m,1H), 3.31(s,3H), 2 .21-2.14(m,2H), 2.12-2.04(m,1H), 1.97-1.90(m,1H), 1.05(t,J=7.6Hz,3H).
[0493] MS (ESI) M / Z: 368.2 [M+H] + .
[0494] Example A09
[0495] Step 1: Synthesis of Compound A09
[0496] Compound INT-5A (30 mg, 0.11 mmol), INT-2 (38 mg, 0.13 mmol), potassium carbonate (46 mg, 0.33 mmol), and 1,1-bis(diphenylphosphino)diphenylferric palladium chloride (8.05 mg, 0.011 mmol) were added to 1,4-dioxane (5 mL) and water (0.5 mL). After nitrogen substitution three times, the mixture was reacted at 90°C for 4 hours. The reaction solution was directly concentrated under reduced pressure and purified by silica gel column chromatography to obtain a crude product. The crude product was then purified by reverse-phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 40 g; mobile phase A: pure water; mobile phase B: acetonitrile; flow rate: 40 mL / min; gradient: 5% B to 95% B over 20 minutes; detector: 214 nm) to obtain compound A09 (9.42 mg).
[0497] Compound A09: analyzed by supercritical fluid chromatography (chromatographic conditions: system: Waters UPCC (CA352); column name: Column dimensions: 100 × 3.0 mm (3.0 μm); mobile phase A: supercritical CO2; mobile phase B: methanol (0.1% DEA), A:B = 70:30; wavelength: 214 nm; flow rate: 1.5 mL / min; column temperature: 35°C; column pressure: 1800 psi, injection volume: 1.0 μL; cycle time: 8.0 min); retention time (RT): 2.020 min, ee = 100%.
[0498] 1 HNMR(400MHz, CDCl3)δ8.37(s,1H),8.32(s,1H),7.69-7.64(m,2H),7.61(d, J=2.0Hz,1H),7.39(d,J=8.8Hz,1H),6.70(d,J=9.2Hz,1H),6.20(d,J=7.2Hz, 1H),5.32-5.28(m,1H),4.42-4.37(m,1H),4.32-4.26(m,1H),3.72(s,3H),2. 36-2.30(m,2H),2.27-2.23(m,1H),2.20-2.13(m,1H),1.24(t,J=7.6Hz,3H).
[0499] MS (ESI) M / Z: 364.2 [M+H] + .
[0500] Examples A10-P1 and A10-P2
[0501] Step 1: Synthesis of Compound A10
[0502] Compound A02-8 (50 mg, 0.18 mmol), C36-3 (127 mg, 0.45 mmol), potassium carbonate (75 mg, 0.54 mmol), and 1,1-bis(diphenylphosphino)diphenylferric palladium chloride (14 mg, 0.018 mmol) were added to a mixed solvent of 1,4-dioxane (5 mL) and water (0.5 mL). The atmosphere was purged with nitrogen three times and the mixture was reacted at 90°C for 16 hours. The reaction solution was directly concentrated under reduced pressure and purified by silica gel column chromatography to obtain compound A10 (61 mg).
[0503] MS (ESI) M / Z: 361.1 [M+H] + .
[0504] Step 2: Synthesis of compounds A10-P1 and A10-P2
[0505] Compound A10 (61 mg) was purified by supercritical fluid chromatography (chromatographic conditions: system: Waters SFC 150; column name: Chromatographic column size: 250×25 mm 10 μm; mobile phase A; supercritical CO2; mobile phase B: ethanol (+0.1% 7.0 mol / L ammonia methanol), A:B=60:40; wavelength: 214 nm; flow rate: 120 mL / min; column temperature: room temperature; column pressure: 100 bar, injection volume: 3.0 mL; cycle time: 9.42 min) was used to purify compound A10-P1 (peak 1, 12.83 mg) and compound A10-P2 (peak 2, 13.19 mg).
[0506] Compound A10-P1: Peak 1 was analyzed by supercritical fluid chromatography. Chromatographic conditions: System: Waters UPCC (CA-352); Column name: Column dimensions: 100 × 3.0 mm (3.0 μm); mobile phase A: supercritical CO2; mobile phase B: methanol (0.1% DEA), A:B = 70:30; wavelength: 214 nm; flow rate: 1.5 mL / min; column temperature: 35°C; column pressure: 1800 psi, injection volume: 1.0 μL; cycle time: 8.0 min); retention time (RT): 3.050 min, ee = 100%.
[0507] 1HNMR (400MHz, DMSO-d6) δ8.37(d,J=8.0Hz,1H),8.30(s,1H),8.24(s,1H),7.80(d,J=1.2Hz,1H),7.68(d,J=8.8Hz,1H),7.55(dd,J=8.8Hz,1.6 Hz,1H),7.47(d,J=0.8Hz,1H),5.14-5.09(m,1H),4.38-4.24(m,2H),3. 93(s,3H),2.20-2.07(m,3H),1.98-1.91(m,1H),1.06(t,J=7.6Hz,3H).
[0508] MS (ESI) M / Z: 361.1 [M+H] + .
[0509] Compound A10-P2: Peak 2, analyzed by supercritical fluid chromatography (chromatographic conditions: system: Waters UPCC (CA-352); column name: Column dimensions: 100 × 3.0 mm (3.0 μm); mobile phase A: supercritical CO2; mobile phase B: methanol (0.1% DEA), A:B = 70:30; wavelength: 214 nm; flow rate: 1.5 mL / min; column temperature: 35°C; column pressure: 1800 psi, injection volume: 1.0 μL; cycle time: 8.0 min); retention time (RT): 3.992 min, ee = 98.5%.
[0510] 1 HNMR (400MHz, DMSO-d6) δ8.38(d,J=7.6Hz,1H),8.30(s,1H),8.24(s,1H),7.80(d,J=0.8Hz,1H),7.68(d,J=8.8Hz,1H),7.55(dd,J=8.8Hz ,1.6Hz,1H),7.47(s,1H),5.14-5.09(m,1H),4.37-4.25(m,2H),3.93(s,3H),2.20-2.07(m,3H),1.98-1.91(m,1H),1.06(t,J=7.6Hz,3H).
[0511] MS (ESI) M / Z: 361.1 [M+H] + .
[0512] Example A13
[0513] Step 1: Synthesis of Compound A13
[0514] To a solution of compound INT-5C (30 mg, 0.10 mol) and compound INT-6 (43 mg, 0.15 mmol) in ethanol (2 mL) and water (0.5 mL) at room temperature were added potassium carbonate (41.46 mg, 0.30 mmol) and tetrakis(triphenylphosphine)palladium (11.56 mg, 0.01 mmol). The resulting mixed reaction liquid was heated at 85°C under nitrogen protection and stirred for 16 hours. The resulting mixed reaction liquid was concentrated under reduced pressure. The residue was purified by HPLC to give compound A13 (17.46 mg).
[0515] Compound A13: analyzed by supercritical fluid chromatography (chromatographic conditions: system: Waters UPCC (CA 415); column name: Column dimensions: 100 × 3.0 mm (3.0 μm); mobile phase A: supercritical CO2; mobile phase B: methanol (0.1% DEA), gradient: B5%-40%; wavelength: 214 nm; flow rate: 1.5 mL / min; column temperature: 35°C; column pressure: 1800 psi, injection volume: 1.00 μL; cycle time: 8.0 min); retention time (RT): 4.022 min, ee = 100%.
[0516] 1 HNMR (400MHz, DMSO-d6) δ8.26(s,1H),8.25(s,1H),7.79(d,J=8.0Hz,1H),7.40(dd,J=8.4Hz,1.0Hz,1H),7.36(d,J=1.6Hz,1H),7.15(d,J=8.4 Hz,1H),4.91-4.81(m,1H),4.38-4.23(m,2H),3.28(s,3H),2.91(d,J=6 .8Hz,2H),2.57(d,J=7.6Hz,2H),2.15-2.04(m,1H),2.02-1.91(m,1H).
[0517] MS (ESI) M / Z: 371.1 [M+H] + .
[0518] Example A15
[0519] Step 1: Synthesis of Compound A15
[0520] Under nitrogen protection, to a mixture of dioxane and water (4 / 0.4 mL) of compound INT-2 (62 mg, 0.217 mmol) were added compound INT-1B ((25 mg, 0.087 mmol), potassium carbonate (36 mg, 0.261 mmol) and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (8 mg, 0.011 mmol), and the resulting mixed reaction liquid was stirred at 90°C under nitrogen protection for 16 hours. The obtained mixed reaction liquid was filtered and concentrated under reduced pressure, and the residue was purified by column chromatography (dichloromethane / methanol = 10 / 1) to obtain 25 mg of a crude product. The crude product was purified by Prep-HPLC (separation conditions: preparation column: Waters sunfire C18 10 μm OBD 19×250 mm, mobile phase: 0.1% FA (formic acid) aqueous solution / CH3CN, flow rate: 20 mL / min, gradient: 13%-25%, detection wavelength: 214 nm / 254 nm, cycle time: 16 min. ) was purified to give compound A15 (7.78 mg).
[0521] Compound A15: analyzed by supercritical fluid chromatography (chromatographic conditions: system: Waters UPCC (CA352); column name: Column dimensions: 100 × 3.0 mm (3.0 μm); mobile phase A: supercritical CO2; mobile phase B: methanol (0.1% DEA), A:B = 60:40; wavelength: 214 nm; flow rate: 1.5 mL / min; column temperature: 35°C; column pressure: 1800 psi, injection volume: 1.0 μL; cycle time: 8.0 min); retention time (RT): 2.878 min, ee = 100%.
[0522] 1 H NMR (400MHz, DMSO-d6) δ8.44(s,1H),8.26(s,1H),7.95(d,J=9.6Hz,1H),7.75(s,1H),7.65-7.60(m,2H),6.68(d,J=9.2Hz,1H) ,6.44(d,J=8.8Hz,1H),5.65(s,1H),4.94-4.90(m,1H),3.66(s,3H),2.63-2.59(m,2H),1.92-1.86(m,1H),1.76-1.66(m,3H).
[0523] MS (ESI) M / Z: 366.1 [M+H] + .
[0524] Example A16
[0525] Step 1: Synthesis of Compound A16
[0526] Under nitrogen protection, to a mixture of compound INT-4 (25 mg, 0.087 mmol) in dioxane and water (4 / 0.4 mL) were added compound INT-1B (50 mg, 0.174 mmol), potassium carbonate (36 mg, 0.261 mmol) and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (8 mg, 0.009 mmol). The resulting mixed reaction solution was stirred at 90°C under nitrogen protection for 16 hours. The resulting mixed reaction solution was filtered, the mother liquor was concentrated under reduced pressure, and the residue was purified by column chromatography to obtain 25 mg of a crude product. The crude product was purified by Prep-HPLC (separation conditions: preparative column: Waters sunfire C18 10 μm OBD 19×250 mm, mobile phase: 0.1% FA aqueous solution / CH3CN, flow rate: 20 mL / min, gradient: 13%-20%, detection wavelength: 214 nm / 254 nm, cycle time: 16 min) to give compound A16 (8.13 mg).
[0527] Compound A16: analyzed by supercritical fluid chromatography (chromatographic conditions: system: Waters UPCC (CA352); column name: Column dimensions: 100 × 3.0 mm (3.0 μm); mobile phase A: supercritical CO2; mobile phase B: methanol (0.1% DEA), A:B = 60:40; wavelength: 214 nm; flow rate: 1.5 mL / min; column temperature: 35°C; column pressure: 1800 psi, injection volume: 1.0 μL; cycle time: 8.0 min); retention time (RT): 3.062 min, ee = 100%.
[0528] 1 HNMR (400MHz, DMSO-d6) δ8.41(s,1H),8.19(s,1H),7.36(dd,J=8.4Hz,2.0Hz,1H),7.29(d,J=1.6Hz,1H),7.18(d,J=8.4Hz,1H),6.42 (d,J=8.8Hz,1H),5.63(s,1H),5.29(s,2H),4.92-4.89(m,1H),3.31(s,3H),2.60-2.56(m,2H),1.88-1.86(m,1H),1.74-1.67(m,3H).
[0529] MS (ESI) M / Z: 370.1 [M+H] + .
[0530] Example A17
[0531] Step 1: Synthesis of Compound A17
[0532] Under nitrogen protection, to a solution of compound INT-5B (40 mg, 0.138 mmol) in dioxane and water (4 / 0.4 mL) were added compound INT-2 (80 mg, 0.277 mmol), potassium carbonate (57 mg, 0.415 mmol), and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (10 mg, 0.014 mmol). The resulting mixed reaction solution was stirred at 90° C. under nitrogen protection for 16 hours. The resulting mixed reaction solution was filtered, the mother liquor was concentrated under reduced pressure, and the residue was purified by column chromatography to obtain 25 mg of a crude product. The crude product was purified by Prep-HPLC (separation conditions: preparative column: Waters sunfire C18 10 μm OBD 19×250 mm, mobile phase: 0.1% FA aqueous solution / CH3CN, flow rate: 20 mL / min, gradient: 13%-25%, detection wavelength: 214 nm / 254 nm, cycle time: 16 min) to give compound A17 (13.14 mg).
[0533] Compound A17: analyzed by supercritical fluid chromatography (chromatographic conditions: system: Waters UPCC (CA352); column name: Column dimensions: 100 × 3.0 mm (3.0 μm); mobile phase A: supercritical CO2; mobile phase B: methanol (0.1% DEA), A:B = 60:40; wavelength: 214 nm; flow rate: 1.5 mL / min; column temperature: 35°C; column pressure: 1800 psi, injection volume: 1.0 μL; cycle time: 8.0 min); retention time (RT): 2.915 min, ee = 100%.
[0534] 1HNMR(400MHz,DMSO-d6)δ8.33(s,1H),8.31(s,1H),7.96(d,J=9.6Hz,1H),7.88 (d,J=2.0Hz,1H),7.79(dd,J=8.8Hz,2.0Hz,1H),7.60(d,J=8.8Hz,1H),6.65(d, J=9.6Hz,1H),6.58(d,J=8.0Hz,1H),5.71(s,1H),4.96-4.91(m,1H),4.39-4.3 4(m,1H), 4.29-4.23(m,1H), 3.65(s,3H), 2.11-2.04(m,1H), 2.00-1.95(m,1H).
[0535] MS (ESI) M / Z: 368.1 [M+H] + .
[0536] Example A18
[0537] Step 1: Synthesis of Compound A18
[0538] Under nitrogen protection, to a mixture of compound INT-5B (40 mg, 0.138 mmol) in dioxane and water (4 / 0.4 mL) were added compound INT-4 (80 mg, 0.277 mmol), potassium carbonate (57 mg, 0.415 mmol), and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (10 mg, 0.014 mmol). The resulting mixed reaction solution was stirred at 90°C under nitrogen protection for 16 hours. The resulting mixed reaction solution was filtered, the mother liquor was concentrated under reduced pressure, and the residue was purified by column chromatography to obtain 27 mg of a crude product. The crude product was purified by Prep-HPLC (separation conditions: preparative column: Waters sunfire C18 10 μm OBD 19×250 mm, mobile phase: 0.1% FA aqueous solution / CH3CN, flow rate: 20 mL / min, gradient: 13%-20%, detection wavelength: 214 nm / 254 nm, cycle time: 16 min) to give compound A18 (8.13 mg).
[0539] Compound A18: analyzed by supercritical fluid chromatography (chromatographic conditions: system: Waters UPCC (CA352); column name: Column dimensions: 100 × 3.0 mm (3.0 μm); mobile phase A: supercritical CO2; mobile phase B: methanol (0.1% DEA), A:B = 60:40; wavelength: 214 nm; flow rate: 1.5 mL / min; column temperature: 35°C; column pressure: 1800 psi, injection volume: 1.0 μL; cycle time: 8.0 min); retention time (RT): 3.140 min, ee = 100%.
[0540] 1 HNMR (400MHz, DMSO-d6) δ8.28(s,1H),8.25(s,1H),7.51(dd,J=8.4Hz,2.0Hz,1H),7.42(d,J=1.6Hz,1H),7.16(d,J=8.4Hz,1H),6.59(d,J=7.6 Hz,1H),5.72(s,1H),5.29(s,2H),4.94-4,89(m,1H),4.37-4.32(m,1H) ,4.27-4.21(m,1H),3.31(s,3H),2.10-2.02(m,1H),1.99-1.91(m,1H).
[0541] MS (ESI) M / Z: 372.1 [M+H] + .
[0542] Example C04
[0543] Step 1: Synthesis of compound C04
[0544] At room temperature, compound INT-2 (20 mg, 0.07 mmol) and compound INT-1A (24 mg, 0.084 mmol) were dissolved in 1,4-dioxane (10 mL) and nitrogen was bubbled for 5 minutes. Then, tetrakis(triphenylphosphine)palladium (8.1 mg, 0.007 mmol) was added. Sodium carbonate (8.9 mg, 0.084 mmol) was dissolved in water (3 mL) and added to the system. The atmosphere was fully replaced with N2, and the system was reacted at 85°C for 1 hour. The reaction solution was cooled to room temperature, diluted with water (30 mL), and extracted with ethyl acetate (30 mL × 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was separated and purified by Prep-HPLC (YMC Triart 20 × 250 mm 5 μm, water (0.01% formic acid) / acetonitrile, 10%-100%, 20 mL / min) to obtain compound C04 (12 mg).
[0545] Compound C04: 1H NMR (400MHz, DMSO-d6) δ8.36(s,1H),8.30-8.28(m,2H),7.96(d,J=9.5Hz,1H),7.75(s,1H),7.63(s,2H),6.68(d,J=9.4Hz,1H) ,5.11(q,J=6.5Hz,1H),3.67(s,3H),2.68-2.59(m,2H),2.16(qd,J=7.4,4.7Hz,2H),1.92-1.65(m,4H),1.06(t,J=7.6Hz,3H).
[0546] MS (ESI) M / Z: 362.2 [M+H] + .
[0547] Example C06
[0548] Step 1: Synthesis of compound C06
[0549] Compound INT-3 (20 mg, 0.069 mmol) and compound INT-1A (23 mg, 0.083 mmol) were dissolved in 1,4-dioxane (10 mL). Tetrakis(triphenylphosphine)palladium (8 mg, 0.0069 mmol) was added, and sodium carbonate (8.8 mg, 0.083 mmol) dissolved in water (3 mL) was added to the mixture. The atmosphere was fully purged with nitrogen, and the mixture was reacted at 85°C under nitrogen for 1 hour. The reaction solution was extracted with ethyl acetate (50 mL) and water (30 mL). The organic phase was washed with saturated sodium chloride (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate concentrated in vacuo to yield the crude product. The crude product was purified by Prep-HPLC (YMC Triart 20×250 mm 5 μm, water (0.01% formic acid) / acetonitrile, 10%-100%, 20 mL / min) to yield compound C06 (15 mg).
[0550] Compound C06: 1H NMR(400MHz,DMSO-d6)δ8.32(s,1H),8.28(d,J=8.5Hz,1H),8.20(s,1H),7.2 4(dd,J=8.2,2.1Hz,1H),7.17(d,J=2.1Hz,1H),7.13(s,1H),7.02(d,J=8.3Hz ,1H),5.09(q,J=6.3Hz,1H),4.33(d,J=2.0Hz,2H),3.20(s,3H),2.64-2.57( m, 2H), 2.16 (qd, J = 7.4, 4.6Hz, 2H), 1.93-1.64 (m, 4H), 1.06 (t, J = 7.6Hz, 3H).
[0551] MS (ESI) M / Z: 365.1 [M+H] + .
[0552] Example C07
[0553] Step 1: Synthesis of compound C07
[0554] Compound INT-4 (20 mg, 0.069 mmol) and compound INT-1A (23 mg, 0.083 mmol) were dissolved in 1,4-dioxane (5 mL). Tetrakis(triphenylphosphine)palladium (8 mg, 0.0069 mmol) was added, and sodium carbonate (8.8 mg, 0.083 mmol) dissolved in water (3 mL) was added to the mixture. The atmosphere was fully purged with nitrogen, and the mixture was reacted at 85°C under nitrogen for 1 hour. The reaction solution was extracted with ethyl acetate (50 mL) and water (30 mL). The organic phase was washed with saturated sodium chloride (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate concentrated in vacuo to yield the crude product. The crude product was purified by Prep-HPLC (YMC Triart 20×250 mm 5 μm, water (0.01% formic acid) / acetonitrile, 10%-100%, 20 mL / min) to yield compound C07 (20 mg).
[0555] Compound C07: 1H NMR (400MHz, DMSO-d6) δ8.33(s,1H),8.27(d,J=8.4Hz,1H),8.21(s,1H),7.36(dd,J=8.3,2.1Hz,1H),7.29(d,J=2.0Hz,1H),7.19(d,J=8.3Hz ,1H),5.30(s,2H),5.13-5.06(m,1H),3.32(s,3H),2.61-2.58(m,2H), 2.15(qd,J=7.5,4.7Hz,2H),1.93-1.64(m,4H),1.05(t,J=7.6Hz,3H).
[0556] MS (ESI) M / Z: 366.2 [M+H] + .
[0557] Example C36
[0558] Step 1: Synthesis of compound C36-2
[0559] Compound C36-1 (300 mg, 1.36 mmol) was dissolved in N,N-dimethylformamide (5 mL), and 60% sodium hydride (190 mg, 5.44 mmol) was slowly added at 0°C. The mixture was stirred at room temperature for 0.5 hours, and then iodomethane (0.23 g, 1.63 mmol) was slowly added dropwise at 0°C. The reaction solution was allowed to react at 25°C for 5 hours. The mixture was diluted with water (15 mL) and extracted twice with ethyl acetate (5 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound C36-2 (306 mg).
[0560] 1 H NMR (400MHz, CDCl3): δ7.80 (s, 1H), 7.48 (dd, J = 8.0Hz, 2.0Hz, 1H), 7.24 (d, J = 8.8Hz, 1H), 7.08 (s, 1H), 3.90 (s, 3H).
[0561] Step 2: Synthesis of compound C36-3
[0562] Compound C36-2 (400 mg, 1.70 mmol), pinacol diboron (1079 mg, 4.25 mmol), potassium acetate (500 mg, 5.1 mmol), and 1,1-bis(diphenylphosphino)diphenylferric palladium chloride (124 mg, 0.17 mmol) were added to 1,4-dioxane (5 mL) and reacted at 90°C under nitrogen for 4 hours. The reaction solution was directly concentrated under reduced pressure and purified by silica gel column chromatography to obtain compound C36-3 (450 mg).
[0563] 1 H NMR (400MHz, CDCl3): δ8.18(s,1H),7.82(d,J=8.4Hz,1H),7.33(d,J=8.4Hz,1H),7.26(s,1H),7.18(s,1H),3.91(s,3H),1.37(s,12H).
[0564] Step 3: Synthesis of compound C36
[0565] Compound INT-1A (30 mg, 0.11 mmol), C36-3 (78 mg, 0.28 mmol), potassium carbonate (46 mg, 0.33 mmol), and 1,1-bis(diphenylphosphino)diphenylferric palladium chloride (9 mg, 0.011 mmol) were added to 1,4-dioxane (5 mL) and water (0.5 mL) and reacted at 90°C under nitrogen for 4 hours. The reaction solution was directly concentrated under reduced pressure and purified by silica gel column chromatography to obtain a crude product. The crude product was then purified by reverse-phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 40 g; mobile phase A: pure water; mobile phase B: acetonitrile; flow rate: 40 mL / min; gradient: 5% B to 95% B over 20 minutes; detector: 214 nm) to obtain compound C36 (10.77 mg).
[0566] Compound C36: analyzed by supercritical fluid chromatography (chromatographic conditions: system: Waters UPCC (CA-352); column name: Column dimensions: 100 × 3.0 mm (3.0 μm); mobile phase A: supercritical CO2; mobile phase B: methanol (0.1% DEA), A:B = 60:40; wavelength: 214 nm; flow rate: 1.5 mL / min; column temperature: 35°C; column pressure: 1800 psi, injection volume: 1.0 μL; cycle time: 8.0 min); retention time (RT): 1.824 min, ee = 100%.
[0567] 1H NMR (400MHz, CDCl3) δ8.52(s,1H),8.32(s,1H),7.55(s,1H),7.43(d,J=8.8Hz,1H),7.31(d,J=8.8Hz,1H),7.18(s,1H),5.86(d,J=8.0Hz,1 H),5.38-5.33(m,1H),3.96(s,3H),2.68-2.56(m,2H),2.29(q,J=7.6Hz,2H),2.11-2.06(m,1H),1.88-1.78(m,3H),1.23(t,J=7.6Hz,3H).
[0568] MS (ESI) M / Z: 359.2 [M+H + ].
[0569] Example D01
[0570] Step 1: Synthesis of compound D01
[0571] Potassium carbonate (63.58 mg, 0.46 mmol) and tetrakis(triphenylphosphine)palladium (26.58 mg, 0.023 mmol) were added to a solution of compound INT-1C (65 mg, 0.23 mmol) and compound INT-6 (132.09 mg, 0.46 mmol) in ethanol (5 mL) and water (1 mL) at room temperature. The resulting mixed reaction solution was heated at 85°C under nitrogen and stirred for 16 hours. The resulting mixed reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain a crude product, which was then purified by Prep-HPLC (Separation conditions: Preparative column: Waters Sunfire C18 10 μm OBD 19 × 250 mm, mobile phase: 0.1% aqueous FA / CH3CN, flow rate: 20 mL / min, gradient: 13%-13%, detection wavelength: 214 nm / 254 nm, cycle time: 16 min) to obtain compound D01 (28.41 mg).
[0572] Compound D01: analyzed by supercritical fluid chromatography (chromatographic conditions: system: Waters UPCC (CA-060); column name: Column dimensions: 100 × 3.0 mm (3.0 μm); mobile phase A: supercritical CO2; mobile phase B: methanol (0.1% DEA), gradient: 5% B to 40% B; wavelength: 214 nm; flow rate: 1.5 mL / min; column temperature: 35°C; column pressure: 1800 psi, injection volume: 1.0 μL; cycle time: 8.0 min); retention time (RT): 2.744 min, ee = 94.7%.
[0573] 1 H NMR (400MHz, DMSO-d6) δ8.40(s,1H),8.18(s,1H),7.26-7.23(m,2H),7.17(d,J=8.0Hz,1H),6.44(d,J=8.8Hz,1H),5.71-5. 68(m,1H),4.93-4.88(m,1H),3.29(s,3H),2.92(t,J=7.2Hz,2H),2.65-2.55(m,7H),1.90-1.84(m,1H),1.74-1.69(m,3H).
[0574] MS (ESI) M / Z: 365.1 [M+H] + .
[0575] Example D05
[0576] Step 2: Synthesis of compound D05
[0577] Compounds INT-1D (30 mg, 0.11 mmol), INT-6 (61 mg, 0.21 mmol) and anhydrous potassium carbonate (44 mg, 0.32 mmol) were dissolved in ethanol / water (5 mL / 1 mL), and tetrakis(triphenylphosphine)palladium (13 mg, 0.01 mmol) was added at room temperature. After the addition was completed, nitrogen was purged and the reaction was stirred at 85 ° C in a closed system for 12 hours. The reaction solution was filtered, concentrated under reduced pressure, added with saturated brine (50 mL), extracted three times with ethyl acetate (20 mL), and the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 1:1) to give a crude product, which was then purified by Prep-HPLC (separation conditions: preparative column: Waters sunfire C18 10 μm OBD 19×250 mm, mobile phase: 0.1% NH4HCO3 aqueous solution / CH3CN, flow rate: 20 mL / min, gradient: 34%-38%, detection wavelength: 214 nm / 254 nm, cycle time: 16 min) to give compound D05 (20.3 mg).
[0578] Compound D05: analyzed by supercritical fluid chromatography (chromatographic conditions: system: Waters UPCC (CA352); column name: Column dimensions: 100 × 3.0 mm (3.0 μm); mobile phase A: supercritical CO2; mobile phase B: methanol (0.1% DEA), A:B = 60:40; wavelength: 214 nm; flow rate: 1.5 mL / min; column temperature: 35°C; column pressure: 1800 psi, injection volume: 1.0 μL; cycle time: 8.0 min); retention time (RT): 4.549 min, ee = 99.3%.
[0579] 1 H NMR (400MHz, CDCl3) δ8.57(s,1H),8.29(s,1H),7.19-7.16(m,1H),7.09(s,1H),7.05(d,J=8.4Hz,1H),5.03-4.97(m,1H),3.74(s,3H) ,3.40(s,3H),2.95(t,J=6.8Hz,2H),2.71(t,J=8Hz,2H),2.67-2.55(m,2H),2.09-2.05(m,1H),1.93-1.84(m,1H),1.82-1.76(m,2H).
[0580] MS (ESI) M / Z: 366.2 [M+H] + .
[0581] Example D08
[0582] Step 1: Synthesis of compound D08
[0583] Compound INT-1B (40 mg, 0.14 mmol), INT-6 (80 mg, 0.28 mmol) and anhydrous potassium carbonate (58 mg, 0.42 mmol) were dissolved in ethanol (6 mL) / water (1 mL), and tetrakis(triphenylphosphine)palladium (16 mg, 0.01 mmol) was added. After the addition was complete, N2 was purged and the reaction was stirred at 85°C for 5 hours. The reaction solution was filtered and concentrated under reduced pressure, diluted with water (100 mL), and extracted three times with ethyl acetate (15 mL). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain a crude product, which was then purified by reverse phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 40 g; mobile phase A: pure water; mobile phase B: acetonitrile; flow rate: 40 mL / min; gradient: 5% B-95% B in 20 minutes; detector: 214 nm) to obtain compound D08 (33.91 mg).
[0584] Compound D08: analyzed by supercritical fluid chromatography (chromatographic conditions: system: Waters UPCC (CA352); column name: Column dimensions: 100 × 3.0 mm (3.0 μm); mobile phase A: supercritical CO2; mobile phase B: methanol (0.1% DEA), A:B = 60:40; wavelength: 214 nm; flow rate: 1.5 mL / min; column temperature: 35°C; column pressure: 1800 psi, injection volume: 0.3 μL; cycle time: 8.0 min); retention time (RT): 4.390 min, ee = 98.5%.
[0585] 1 H NMR (400MHz, DMSO-d6) δ8.40(s,1H),8.18(s,1H),7.24(d,J=8.0Hz 1H),7.23(s,1H),7.17(d,J=8.0Hz 1H),6.41(d,J=8.4Hz 1H), 5.63 (s, 1H), 4.93-4.88 (m, 1H), 3.29 (s, 3H), 2.92 (t, J = 7.2Hz, 2H), 2.62-2.57 (m, 4H), 1.88-1.86 (m, 1H), 1.74-1.66 (m, 3H).
[0586] MS (ESI) M / Z: 368.2 [M+H] + .
[0587] Example D11
[0588] Step 1: Synthesis of compound D11
[0589] To a solution of compound INT-1E (55 mg, 0.18 mmol) and compound INT-6 (103.38 mg, 0.36 mmol) in ethanol (5 mL) and water (1 mL) at room temperature were added potassium carbonate (49.76 mg, 0.36 mmol) and tetrakistriphenylphosphine palladium (20.80 mg, 0.018 mmol). The resulting mixed reaction solution was heated at 85°C and stirred under nitrogen for 16 hours. The resulting mixed reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain a crude product. The crude product was purified by Prep-HPLC (Separation conditions: Preparative column: Waters Sunfire C18 10 μm OBD 19 × 250 mm, mobile phase: 0.1% aqueous FA / CH3CN, flow rate: 20 mL / min, gradient: 13%-20%, detection wavelength: 214 nm / 254 nm, cycle time: 16 min) to obtain compound D11 (14.83 mg).
[0590] Compound D11: analyzed by supercritical fluid chromatography (chromatographic conditions: system: Waters UPCC (CA-352); column name: Column dimensions: 100 × 3.0 mm (3.0 μm); mobile phase A: supercritical CO2; mobile phase B: methanol (0.1% DEA), gradient: 5% B to 40% B; wavelength: 214 nm; flow rate: 1.5 mL / min; column temperature: 35°C; column pressure: 1800 psi, injection volume: 1.0 μL; cycle time: 8.0 min); retention time (RT): 4.029 min, ee = 100%.
[0591] 1 HNMR(400MHz,DMSO-d6)δ8.38(s,1H),8.18(s,1H),7.25-7.23(m,2H),7.17(d,J=8.4Hz,1H),6.66(d,J=8.4Hz,1H),5.00 -4.95(m,1H),3.29(s,3H),2.92(t,J=6.8Hz,2H),2.84(s,6H),2.66-2.55(m,4H),1.90-1.72(m,3H),1.66-1.61(m,1H).
[0592] MS (ESI) M / Z: 379.2 [M+H] + .
[0593] Example D15
[0594] Step 1: Synthesis of compound D15
[0595] To a solution of compound INT-1F (26 mg, 0.062 mmol) and compound INT-6 (27 mg, 0.093 mmol) in ethanol (2 mL) and water (0.5 mL) at room temperature were added potassium carbonate (26.00 mg, 0.19 mmol) and tetrakis(triphenylphosphine)palladium (7.2 mg, 0.006 mmol). The resulting mixed reaction liquid was heated at 85°C under nitrogen protection and stirred for 16 hours. The resulting mixed reaction liquid was concentrated under reduced pressure. The residue was purified by HPLC to give compound D15 (2.67 mg).
[0596] Compound D15: analyzed by supercritical fluid chromatography (chromatographic conditions: system: Waters UPCC (CA060); column name: Column dimensions: 100 × 3.0 mm (3.0 μm); mobile phase A: supercritical CO2; mobile phase B: methanol (0.1% DEA), gradient: B5%-40%; wavelength: 214 nm; flow rate: 1.5 mL / min; column temperature: 35°C; column pressure: 1800 psi, injection volume: 1.00 μL; cycle time: 8.0 min); retention time (RT): 2.630 min, ee = 100%.
[0597] 1 HNMR (400MHz, DMSO-d6) δ8.39(s,1H),8.22(s,1H),7.70(d,J=8.4Hz,1H),7.25(J=8.4Hz,1H),7.24(s,1H),7.17(d,J=8. 0Hz,1H),4.87-4.77(m,1H),3.29(s,3H),2.92(t,J=6.8Hz,2H),2.69-2.55(m,4H),1.98-1.87(m,1H),1.85-1.59(m,3H).
[0598] MS (ESI) M / Z: 369.1 [M+H] + .
[0599] Example A50
[0600] Under nitrogen protection, to the compound INT-5C (40 mg, 0.14 mmol) in ethanol and water (5 mL / 1 mL), the compound INT-7 (63 mg, 0.21 mmol), potassium carbonate (57 mg, 0.41 mmol) and tetrakis(triphenylphosphine)palladium (16 mg, 0.014 mmol) were added. The resulting mixed reaction liquid was stirred at 85 ° C under nitrogen protection for 8 hours. The obtained mixed reaction liquid was filtered, the mother liquor was concentrated under reduced pressure, and the residue was purified by column chromatography to obtain 40 mg of a crude product. The crude product was purified by Prep-HPLC (separation conditions: preparative column: Waters sunfire C18 10 μm OBD 19×250 mm, mobile phase: 0.1% FA aqueous solution / CH3CN, flow rate: 20 mL / min, gradient: 13%-25%, detection wavelength: 214 nm / 254 nm, retention time: 8.0-9.6 min of 16 min) to obtain compound A50 (16.19 mg).
[0601] MS (ESI) M / Z: 387.1 [M+H] + .
[0602] Compound A50: Supercritical fluid chromatography (chromatographic conditions: system: Waters UPCC (CA-352); column name: Chromatographic column dimensions: 100 × 3.0 mm, 3.0 μm; mobile phase A: supercritical CO2; mobile phase B: methanol (0.1% DEA), gradient: 5% B to 40% B; wavelength: 214 nm; flow rate: 1.5 mL / min; column temperature: 35°C; column pressure: 1800 psi; cycle time: 8.0 min) analysis, retention time (RT): 4.062 min.
[0603] 1 H NMR (400MHz, DMSO-d6) δ8.39(s,1H),8.32(s,1H),7.97(dd,J=9.6Hz,1.6Hz,1H),7.80(d,J=8.4Hz,1H),7.75(d,J=2.0Hz,1H),7.67(dd,J=1 6.0Hz, 2.0Hz, 1H), 6.71 (d, J = 9.6Hz, 1H), 4.90-4.85 (m, 1H), 4.41-4.31 (m, 2H), 3.81 (d, J = 8.4Hz, 3H), 2.14-2.09 (m, 1H), 2.02-1.97 (m, 1H).
[0604] 19 F NMR(376MHz,DMSO-d6)δ-121.58.
[0605] Example C41
[0606] Compound INT-1A (33 mg, 0.12 mmol) was dissolved in 1,4-dioxane (5 mL) and water (0.5 mL). Compound INT-7 (73 mg, 0.24 mmol), potassium carbonate (50 mg, 0.36 mmol), and 1,1-bis(diphenylphosphino)diphenylferric palladium chloride (9 mg, 0.012 mmol) were added sequentially. The atmosphere was purged with nitrogen three times and the mixture was allowed to react at 85°C for 16 hours. LCMS monitored the reaction for completion. The reaction solution was directly concentrated under reduced pressure and purified by silica gel column chromatography to obtain the crude product. The crude product was then purified by reverse-phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 40 g; mobile phase A: pure water; mobile phase B: acetonitrile; flow rate: 40 mL / min; gradient: 5% B to 95% B over 20 minutes; detector: 214 nm). Compound C41 (32.17 mg) was collected when the mobile phase B content reached 25%.
[0607] MS (ESI) M / Z: 380.2 [M+H] + .
[0608] 1 HNMR(400MHz, DMSO-d6)δ8.38(s,1H),8.29(s,1H),8.29(d,J=7.2Hz,1H),7.97(dd,J=9.6Hz,1.6Hz,1H),7.60-7.55(m,2H),6.73(d,J=9.6Hz,1H) ,5.13-5.08(m,1H),3.82(d,J=8.4Hz,3H),2.66(t,J=10.0Hz,1H),2.20- 2.13(m,2H),1.91-1.87(m,1H),1.82-1.70(m,3H),1.06(t,J=7.6Hz,3H).
[0609] Example C43
[0610] Under nitrogen protection, to a mixture of compound INT-8 (64 mg, 0.22 mmol) in dioxane and water (5 / 0.5 mL) were added compound INT-1A (30 mg, 0.11 mmol), potassium carbonate (44 mg, 0.32 mmol), and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (8 mg, 0.011 mmol). The resulting mixed reaction solution was stirred at 90°C under nitrogen protection for 16 hours. The resulting mixed reaction solution was filtered and concentrated under reduced pressure, and the residue was purified by column chromatography to obtain 39 mg of a crude product. The crude product was purified by reverse phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 25 g; mobile phase A: containing 0.1% formic acid; mobile phase B: acetonitrile; flow rate: 35 mL / min; gradient: 5% B-95% B in 30 minutes; detector: 214 nm). When the mobile phase B content reached 30%, the product was collected and concentrated under reduced pressure to give compound C43 (17.52 mg).
[0611] MS (ESI) M / Z: 376.1 [M+H] + .
[0612] 1 HNMR(400MHz,DMSO-d6)δ8.35(s,1H),8.28(d,J=8.4Hz,1H),8.27(s,2H),7.90(d ,J=9.2Hz,1H),7.56(d,J=2.0Hz,1H),7.42(d,J=2.0Hz,1H),6.64(d,J=9.6Hz,1H) ,5.13-5.08(m,1H),3.79(s,3H),2.77(s,3H),2.65-2.62(m,2H),2.18-2.10(m,2H ),2.19-2.13(m,2H),1.92-1.87(m,1H),1.79-1.68(m,3H),1.06(t,J=7.6Hz,3H).
[0613] Example C44
[0614] Potassium carbonate (40.63 mg, 0.29 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (8.00 mg, 0.0098 mmol) were added to a solution of compound INT-9 (30 mg, 0.098 mmol) and compound INT-1A (24.97 mg, 0.088 mmol) in 1,4-dioxane (5.0 mL) and water (0.5 mL). The resulting mixed reaction liquid was heated at 85°C under nitrogen protection and stirred for 5 hours. LCMS monitoring showed the disappearance of the starting material, and the residue was purified by Prep-HPLC to give compound C44 (3.16 mg).
[0615] MS (ESI) M / Z: 384.1 [M+H] + .
[0616] 1 HNMR (400MHz, DMSO-d6) δ8.35(s,1H),8.27(d,J=8.4Hz,1H),8.23(s,1H),7.33(d,J=13.6Hz,1.6Hz,1H),7.17(d,J=1.2Hz,1H),5.28(s,2H), 5.14-5.05(m,1H),3.43(d,J=6.0Hz,3H),2.68-2.59(m,2H),2.22-2.0 9(m,2H),1.94-1.83(m,1H),1.80-1.63(m,3H),1.05(t,J=7.6Hz,3H).
[0617] Example A14
[0618] To a solution of INT-5D (25 mg, 0.087 mol) and INT-6 (37.47 mg, 0.13 mmol) in ethanol (2 mL) and water (0.5 mL) was added potassium carbonate (36.07 mg, 0.26 mmol) and tetrakis(triphenylphosphine)palladium (10.05 mg, 0.0087 mmol) at room temperature. The resulting mixed reaction solution was heated at 85°C under nitrogen protection and stirred for 16 hours. The resulting mixed reaction solution was concentrated under reduced pressure. The residue was purified by HPLC to give compound A14 (22.02 mg).
[0619] MS (ESI) M / Z: 368.1 [M+H] + .
[0620] 1HNMR(400MHz,DMSO-d6)δ8.26(s,1H),8.25(s,1H),7.80(d,J=8.0Hz,1H),7.39(d,J=8.4Hz,1H),7.36(s,1H),7.15(d,J=8.4Hz,1H),4.90-4 .81(m,1H),4.38-4.23(m,2H),3.61(s,3H),3.28(s,3H),2.91(d,J=6. 8Hz,2H),2.57(d,J=8.0Hz,2H),2.15-2.04(m,1H),2.02-1.91(m,1H).
[0621] Example A37
[0622] To a solution of INT-5E (25 mg, 0.087 mol) and C36-3 (36.82 mg, 0.13 mmol) in ethanol (2 mL) and water (0.5 mL) at room temperature were added potassium carbonate (36.07 mg, 0.26 mmol) and tetrakis(triphenylphosphine)palladium (10.05 mg, 0.0087 mmol). The resulting mixed reaction solution was heated at 85°C under nitrogen and stirred for 16 hours. The resulting mixed reaction solution was concentrated under reduced pressure. The residue was purified by HPLC to give compound A37 (5.23 mg).
[0623] The chromatographic conditions were as follows: supercritical fluid chromatography (HPLC system: Waters UPCC (CA060); column name: Chromatographic column dimensions: 100 × 3.0 mm, 3.0 μm; mobile phase A: supercritical CO2; mobile phase B: methanol (0.1% DEA), A:B = 60%-40%; wavelength: 214 nm; flow rate: 1.5 mL / min; column temperature: 35°C; column pressure: 1800 psi, injection volume: 1.00 μL; cycle time: 8.0 min) analysis, retention time (RT): 1.778 min.
[0624] MS (ESI) M / Z: 362.1 [M+H] + .
[0625] 1HNMR(400MHz,DMSO-d6)δ8.29(s,1H),8.28(s,1H),7.80(d,J=0.8Hz,1H),7.67 (d,J=8.8Hz,1H),7.54(dd,J=8.8Hz,1.6Hz,1H),7.47(s,1H),6.58(d,J=7.6Hz, 1H),5.73(q,J=4.8Hz,1H),4.98-4.89(m,1H),4.39-4.30(m,1H),4.29-4.19(m ,1H),3.93(s,3H),2.61(d,J=4.8Hz,3H),2.13-2.02(m,1H),2.01-1.90(m,1H).
[0626] Biological evaluation
[0627] The present disclosure is further described and explained below in conjunction with test examples, but these embodiments are not intended to limit the scope of the present disclosure.
[0628] Test Example 1: Inhibitory effect of the disclosed compounds on CYP11B2
[0629] G402 cells (ATCC, CRL 1440) are epithelial cells isolated from the kidneys of a Caucasian female patient with renal failure. They are a type of leiomyoblastoma. To screen for highly specific CYP11B2 inhibitors, we developed G402 cell lines stably expressing either human CYP11B2 or human CYP11B1.
[0630] Stable cell line construction: Expression plasmids containing an appropriate promoter, a suitable drug resistance marker, and the human CYP11B1 or CYP11B2 ORF were transfected into G402 cells using standard techniques. These cells were then selected using the specific drug resistance marker puromycin. Monoclonal cells stably expressing human CYP11B2 were selected for expansion, and enzyme activity was assessed for aldosterone production using 11-deoxycorticosterone (11-DOC) as a specific substrate. Monoclonal cells stably expressing human CYP11B1 were also selected for expansion, and enzyme activity was specifically assessed using 11-deoxycortisol (11-DC) as a specific substrate and cortisol production as a target. G402 cell lines stably expressing CYP11B1 / CYP11B2 were cultured at 37°C in 5% CO2, 95% air, and complete medium (McCoy's 5A + 10% FBS + 1% PS + 0.5 μg / mL puromycin).
[0631] Enzyme inhibition assay: CYP11B1 G402 / CYP11B2 G402 cells were plated in cell culture plates. After 24 hours, the enzyme assay system (DMEM / F12 + 2.5% carbon-bound FCS) was replaced. A series of small molecule inhibitors at varying concentrations were added. One hour later, the appropriate concentration of specific substrate (1 μM 11-DOC / 1 μM 11-DC) was added. The cells were incubated for 16 hours and then harvested. Specific product detection (aldosterone for CYP11B2 enzymes and cortisol for CYP11B1 enzymes) was performed using an AB SCIEX TRIPLE QUAD 5500+, CTO-40S instrument using LC / MC methods.
[0632] IC of the compound 50 The values are based on the G402 assay system. Based on the formation of compound product at various concentrations, dose inhibition of enzyme activity was calculated by plotting the inhibitor concentration (x-axis) against the percentage of inhibitory activity of the control product (y-axis). XLfit 5.5.0 was then used to perform a four-parameter least squares fit on the following data:
[0633] Y=Bottom+(Top-Bottom) / (1+10^((LogIC 50 -X)×HillSlope); X-axis: Log value of inhibitor concentration;
[0634] Y axis: percentage of product inhibitory activity relative to the control group;
[0635] logIC 50 : Using XLFit to determine IC 50 .
[0636] The maximum enzyme activity corresponds to the amount of steroid / aldosterone produced by the control group in the absence of the inhibitor, which is 100%, and the minimum enzyme activity corresponds to the amount of steroid / aldosterone produced by the reference control group in the presence of the inhibitor.
[0637] Table 3 Inhibitory activity of the disclosed compounds against CYP11B2 and CYP11B1
[0638] The results showed that the compounds disclosed herein have a significant inhibitory effect on CYP11B2, and have a significant selective inhibitory effect.
[0639] Test Example 2: Pharmacokinetics of the compounds disclosed in mice and rats
[0640] Mice and rats were used as test animals to study the pharmacokinetic behavior of the disclosed compounds in the plasma of mice and rats after oral administration (PO). Plasma samples were collected at specific time points, and the compound concentrations in plasma were detected by LC-MS / MS. PK parameters were calculated and the pharmacokinetic behavior of the disclosed compounds in the plasma of mice and rats was evaluated.
[0641] 1. Experimental Plan
[0642] 1.1 Investigational Drugs:
[0643] Some compounds are disclosed.
[0644] 1.2 Experimental animals
[0645] Mouse, CD-1, male, Zhejiang Weitonglihua Laboratory Animal Technology Co., Ltd.
[0646] Male Sprague-Dawley rats were purchased from Zhejiang Weitonglihua Laboratory Animal Technology Co., Ltd. and Shanghai Jihui Laboratory Animal Breeding Co., Ltd.
[0647] 1.3 Administration
[0648] 1.3.1 Dosing of mice:
[0649] Dosage: PO; Dosing information: 3 mice, dose: 10 mg / kg, dosing volume: 10 mL / kg, dosing vehicle: 5% DMSO / 10% Solutol HS15 / 85% water (5 vol% dimethyl sulfoxide + 10 vol% solubilizer HS15 + 85 vol% water);
[0650] Compounds administered: Example compound C07, Example compound A16, Example compound A50, Example compound C41, Example compound C44, and reference compound;
[0651] 1.3.2 Dosing in rats:
[0652] Administration: PO; Administration information: 3 rats, the administration dose is 10 mg / kg, the administration volume is 10 mL / kg, and the administration solvent is 5% DMSO / 10% Solutol HS15 / 85% water.
[0653] Compounds administered: Example compound A02-P2, Example compound A09, Example compound C43, and reference compound.
[0654] 1.4 Experimental Equipment
[0655] The centrifuge was purchased from Eppendorf, the pipette was purchased from Eppendorf, and the vortexer was purchased from IKA.
[0656] 1.5 Sample collection
[0657] After administration to mice and rats, 0.03 mL and 0.2 mL of venous blood were collected at 0.0833 (IV), 0.25, 0.5, 1, 2, 4, 8, and 24 hours, respectively. The blood was placed in EDTA-K2 tubes, centrifuged at 4000 g for 5 minutes at 4°C to separate the plasma, and stored at -80°C.
[0658] 1.6 Sample processing
[0659] Mouse plasma sample processing:
[0660] 1) 10 μL of plasma sample was added to 200 μL of acetonitrile for precipitation, vortexed and centrifuged for 15 minutes.
[0661] 2) The supernatant after treatment was diluted with water and analyzed by LC / MS / MS for the concentration of the test compound.
[0662] Rat plasma sample processing:
[0663] 1) 50 μL of plasma sample was added to 200 μL of acetonitrile for precipitation, vortexed and centrifuged for 15 minutes.
[0664] 2) The supernatant after treatment was diluted with water and analyzed by LC / MS / MS for the concentration of the test compound.
[0665] 2. Experimental Results
[0666] The pharmacokinetic parameters were calculated using WinNonlin 8.3. The pharmacokinetic parameters of mouse PO are shown in Table 4, and the pharmacokinetic parameters of rat PO are shown in Table 5. max Indicates the maximum blood drug concentration, T 1 / 2 Indicates terminal elimination half-life, MRT Inf AUC represents the area under the drug-dose curve.
[0667] Table 4 Pharmacokinetic parameters of the disclosed compounds in mice Note: “ / ” indicates not measured
[0668] Conclusion: As can be seen from Table 4, the compounds disclosed herein have good pharmacokinetic properties in mice.
[0669] Table 5 Pharmacokinetic parameters of the disclosed compounds in rats
[0670] Conclusion: As can be seen from Table 5, the compounds of the present disclosure have good pharmacokinetic properties in rats.
[0671] Test Example 3: Pharmacokinetics of the Disclosed Compounds in Monkeys
[0672] Cynomolgus monkeys were used as test animals to study the pharmacokinetic behavior of the disclosed compounds in cynomolgus monkey plasma after oral administration (PO). Plasma samples were collected at specific time points, and the compound concentration in plasma was detected by LC-MS / MS. PK parameters were calculated to reflect the pharmacokinetic behavior of the disclosed compounds in cynomolgus monkey plasma.
[0673] 1. Experimental Plan
[0674] 1.1 Investigational Drugs:
[0675] Some compounds are disclosed.
[0676] 1.2 Experimental animals
[0677] Cynomolgus macaques, male, Ankai Yibo (Zhanjiang) Biotechnology Co., Ltd.
[0678] 1.3 Administration
[0679] Administration: PO; dosage: 1 mg / kg; administration volume: 5 mL / kg; administration vehicle: 5% DMSO / 10% Solutol HS15 / 85% water;
[0680] Compounds administered: Example compound A02-P2, Example compound A10-P2, Example compound A50, Example compound C43 and reference compound.
[0681] 1.4 Experimental Equipment
[0682] The centrifuge was purchased from Eppendorf, the pipette was purchased from Eppendorf, and the vortexer was purchased from IKA.
[0683] 1.5 Sample collection
[0684] After administration to cynomolgus monkeys, 0.3 mL of venous blood was collected at 0.25, 0.5, 1, 2, 4, 8, and 24 hours, placed in EDTA-K2 tubes, centrifuged at 4°C, 4000 g for 5 min to separate plasma, and stored at -80°C.
[0685] 1.6 Sample processing
[0686] Cynomolgus monkey plasma sample processing:
[0687] 1) 50 μL of plasma sample was added to 200 μL of acetonitrile for precipitation, vortexed and centrifuged for 15 minutes.
[0688] 2) The supernatant after treatment was diluted with water and analyzed by LC / MS / MS for the concentration of the test compound.
[0689] 2. Experimental Results
[0690] The pharmacokinetic parameters were calculated using WinNonlin 8.3. The pharmacokinetic parameters of the drug administered orally to cynomolgus monkeys are shown in Table 6. max Indicates the maximum blood drug concentration, T 1 / 2 Indicates terminal elimination half-life, MRT Inf AUC represents the area under the drug-dose curve.
[0691] Table 6 Pharmacokinetic parameters of the disclosed compounds in monkeys Note: “ / ” indicates not measured
[0692] Conclusion: As can be seen from Table 6, the compounds of the present disclosure have good pharmacokinetic properties in cynomolgus monkeys.
[0693] Test Example 4: Pharmacodynamics of the Disclosed Compounds in Monkeys
[0694] Cynomolgus monkeys were used as test animals to study the pharmacodynamics of various compounds of the present disclosure at various doses, such as 0.1 mpk (eg, 0.03 mpk, 0.1 mpk, and 0.3 mpk), administered orally (PO) on various plasma hormone levels in vivo.
[0695] 1. Experimental Plan
[0696] 1.1 Investigational Drugs:
[0697] Some compounds disclosed herein: Example Compound A02-P2, Example Compound A09, Example Compound C43, Example Compound C44, Example Compound A50.
[0698] 1.2 Experimental animals
[0699] Male cynomolgus macaques were obtained from Suzhou Xishan Zhongke Experimental Animal Co., Ltd., animal production license number SCXK(Su)2023-0001, and animal use license number SYXK(Su)2020-0017.
[0700] 1.3 Dosage regimen:
[0701] Male cynomolgus monkeys were gavaged (PO) at doses of 0 mpk (vehicle group), 0.03 mpk, 0.1 mpk, and 0.3 mpk. One hour after dosing, each group received an intramuscular injection of 15 μg / kg ACTH. Serial venous blood samples were collected from each group 1 hour before dosing and at multiple time points after dosing. Plasma aldosterone and its precursor, and corticosterone and its precursor, were analyzed by LC / MS at various time points.
[0702] 1.4 Experimental equipment:
[0703] Table 7 Experimental equipment
[0704] 1.5 Sample collection
[0705] 1-2 hours before oral administration and at multiple time points after intramuscular administration of ACTH (adrenocorticotropic hormone), venous blood was collected and placed in EDTA-K2 tubes. The blood was centrifuged at 2600 g for 10 minutes at 4°C to separate the plasma, which was then stored at -80°C.
[0706] 1.6 Liquid phase analysis
[0707] HPLC: Waters ACQUITY UPLC I-Class PLUS;
[0708] Mass spectrometry conditions: ATriple Quad TM 7500 (Serial No. FA224362212) mass spectrometer;
[0709] Chromatographic column: Phenomenex Kinetex 2.6 μm C8 100A 50 × 4.60 mm;
[0710] Mobile phase: Liquid A is a 0.5 mM ammonium fluoride solution containing 0.1% formic acid, and Liquid B is MeOH.
[0711] 2. Experimental Results and Analysis
[0712] The pharmacodynamic results are shown in Tables 8, 9, 10, 11, 12, Figures 1, 2, 3, 4, and 5. Figure 1 shows the pharmacodynamic results of Example Compound C44 in monkeys; Figure 2 shows the pharmacodynamic results of Example Compound A09 in monkeys; Figure 3 shows the pharmacodynamic results of Example Compound A50 in monkeys; Figure 4 shows the pharmacodynamic results of Example Compound C43 in monkeys; and Figure 5 shows the pharmacodynamic results of Example Compound A02-P2 in monkeys.
[0713] The data in Figures 1, 2, 3, 4, and 5 were analyzed based on the changes in PD 30 minutes after ACTH stimulation. The percentage of PD 30 minutes after ACTH stimulation relative to the control group (Veh group) was used as the main basis for efficacy evaluation and was calculated according to the following formula:
[0714] The percentage of PD relative to the control group is (PD of the drug-treated group 30 minutes after ACTH stimulation / PD of the control group 30 minutes after ACTH stimulation) × 100%, where PD is aldosterone or cortisol.
[0715] Table 8 Pharmacodynamic evaluation of Example compound C44 in monkeys
[0716] Table 9 Pharmacodynamic evaluation of Example Compound A09 in monkeys
[0717] Table 10 Pharmacodynamic evaluation of Example Compound A50 in monkeys
[0718] Table 11 Pharmacodynamic evaluation of Example compound C43 in monkeys
[0719] Table 12 Pharmacodynamic evaluation of Example compound A02-P2 in monkeys
[0720] Conclusion: It can be seen from Tables 8, 9, 10, 11, 12 and Figures 1 to 5 that the compounds disclosed herein can effectively inhibit the release of aldosterone induced by ACTH stimulation without causing significant changes in hormones such as cortisol.
[0721] The above description is only a preferred embodiment of the present application and is not intended to limit the present application. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present application shall be included in the scope of protection of the present application.
Claims
1. A compound represented by the general formula (IA), its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt; in: Ring A is selected from 5- to 6-membered heteroaryl groups; Ring B is selected from a 3- to 8-membered heterocyclic group, a 3- to 8-membered monocyclic cycloalkyl group, a 3- to 8-membered monocyclic cycloalkenyl group, a 5- to 10-membered fused cyclic group, a 5- to 10-membered spirocyclic group, and a 5- to 10-membered bridged cyclic group; Ring C is selected from phenyl, 5- to 6-membered heteroaryl, 7- to 14-membered fused aryl, 6- to 14-membered fused heterocyclyl, 6- to 14-membered fused heteroaryl and 6- to 14-membered fused cyclyl; L is selected from -NR n1 -, -(CR d R e ) r -, -(CR d =CR e ) r -, -O-(CR d R e ) r -, -(CR d R e ) r -O-, -NR n1 -(CR d R e ) r -, -(CR d R e ) r -NR n1 -, -(CR d R e ) r -C(O)-, -C(O)-(CR d R e ) r -, -O-C(O)-, -C(O)-O-, -O-C(O)-NR n1 -, -NR n1 -C(O)-O-, -NR n1 -C(O)-NR n1 -, -(CR d R e ) r -NR n1 -C(O)-, -C(O)-NR n1 -(CR d R e ) r -, -NR n1 -C(O)-(CR d R e ) r -, -NR n1 -S(O)2- and -S(O)2-NR n1 -; R is selected from hydrogen atom, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen, cyano, -OR o 、-NR n2 R n3 , 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl, wherein the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 The alkynyl group, the 3- to 8-membered heterocyclic group, the 3- to 8-membered cycloalkyl group, the 3- to 8-membered cycloalkenyl group, the 6- to 10-membered aryl group and the 5- to 10-membered heteroaryl group are each independently optionally selected from a deuterium atom, a halogen, an oxo group, a C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o , hydroxyl, hydroxyl C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; or R n1 and R and the atoms connected thereto together form a 3- to 8-membered heterocyclic group or a 5- to 10-membered heteroaryl group; wherein the 3- to 8-membered heterocyclic group or the 5- to 10-membered heteroaryl group are each independently selected from a deuterium atom, a halogen, an oxo group, a C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , Hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; Each R a , R b and R c are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a C 1-6 Alkyl, -OR o 、-NR n2 R n3 , halogen, cyano, oxo, -C(O)NR n2 R n3 、-C(O)R o 、-C(O)OR o 、-C(O)NR n1 OR o , 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl, wherein the C 1-6 The alkyl, 3- to 8-membered heterocyclic, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl and 5- to 10-membered heteroaryl groups are each independently optionally selected from deuterium atoms, halogens, oxo groups, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o , hydroxyl, hydroxyl C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; Or two of the R b The atoms connected thereto form a 3- to 8-membered heterocyclic group or a 3- to 8-membered cycloalkyl group, wherein the 3- to 8-membered heterocyclic group and the 3- to 8-membered cycloalkyl group are each independently selected from deuterium atoms, halogens, oxo groups, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , Hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; Or two of the R c The atoms connected thereto form a 3- to 8-membered heterocyclic group or a 3- to 8-membered cycloalkyl group, wherein the 3- to 8-membered heterocyclic group and the 3- to 8-membered cycloalkyl group are each independently selected from deuterium atoms, halogens, oxo groups, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , Hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; or R b and R and the atoms connected thereto together form a 3- to 8-membered heterocyclic group, a 3- to 8-membered cycloalkyl group, a 3- to 8-membered cycloalkenyl group, a 6- to 10-membered aryl group and a 5- to 10-membered heteroaryl group; wherein the 3- to 8-membered heterocyclic group, the 3- to 8-membered cycloalkyl group, the 3- to 8-membered cycloalkenyl group, the 6- to 10-membered aryl group and the 5- to 10-membered heteroaryl group are each independently selected from deuterium atoms, halogens, oxo groups, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , Hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; R d and R e are the same or different at each occurrence and are each independently selected from a hydrogen atom, a deuterium atom, a C 1-6 Alkyl, halogen, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, -OR o and halogenated C 1-6 Alkoxy; R o are the same or different at each occurrence and are independently selected from hydrogen atoms, C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 alkynyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 The alkynyl group, the 3- to 8-membered heterocyclic group, the 3- to 8-membered cycloalkyl group, the 3- to 8-membered cycloalkenyl group, the 6- to 10-membered aryl group and the 5- to 10-membered heteroaryl group are each independently optionally selected from a deuterium atom, a halogen, an oxo group, a C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 , -C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , Hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; R n1 , R n2 , R n3 , R n4 and R n5 are the same or different at each occurrence and are independently selected from hydrogen atoms, C 1-6 Alkyl, hydroxyl C 1-6 alkyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein, the C 1-6 The alkyl, 3- to 8-membered heterocyclic, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl and 5- to 10-membered heteroaryl groups are each independently optionally selected from deuterium atoms, halogens, oxo groups, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , Hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; or R n2 and R n3 , R n4 and R n5 Together with the nitrogen atoms to which they are connected, they form a 3- to 8-membered heterocyclic group; wherein the 3- to 8-membered heterocyclic group is optionally selected from a deuterium atom, a halogen, an oxo group, a C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , Hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; m is 0, 1, 2, 3, 4, 5 or 6; p is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; and r is 0, 1, 2, 3 or 4.
2. The compound according to claim 1, its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt, wherein Ring A is selected from a 5- to 6-membered heteroaryl group containing 1 to 3 nitrogen atoms; Preferably, ring A is selected from pyridyl, pyrimidinyl, pyridazinyl and a 5-membered heteroaryl group containing 1 to 3 nitrogen atoms.
3. The compound according to claim 1 or 2, its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt, which is a compound represented by general formula (I), its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt; in: R a1 , R a2 The same or different, and each independently as in claim 1 R a defined; Ring B is selected from a 3- to 8-membered heterocyclyl, a 5- to 6-membered cycloalkenyl, a 7- to 8-membered monocyclic cycloalkyl, a 5- to 10-membered fused cyclic group, a 5- to 10-membered spirocyclic group, and a 5- to 10-membered bridged cyclic group; Ring C is selected from phenyl, 5- to 6-membered heteroaryl, 7- to 14-membered fused aryl, 6- to 14-membered fused heterocyclyl, 6- to 14-membered fused heteroaryl and 6- to 14-membered fused cyclyl; L is selected from -NR n1 -、-NR n1 -C(O)-、-NR n1 -C(O)-NR n1 -and-CR d =CR e -; or R n1 and R and the atoms connected thereto together form a 3- to 8-membered heterocyclic group or a 5- to 10-membered heteroaryl group; wherein the 3- to 8-membered heterocyclic group or the 5- to 10-membered heteroaryl group are each independently selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , Hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; or R b and R and the atoms connected thereto together form a 3- to 8-membered heterocyclic group, a 3- to 8-membered cycloalkyl group, a 3- to 8-membered cycloalkenyl group, a 6- to 10-membered aryl group and a 5- to 10-membered heteroaryl group; wherein the 3- to 8-membered heterocyclic group, the 3- to 8-membered cycloalkyl group, the 3- to 8-membered cycloalkenyl group, the 6- to 10-membered aryl group and the 5- to 10-membered heteroaryl group are each independently selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , Hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; The condition is that the compound represented by the general formula (I) is not a compound whose cas is 1428652-88-3; R, R a , R b , R c , R n1 , R n4 , R n5 , R o , R d , R e , n and p are as defined in claim 1.
4. The compound according to claim 3, its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt, wherein the structural unit wherein ring B is selected from a 5- to 6-membered heterocyclic group, a 5- to 6-membered cycloalkenyl group, a 6- to 10-membered fused ring group, and a 6- to 10-membered bridged ring group, and R a1 , R a2 The same or different, and each independently as in claim 1 R a As defined, n and R b As defined in claim 1; Preferably, the structural unit wherein ring B is selected from a 5- to 6-membered heterocyclic group, a 5- to 6-membered cycloalkenyl group, a 6- to 10-membered fused ring group, and a 6- to 10-membered bridged ring group, and each R b are the same or different and are each independently selected from halogen, hydroxyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 Alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 Alkoxy, n is 0, 1, 2, 3 or 4, R a1 , R a2 are the same or different and are each independently selected from hydrogen, halogen, hydroxyl, hydroxyl 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 Alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 Alkoxy; More preferably, Selected from in Connected to L, each R b are the same or different and are each independently selected from halogen, hydroxyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 Alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 Alkoxy, n is 0, 1, 2, 3 or 4, R a1 , R a2 are the same or different and are each independently selected from hydrogen, halogen, hydroxyl, hydroxyl 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 Alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 Alkoxy; More preferably, Selected from in Connected to L, each R b are the same or different and are each independently selected from halogen, hydroxyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 Alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 Alkoxy, n is 0, 1, 2, 3 or 4; More preferably, Selected from in Connected to L.
5. The compound according to any one of claims 1 to 4, its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt, wherein ring B is selected from a 5- to 6-membered heterocyclic group, a 5- to 6-membered cycloalkenyl group, a 6- to 10-membered fused ring group and a 6- to 10-membered bridged ring group.
6. The compound according to any one of claims 1 to 5, its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt, wherein ring B is selected from in Connected to L.
7. The compound according to claim 1 or 2, its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt, which is a compound represented by general formula (IV) or general formula (IV-1), its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt; in: R a1 , R a2 As claimed in claim 1, R a defined; s is 0, 1, 2, 3, or 4; Ring C is selected from phenyl, 5- to 6-membered heteroaryl, 7- to 14-membered fused aryl, 6- to 14-membered fused heterocyclyl, 6- to 14-membered fused heteroaryl, and 6- to 14-membered fused cyclyl; and Not for L is selected from -NR n1 -、-NR n1 C(O)-、-NR n1 -C(O)-NR n1 -and-CR d =CR e -; or R n1 and R and the atoms connected thereto together form a 3- to 8-membered heterocyclic group or a 5- to 10-membered heteroaryl group; wherein the 3- to 8-membered heterocyclic group or the 5- to 10-membered heteroaryl group are each independently selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , Hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; or R b and R and the atoms connected thereto together form a 3- to 8-membered heterocyclic group, a 3- to 8-membered cycloalkyl group, a 3- to 8-membered cycloalkenyl group, a 6- to 10-membered aryl group and a 5- to 10-membered heteroaryl group; wherein the 3- to 8-membered heterocyclic group, the 3- to 8-membered cycloalkyl group, the 3- to 8-membered cycloalkenyl group, the 6- to 10-membered aryl group and the 5- to 10-membered heteroaryl group are each independently selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , Hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; R, R a , R b , R c , R n1 , R n4 , R n5 , R o , R d , R e , n and p are as defined in claim 1.
8. The compound according to claim 1 or 2, its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt, which is a compound represented by general formula (V) or general formula (V-1), its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt; in: R a1 , R a2 As claimed in claim 1, R a defined; s is 0, 1, 2, 3, or 4; Ring C is selected from phenyl, 5- to 6-membered heteroaryl, 7- to 14-membered fused aryl, 6- to 14-membered fused heterocyclyl, 6- to 14-membered fused heteroaryl and 6- to 14-membered fused cyclyl; L is selected from -NR n1 -、-NR n1 C(O)-、-NR n1 -C(O)-NR n1 -and-CR d =CR e -; or R n1 and R and the atoms connected thereto together form a 3- to 8-membered heterocyclic group or a 5- to 10-membered heteroaryl group; wherein the 3- to 8-membered heterocyclic group or the 5- to 10-membered heteroaryl group are each independently selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , Hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; or R b and R and the atoms connected thereto together form a 3- to 8-membered heterocyclic group, a 3- to 8-membered cycloalkyl group, a 3- to 8-membered cycloalkenyl group, a 6- to 10-membered aryl group and a 5- to 10-membered heteroaryl group; wherein the 3- to 8-membered heterocyclic group, the 3- to 8-membered cycloalkyl group, the 3- to 8-membered cycloalkenyl group, the 6- to 10-membered aryl group and the 5- to 10-membered heteroaryl group are each independently selected from halogen, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n4 R n5 、-C(O)NR n4 R n5 、-C(O)R o 、-C(O)OR o 、-C(O)NR n4 OR o 、-OR o , Hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered cycloalkyl, 3- to 8-membered cycloalkenyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; When L is selected from -NHC(O)-, R is not methyl, ethyl, cyclopropyl, CH3CH(OH)- and R, R a , R b , R c , R n1 , R n4 , R n5 , R o , R d , R e , n and p are as defined in claim 1.
9. The compound according to any one of claims 1 to 8, its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt, which is a compound represented by general formula (I-1) or general formula (I-2), its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt; in: Ring C, R, R n1 , R b , R c , n and p are as defined in any one of claims 1 to 8.
10. The compound according to any one of claims 1 to 9, its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt, wherein the structural unit wherein ring C is selected from phenyl, 5- to 6-membered heteroaryl, 7- to 14-membered fused aryl, 6- to 14-membered fused heterocyclyl and 6- to 14-membered fused heteroaryl, and each R c are the same or different and are each independently selected from halogen, hydroxy, oxo, hydroxy 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 Alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 The 3 to 8-membered cycloalkyl, 3 to 8-membered cycloalkenyl, 3 to 8-membered heterocyclyl and 5 to 6-membered heteroaryl groups are optionally selected from halogen, hydroxy, oxo, hydroxy, C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 Alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 The alkoxy group is substituted by one or more substituents, and p is 0, 1, 2, 3 or 4; Preferably, the structural unit wherein Ring C is selected from phenyl, 5- to 6-membered heteroaryl, 5- to 8-membered monocyclic heterocyclylphenyl, 7- to 10-membered fused heterocyclylphenyl, 7- to 10-membered spiroheterocyclylphenyl, 5- to 8-membered monocyclic heterocyclyl and 5- to 6-membered heteroaryl, 7- to 10-membered fused heterocyclyl and 5- to 6-membered heteroaryl, 5- to 6-membered heteroarylphenyl, and each R c are the same or different and are each independently selected from halogen, hydroxy, oxo, hydroxy 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 Alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 3 to 8 membered heterocyclyl, 5 to 6 membered heteroaryl, wherein the 3 to 8 membered cycloalkyl, 3 to 8 membered cycloalkenyl, 3 to 8 membered heterocyclyl, 5 to 6 membered heteroaryl are optionally selected from halogen, hydroxy, oxo, hydroxy 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 Alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 The alkoxy group is substituted by one or more substituents, and p is 0, 1, 2, 3 or 4; More preferably, the structural unit Selected from Each R c are the same or different and are each independently selected from hydrogen, halogen, hydroxyl, oxo, hydroxyl, 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 Alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, 3 to 6 membered cycloalkyl and 5 to 6 membered heteroaryl, wherein the 3 to 6 membered cycloalkyl and 5 to 6 membered heteroaryl are optionally selected from halogen, hydroxy, oxo, hydroxy 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 Alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 The alkoxy group is substituted by one or more substituents, and p is 0, 1, 2, 3 or 4; More preferably, the structural unit Selected from 11. The compound according to any one of claims 1 to 10, its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or a pharmaceutically acceptable salt thereof, wherein Ring C is selected from phenyl, 5- to 6-membered heteroaryl, 5- to 8-membered monocyclic heterocyclylphenyl, 7- to 10-membered fused heterocyclylphenyl, 5- to 8-membered monocyclic heterocyclyl and 5- to 6-membered heteroaryl, 7- to 10-membered fused heterocyclyl and 5- to 6-membered heteroaryl, 5- to 6-membered heteroarylphenyl, 5- to 6-membered heteroaryl and 5- to 6-membered heteroaryl.
12. The compound according to any one of claims 1 to 11, its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt, wherein ring C is selected from 13. The compound according to any one of claims 1 to 12, its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt, wherein each R c are the same or different and are each independently selected from hydrogen, halogen, oxo, halogenated C 1-6 Alkyl, cyano, -CONH2, amino, C 1-6 Alkyl, deuterated C 1-6 alkyl, 3 to 8 membered cycloalkyl optionally substituted with -CONH2, and optionally C 1-6 alkyl-substituted 5- to 6-membered heteroaryl; or two R attached to the same carbon atom or to adjacent carbon atoms c Together with the carbon atom to which it is attached, it forms a 3- to 6-membered cycloalkyl group.
14. The compound according to any one of claims 1 to 13, its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt, wherein each R c are the same or different and are each independently selected from hydrogen, F, methyl, amino, -CONH2, Cyano, -CHF2, cyclopropyl, -CD3 and Cl.
15. The compound according to any one of claims 1 to 14, its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt, wherein L is selected from -NR n1 -、-NR n1 C(O)-、-NR n1 -C(O)-NR n1 -and-CR d =CR e -; R n1 , R d , R e As defined in claim 1; R is selected from C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy 1-6 Alkyl, cyclopropyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, deuterated C 1-6 Alkoxy and C 1-6 Alkoxy C 1-6 Alkyl; or R n1 and the atom to which R is attached together form a 3- to 8-membered heterocyclic group or a 5- to 10-membered heteroaryl group; or R b and the atom to which R is attached together form a 3- to 6-membered heterocyclic group; in, The 3 to 8 membered heterocyclic group, the 3 to 6 membered heterocyclic group and the 5 to 10 membered heteroaryl are each independently selected from halogen, hydroxyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 Alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 substituted by one or more substituents in the alkoxy group; Preferably, L is selected from -NR n1 C(O)-、-NR n1 -C(O)-NR n1 -and-CR d =CR e -; R n1 Selected from hydrogen atoms, C 1-6 Alkyl and deuterated C 1-6 Alkyl, R d , R e are the same or different and are each independently selected from a hydrogen atom, a C 1-6 Alkyl and halogen, R is selected from C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy 1-6 Alkyl, cyclopropyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, deuterated C 1-6 Alkoxy and C 1-6 Alkoxy C 1-6 Alkyl; or R n1 and the atom to which R is attached together form a 5- to 8-membered heterocyclic group; or R b and R and the atoms connected thereto together form a 5- to 6-membered heterocyclic group; wherein the 5- to 8-membered heterocyclic group and the 5- to 6-membered heterocyclic group are each independently selected from halogen, hydroxyl, hydroxyl C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 Alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 substituted by one or more substituents in the alkoxy group; More preferably, L is selected from -NR n1 C(O)-、-NR n1 -C(O)-NR n1 -and-CR d =CR e -; R n1 Selected from hydrogen atoms, C 1-6 Alkyl and deuterated C 1-6 Alkyl, R d , R e are the same or different and are each independently selected from a hydrogen atom, a C 1-6 Alkyl and halogen, R is selected from C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy 1-6 Alkyl, cyclopropyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, deuterated C 1-6 Alkoxy and C 1-6 Alkoxy C 1-6 Alkyl; or R n1 Together with R and the atoms it is connected to, or R b Together with R and the atoms it is connected to, Each R f and R g are the same or different and are each independently selected from hydrogen, halogen, hydroxyl, hydroxyl 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, amino, -CONH2, NH(C 1-6 Alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl, C 1-6 Alkoxy, t is 0, 1, 2, 3 or 4, and u is 0, 1, 2, 3, 4 or 5; More preferably, L is selected from -NHC(O)-, -NH-C(O)-NH-, -NH-C(O)-N(CH3)-, -NH-C(O)-N(CD3)- and -CH=CF-; R is selected from C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, deuterated C 1-6 Alkoxy and C 1-6 Alkoxy C 1-6 Alkyl; or R n1 Together with R and the atoms it is connected to, or R b Together with R and the atoms it is connected to, 16. The compound according to any one of claims 1 to 15, its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt, wherein L is selected from -NR n1 C(O)-、-NR n1 -C(O)-NR n1 -and-CR d =CR e -; R n1 Selected from hydrogen atoms, C 1-6 Alkyl and deuterated C 1-6 Alkyl, R d , R e are the same or different and are each independently selected from a hydrogen atom, a C 1-6 Alkyl and halogen.
17. The compound according to any one of claims 1 to 16, its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt, which is a compound represented by general formula (Ia), its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt; in: X is selected from -CH2-, -O-, -NH-, -S-; L is selected from -NR n1 C(O)-、-NR n1 -C(O)-NR n1 -; Bond a is a single bond or a double bond; When bond a is a single bond, Y and Z are the same or different and are each independently selected from -O-, -NH- and -CR c5 R c6 -; When bond a is a double bond, Y and Z are the same and are both selected from CH; R c1 Selected from hydrogen atoms, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, 3- to 6-membered heterocyclyl, and 3- to 6-membered cycloalkyl; R c2 , R c3 , R c4 , R c5 , R c6 are the same or different and are each independently selected from hydrogen atoms, halogens, C 1-6 Alkyl and halogenated C 1-6 alkyl; R n1 and R is as defined in Formula (IA); The condition is: when X is -CH2-, They are not -CH2-CH2- at the same time, and -LR is not -NHC(O)-CH2CH3 at the same time.
18. The compound according to any one of claims 1 to 17, its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt, wherein X is selected from -CH2-, -O-.
19. The compound according to any one of claims 1 to 18, its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt, wherein when bond a is a single bond, one of Y and Z is selected from -O-, and the other is selected from -CR c5 R c6 -; R c5 and R c6 As defined in claim 17.
20. The compound according to any one of claims 1 to 19, its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt, wherein R c2 , R c3 , R c4 , R c5 , R c6 are the same or different and are each independently selected from a hydrogen atom, F, Cl, -CHF2 and a methyl group.
21. The compound according to any one of claims 1 to 20, its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt, wherein R c1 is selected from hydrogen, cyclopropyl, methyl, deuterated methyl; preferably, R c1 is selected from methyl and deuterated methyl; more preferably, R c1 Selected from methyl and -CD3.
22. A compound according to any one of claims 1 to 20, a stereoisomer thereof, an isotopic derivative thereof, a prodrug thereof, a nitrogen oxide thereof, a solvate thereof or a pharmaceutically acceptable salt thereof, wherein L is selected from -NHC(O)-, -NH-C(O)-NH-, -NH-C(O)-N(CH3)-, -NH-C(O)-N(CD3)- and -CH=CF-; preferably, L is selected from -NHC(O)-, -NH-C(O)-NH-.
23. The compound according to any one of claims 1 to 22, its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt, wherein R is selected from halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 1-6 Alkyl, C 1-6 Alkoxy and deuterated C 1-6 Alkoxy; and / or R n1 Selected from hydrogen atoms, C 1-6 Alkyl and deuterated C 1-6 alkyl.
24. The compound according to any one of claims 1 to 23, its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt, wherein R is selected from Ethyl, methyl, methoxy and 25. The compound according to any one of claims 1 to 24, its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt, wherein the structural unit Selected from 26. The compound according to any one of claims 1 to 25, its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt, wherein the compound is selected from:
27. A pharmaceutical composition comprising a compound according to any one of claims 1 to 26, a stereoisomer thereof, an isotopic derivative thereof, a prodrug thereof, a nitrogen oxide thereof, a solvate thereof or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.
28. Use of the compound according to any one of claims 1 to 26, its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt, or the pharmaceutical composition according to claim 27 in the preparation of a medicament for inhibiting CYP11B2, preferably in the preparation of a medicament for selectively inhibiting CYP11B2.
29. Use of the compound according to any one of claims 1 to 26, its stereoisomer, its isotopic derivative, its prodrug, its nitrogen oxide, its solvate or its pharmaceutically acceptable salt or the pharmaceutical composition according to claim 27 in the preparation of a medicament for treating and / or preventing a CYP11B2-mediated disease.
30. The use according to claim 29, wherein the disease is selected from hypertension, chronic kidney disease, diabetic nephropathy, primary aldosteronism, chronic kidney disease, diabetic nephropathy; the hypertension is preferably selected from refractory hypertension, uncontrolled hypertension, low renin hypertension, essential hypertension.
31. Use of a compound according to any one of claims 1 to 26, a stereoisomer thereof, an isotopic derivative thereof, a prodrug thereof, a nitrogen oxide thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 27 in the preparation of a medicament for reducing aldosterone levels in a subject.
